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ABSTRACT OF THESIS 
 
COLLAGEN CROSSLINKING REAGENT UTILIZED TO MODIFY THE MECHANICAL 
PROPERTIES OF THE SOFT PALATE IN EQUINE SNORING AND APNEA 
APPLICATIONS 
Snoring is a sleep disruption that can lead to obstructive sleep apnea (OSA), 
which interrupts breathing by obstructing the airway. Injecting a protein crosslinker, such 
as genipin, into the soft palate could decrease the severity of snoring and OSA by 
stiffening the soft palate. Equine soft palates modeled human palates due to a high 
incidence of awake snoring and apnea. 
 The pilot in vivo study treated six horses with two 100 mM injections of the 
buffered genipin reagent.  The efficacy phase horses underwent respiratory audio 
recordings to document snoring changes using Matlab and ImageJ in the time and 
frequency domains. Histological analysis was completed on the safety phase palates 
post treatment. 
All horses were successfully treated with the genipin injections. At least one 
horse showed high frequency amplitude reductions, and all horses had low frequency 
amplitude reductions, correlating to a reduction in palatal displacement and snoring 
loudness. One efficacy horse appears to have been completely cured.  The histological 
analysis presented tissue damage, mucosal tissue damage, and mild inflammation due 
to palate expansion and errant injections.  
Different injection volumes and techniques should be investigated next.  Applying 
this treatment to human studies for snoring and OSA applications is the ultimate goal.  
 
KEYWORDS: Obstructive sleep apnea, snoring, soft palate stiffening, sound analysis of 
snoring, biomechanical testing of soft tissue 
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1. Introduction 
Snoring is a highly prevalent condition that affects people of all ages, caused by 
the vibration of the tissues in the airway of the nose and throat, especially the soft 
palate.  Conditions leading to snoring are exacerbated by obesity, allergies, aging, 
medication use, or alcohol consumption.  Snoring can lead to sleep cycle disruptions for 
the snorer and their family, sleep deprivation, daytime lethargy, and drowsiness [1-4].  In 
some instances, snoring can advance into a more serious, and sometimes life 
threatening condition, obstructive sleep apnea (OSA).   In OSA, breathing is interrupted 
during sleep by physical obstruction of the airway caused by excessive compliance of 
the soft palate and abnormalities in the geometry of air passages.   Repeated trauma to 
the soft palate caused by snoring can increase its passive deformability and damage its 
muscle fibers and peripheral nerve fibers, increasing the chance of obstruction.  OSA 
can lead to respiratory and cardiovascular complications, such as high blood pressure, 
stroke, heart failure, diabetes and depression [1-5].  
 Current treatments for snoring and OSA follow a 4-phase path.  The first step is 
simple lifestyle changes, such as weight loss or changing eating or drinking habits.  The 
second phase consists of over the counter medications, oral devices and nasal dilators.   
One common example of over the counter products is nasal snoring strips.  The third 
phase consists of non-surgical devices, such as the continuous positive air pressure 
machine (CPAP) that provides continuous air to the patient to counter the narrowing of 
the air passage.   The final phase consists of various surgical treatments aimed at either 
removal of offending tissues or stiffening the soft palate through the formation of scar 
tissue.  Examples of common surgical procedures include radiofrequency ablation, 
injection of sclerosants, uvulectomy surgery, and the Pillar procedure [1,4,5,6-15]. 
 The treatments for both snoring and OSA are relatively unsuccessful.   A majority 
of the current surgery procedures rely on stiffening the soft palate to increase damping, 
and therefore to improve airflow induced vibrations.   Typically, the stiffening is the result 
of fibrosis formation, which is an inflammatory wound-healing response resulting in 
fibroblast activation and production of a poorly organized extracellular matrix [6-15]. 
Short-term results are promising for these treatments; however, fibrosis contributes to 
mechanical degradation of the overloaded soft palate, leading to eventual loss of 
treatment benefits.  Generally, the collagen network created in fibrotic lesions is not the 
same type of collagen originally present in the tissue, leading to degradation of the 
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mechanical properties and reduction of the tissue’s durability, or fatigue resistance [8,15-
17].  Additionally, the tissue-material interfaces produced in some procedures can cause 
micro-motion, wear, particle-release, inflammatory or cellular responses and tissue 
damage [13-16].  Treatments that rely on heat denaturation of the target tissue can 
produce inferior mechanical properties, substandard molecular and micro-structural 
geometries and loss of initial treatment-related benefits [6-12].   With less than ideal 
results from current treatments, along with an increasing number of patients diagnosed 
with snoring and OSA, a new treatment is necessary that can stiffen the soft palate while 
improving the mechanical properties of the tissue.  
 The hypothesis of this study was that an injection of a non-toxic protein cross-
linking reagent into the soft palate would augment the mechanical properties and reduce 
deformation and vibration of the palate when subjected to physiologic air flow, thus 
decreasing severity of snoring and the likelihood of airway collapse, while also 
increasing the tissue’s resistance to mechanical degradation.   Instead of creating scar 
tissue that degrades over time, crosslink augmentation stabilizes the tissue while 
preserving the microstructural and compositional integrity.  More specifically, this method 
can modify the viscoelastic, elastic-plastic, and durability properties by increasing the 
strength, stiffness, fatigue resistance and energy required to permanently deform or fail 
the tissue [18-26]. Compared to other treatments, protein crosslinking is less intrusive, 
less expensive, faster (same-day benefit), and less harsh in regards to induction of 
inflammatory responses.  
An alternative to animal model research was unsuccessful in simulating the multi-
faceted conditions leading to soft palate degradation, tissue vibration and air passage 
obstruction.  Likewise, the inflammatory and immunogenic responses and the 
mechanically activated cellular responses to a non-physiologically altered matrix cannot 
be simulated to an acceptable level in a non-living model.  Therefore, equine soft palates 
were used as a relevant model to represent human snoring and OSA due to a high 
incidence of awake snoring and apnea, otherwise known as dorsal displacement of the 
soft palate, or DDSP.  This disease is a naturally occurring soft palate disorder caused 
by the displacement of the caudal edge of the soft palate, which interferes with normal 
airflow through the nasopharynx, producing mechanical property deficiencies, snoring, 
and temporary obstruction of the airway.  DDSP occurs in 10 to 20% of competitive 
horses; however, this is only an estimate because horses with this malady are often 
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quietly euthanized [27].  Current treatments include the tie-forward procedure, laser 
staphylectomy, myectomy, and the Cornell Collar that focus on immobilizing the larynx 
or stiffening the soft palate to prevent displacement of the soft palate, all of which have 
about a 50-60% success rate [27-33]. 
 The hypotheses of this study were tested through in vivo and in vitro methods 
using equine soft palates as a relevant model for human snoring and OSA.   A pilot 
equine in vivo study tested the efficacy and safety of genipin injection treatment of the 
soft palate.  The in vitro mechanical testing study used cadaveric equine soft palates to 
determine the effects of the genipin treatment on the mechanical properties of the soft 
palate.   Together, these studies provided a glimpse into the potential treatment benefits 
of injecting a genipin crosslinking reagent into the soft palate for treatment of human 
snoring and OSA, as well as equine DDSP.  
 Prior to starting any work on the current study, a previous in vitro equine soft 
palate study was completed by Dr. Jonathan Kuo and his team from Orthopeutics, LP in 
Lexington, KY that was used to determine the concentrations of the genipin treatment 
used in both the pilot in vivo study and the in vitro mechanical testing study.   Kuo et al. 
designed and constructed a custom wind tunnel, equipped with a mounting clamp that 
mimicked the support provided to the soft palate by the hard palate and connective 
tissues, to simulate the equine respiratory tract as shown in Figure 1.1   The wind tunnel 
system produced transient and steady state wind flow up to 14 meters/second over the 
mounted soft palate to simulate breathing conditions.  A laser reflection transducer 
(Keyence LK-081, Itaska, IL) was mounted above the samples to measure the 
displacement amplitudes and vibration frequency and amplitudes of the specimens.  
Three different concentrations for genipin injection were tested, including 50 mM, 100 
mM and 150 mM.  Additionally, untreated controls and 0.33% genipin soaked samples 
were tested to serve as baselines for untreated tissue and maximum genipin crosslinked 
tissue, respectively.  Changes in displacement and frequency were measured and 
compared between treated and untreated samples.  The genipin injected soft palates 
resulted in localized crosslinking around the injection side.  The 50 mM, 100 mM and 
150 mM genipin concentration injection had 44%, 46% and 64% respective decrease in 
transient displacement of the soft palate compared to the untreated samples.   For 
steady state displacements (vibration amplitudes), there was a 36%, 23%, and 42% 
decrease compared to the control samples for the 50 mM, 100 mM, and 150 mM genipin 
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concentration injections, respectively.   The genipin injections covered 40%, 49% and 
51% of the soft palate for the 50 mM, 100 mM, and 150 mM genipin concentration 
injections, respectively, based on the area of crosslinking region, which appears blue 
due to the genipin reaction. 
 
Figure 1.1: The wind tunnel was custom designed to mimic the equine breathing flow (left).  It 
consisted of a fan that blew wind over the soft palate to measure changes in the displacements 
using a laser displacement measurement system.  The wind tunnel supported the soft palate (right) 
similar to how the hard palate and connective tissue support it in the horse’s airway. 
 Based on the results of the wind tunnel study, the 100 mM concentration of 
genipin injections was used for the in vivo study for a variety of reasons.  First, the 100 
mM concentration showed a decrease in both deformation and vibration of the palate.  
Also, it treated about half of the palate, as demonstrated by the area of the blue genipin 
crosslinking region.  The amount of area covered by the genipin was important in the 
equine studies because the soft palate is larger, thus more coverage is needed to 
effectively treat the tissue.  Finally, a previous safety study completed by Orthopeutics, 
LP, showed no adverse acute reactions at the 100 mM genipin concentration when 
injecting it into the equine soft palate in vivo.   Overall, the 100 mM concentration for the 
genipin injections showed the most promise to produce a noticeable treatment effect for 
horses afflicted with DDSP.  
For the equine soft palate mechanical testing study, the 50 mM genipin 
concentration was chosen because it was the preferred concentration for potential 
human snoring and OSA applications.  The 50 mM concentration was picked because it 
had minimal toxicity based on previous studies while demonstrating a similar effect in the 
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wind tunnel as higher concentrations.  Also, no DMSO was required to solubilize the 
genipin at a lower concentration.  
The pilot equine in vivo study consisted of two phases: the efficacy phase, which 
tested the success of the genipin injections for treating DDSP, and the safety phase, 
which tested the short-term biological effects of the genipin injections on the soft palate.  
The efficacy phase consisted of three horses diagnosed with DDSP, while the safety 
phase consisted of three horses with no apparent breathing disorders.  The efficacy 
phase horses underwent dynamic endoscope examinations and respiratory audio 
recordings prior to and after the soft palate injections to qualitatively and quantitatively 
measure the effects of the genipin treatment.   The respiratory audio recordings were 
analyzed using Matlab in the time domain and frequency domain to determine if there 
were any changes in the snoring loudness or frequency of DDSP associated with the 
genipin treatment.   At the completion of the study, the soft palates from the safety phase 
horses were harvested for histological analysis using hematoxylin and eosin (H&E) stain 
to determine any presence of inflammation or fibroplasia infiltrates.  
The mechanical testing study used cadaveric equine soft palates to test the 
effect of the genipin treatment on the mechanical properties of the tissue.  Three test 
groups, including untreated control samples, buffer-only injected samples, and buffered 
genipin treated samples, underwent three mechanical tests using a universal testing 
machine.  Each sample underwent a cyclical loading (hysteresis), stress relaxation and 
tensile loading to failure test in order to determine quantitative changes between the 
treated samples and untreated samples.  First cycle hysteresis, change in hysteresis, 
hysteresis ratio, stress relaxation, relaxation modulus, normalized relaxation modulus, 
ultimate tensile stress and strain, toe region slope, Young’s modulus, yield point stress 
and strain, toughness, energy, and resilience were calculated from the results of the 
mechanical tests.  Statistical analysis was completed using the F-test, Student’s t-test 
and the Mann-Whitney U non-parametric test to determine any statistically significant 
differences between the three test groups.  
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2. Background 
2.1 Snoring and Obstructive Sleep Apnea 
2.1.1 Overview 
Snoring is a respiratory sound generated primarily by inspiration in the upper 
airway during sleep [1].  The functions of the upper airway, which is the part of the 
respiratory system between the nostrils and trachea, include air warming, humidification, 
pathways for olfaction, coordination of ventilation with swallowing, protection from 
aspiration of food, and primary defense against infection [2].  These functions are 
controlled by the neuromuscular systems under both voluntary and involuntary control 
[2].  Snoring is worsened by alcohol consumption, weight gain, sedative medications, 
sleep deprivations, and supine sleeping positions.   The symptoms of snoring include 
drooling, dry mouth and restless sleep [3].  Additionally, patients experience excessive 
daytime sleepiness (EDS), which is measured by the Epworth Sleepiness Scale (ESS) 
[3].  Overall, snoring affects people of all ages, occurring in 35-45% of men and 15-28% 
of women [4]. However, it is more prevalent in the elderly, occurring in 28-67% of elderly 
men and in 20-54% of elderly women [4].  
Obstructive sleep apnea (OSA) is a potentially life threatening condition caused 
by repetitive partial or complete collapse of the upper airway during sleep.  OSA occurs 
when an imbalance persists between the forces dilating and occluding the pharynx due 
to insufficiencies in luminal patency and airway stability, including slowly varying 
vascular pressure and tissue elasticity and quickly varying muscular effects [1,34].   OSA 
is a gradually progressive disease caused by a variety of factors, including palatal 
denervation, a thickened soft palate, an enlarged tongue volume, a receding jaw, an 
enlarge uvula or a lack of muscle tone in the throat [1-4].  Additionally, a lack of rigidity 
caused by a decrease in mechanical properties of the pharyngeal tissues can also lead 
to airway occlusion, including the upper airway muscles, larynx and soft palate [34]. 
These conditions lead to apneas - a cessation of breathing, or hypopneas - reduced 
breathing phases [1].  During sleep, the upper airway is particularly vulnerable because 
the reflexes are relaxed, leaving the airway susceptible to collapse, leading to OSA 
conditions [2,4].  OSA occurs in about 2-11% of the population aged 16 or older, or 
approximately 10 million individuals.  Men are twice as likely to experience OSA than 
women.  Additionally, OSA is more common in Pacific Islanders, Hispanic Americans, 
and African Americans [1,4,5].  
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OSA is characterized by a loud snore alternating with 20- to 30- second intervals 
of silence, terminated by loud snorts, gasps, moans or other vocalizations, and 
sometimes in conjunction with brief awakenings and body movements [3].  Additionally, 
18-31% of patients experience nocturnal dyspnea, or a sensation of choking or 
suffocating, in relationship with OSA [3].  Nocturnal symptoms of OSA consist of 
intermittent snoring, nocturnal enuresis, witnessed apneas, dyspnea, drooling, dry 
mouth, bruxism, restless sleep/frequent arousals, gastroesophageal reflux and nocturia 
[1,4].  Daytime symptoms include daytime sleepiness, diminished intellectual 
performance, personality changes, morning headaches, diminished quality of life, 
depression, anxiety, irritability, and sexual dysfunction [1,4].    Excessive body weight 
and genetic factors play a role in OSA, as well [1,4].   As OSA worsens, it leads to more 
serious respiratory and cardiovascular complications, including hypertension, 
cardiovascular disease, stroke, obesity, insulin resistance, and myocardial infarction 
[1,3,5]. 
OSA is diagnosed according to the apnea hypopnea index (AHI), physical 
examinations, and patient symptoms [1,3].  AHI is defined as the number of apneas plus 
the number of hypopneas per hour of sleep. Typically, if a patient experiences more than 
five respiratory collapses per hour (AHI ≥ 5), they are diagnosed with OSA.  OSA is then 
categorized based on severity: mild OSA from 5 ≤ AHI < 20; moderate OSA from 20 ≤ 
AHI < 40; and severe OSA with AHI ≥ 40 [1,3].  Diagnosing sleep apnea through 
symptoms alone is only successful about 50% of the time; therefore, sleep endoscopic 
examinations or polysomnography tests are utilized for a more accurate diagnosis [3,5].  
Sleep endoscopic examinations are completed using a flexible endoscope to view the 
nasal passage while a patient is sleeping.  There are a few disadvantages associated 
with endoscopic examinations that interfere with the validity of the test, including 
reduction of the cross-section of the airway by the endoscope, arousal reactions due to 
mechanical stimulus, to visual obstruction by phlegm, and to simultaneous assessment 
of only one level of the airway [1].  A polysomnography test, which is the current ‘gold 
standard’ for diagnosing OSA, is a sleep study completed overnight that observes 
various sleep irregularities.  However, sleep studies are expensive and time consuming, 
which dissuades patients from undergoing them [3].  In both techniques, an apnea is 
identified as the cessation of airflow for at least ten seconds [6].  Additionally, according 
to the American Academy of Sleep Medicine Task Force, hypopnea is defined as either 
greater than 50% reduction in airflow, or less than 50% reduction in airflow associated 
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with a desaturation of greater than 3%, or a moderate reduction in airflow with 
associated arousal by electroencephalogram (EEG) [35].  
2.1.2 Current Treatments 
Current treatments for snoring and OSA range from conservative options to 
apparatus therapies to invasive surgeries, all of which have respective advantages and 
disadvantages.  The goal of all snoring treatments is to reduce or stop vibration of the 
relevant airway structures, while the goals of OSA treatments are to enlarge the airway 
or to alter mechanical properties of the pharyngeal tissues to prevent collapse and 
eliminate apneas, hypopneas, and other related symptoms [1,34,36].  The first treatment 
option for both snoring and OSA are conservative treatments, which consist of weight 
reduction, optimization of sleep hygiene, avoidance of certain sleeping positions, and 
cessation of certain medication, alcohol and tobacco use [1,37].  
The next phase consists of oral devices and apparatus therapies.  One common 
oral device is mandibular repositioning appliance (MRA), which manually moves the 
mandible forward to improve the upper airway patency [37].  Typically, the MRA has a 
50-70% success rate for mild to moderate severe OSA [1].  In general, the oral devices 
are bulky and uncomfortable, leading to hypersalivation, xerostomy, jaw pain, dental 
pain and permanent teeth misalignments [1,4].  
The most widely used apparatus therapy is the continuous positive airway 
pressure (CPAP) machine, which delivers a continuous flow of air through a nasal mask, 
creating a constant pressure during the respiratory cycle to eliminate obstructive apneas, 
as shown in Figure 2.1 [4].  The CPAP machine works by counteracting the negative 
transmural pressure that promotes collapse and narrowing of the floppy-toned upper 
airway pharyngeal musculature by pneumatically splinting open the upper airway via the 
application of a positive pressure across the airway walls to prevent narrowing or 
collapse [37].  With a potential success rate of 98%, the CPAP machine is the ‘gold 
standard’ therapy in OSA treatments; however, there are patient compliance issues 
resulting in only 60-80% of patients using it due to common side effects, including nasal 
congestion, rhinorrhea, dryness, sneezing, complaints of machine noise, loss of mask 
seal against face, and intolerance to the level of positive pressure [1-5].  
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Figure 2.1: The CPAP machine is an external device used to treated OSA and severe snoring.  The 
machine is bulky and noisy, causing sleep cycle disruptions for the patient and their family. 
Nasal surgery options are typically used in conjunction with the CPAP machine to 
assist in snoring reduction and OSA.  Common nasal surgeries include: septoplasty, 
septorhinoplasty, turbinate reduction, and endoscopic sinus surgery [5].  Overall, nasal 
surgeries are successful at reducing snoring 34-69% of the time and OSA 20% of the 
time in combination with the CPAP machine [4].    
When simple lifestyle changes and apparatus therapies fail, surgical procedures 
focus on altering the soft palate and surrounding tissues for treatment of snoring and 
OSA.  The uvulopalatopharyngoplasty (UPPP) consists of ablating the excessive tissue 
of posterior margin of the soft palate, uvula, and lateral pharyngeal wall with a laser, 
cautery or cold knife to relieve oropharyngeal obstruction and to increase stiffness 
through postoperative scarring [4,36,38]. Typically, the UPPP procedure is completed in 
conjunction with a tonsillectomy [4].   In general, there is a long-term success rate of 
70% for snoring and of 50% for OSA [5].  The success of the treatment relies on the 
amount of soft palate tissue resected.  Excessive resection can cause palatal 
malfunction, and conservative resection can still produce snoring or OSA symptoms [38].  
The procedure is considered to be relatively painful with high morbidity and mortality 
rates and common side effects, including post-op bleeding, voice changes, 
nasopharyngeal stenosis, persistent dry throat, swallowing abnormalities, respiratory 
distress and palatal incompetence [4,5,38]. 
Another surgery treatment is the laser-assisted uvulopalatoplasty (LAUP), which 
reduces snoring by trimming the palate and surrounding tissues and by increasing the 
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stiffness through postoperative scarring [36].  The procedure consists of ablation of the 
palate, velum, and uvula using a carbon dioxide laser under local anesthesia [4].  
Overall, the side effects are minor with the biggest complaint being severe pain and 
potential ineffectiveness [4].   The effectiveness was reported as 69% successful at 9 
months and as 55% successful at 59 months post treatment.  In general, success rates 
deteriorated from 70% to 30% over time, with differences in laryngeal anatomy being the 
biggest reason for failure [5].  In some cases, treatments can be repeated every six 
weeks to improve effectiveness [5].  
Many surgical treatments focus on stiffening the soft palate to prevent vibration 
and obstruction, such as radiofrequency thermotherapy, the injection of sclerosants, the 
Pillar procedure, and laser soft palate stiffening.  Radiofrequency thermotherapy is 
accomplished by using radiofrequency energy to create thermal lesions with subsequent 
fibrosis leading to stiffening and some shrinkage of the palate and tongue base [5].  This 
outpatient procedure works best for mild to moderate OSA, with effectiveness being 
related to the total energy delivered and to the location of the lesions that increase scar 
tissue [5,35].   Common complications include pain, dryness, or recurrence of snoring 
[35].  Similarly, the injection of sclerosants stiffens the palate by injecting chemicals, 
such as sodium tetradecyl sulphate, into the tissue to induce scarring and stiffening of 
the palate [5].  Again, complications include pain, dryness, foreign body sensation, and 
recurrence of snoring [36].  
The Pillar procedure consists of inserting palatal implants into the soft palate to 
reduce vibration and narrowing of the soft palate by increasing the stiffness of the palate 
[5,36].  Three small, rectangular implants, made of a woven polyester material, are 
inserted into the soft palate in a parallel orientation for the treatment of OSA [36].   
Initially, the treatment reduces AHI in patients with mild to moderate OSA as long as the 
implant stays in place.  However, over time, the effectiveness decreases because the 
fibrotic encapsulation around the implants leads to tissue degradation [36].   The most 
common side effect of the Pillar procedure is the extrusion of the implant at a rate of 0-
25% due to chronic inflammatory responses and fibrous capsule formation.  This side 
effect is remedied by replacing the implant  [36].    
Comparably, the laser soft palate stiffening procedure stiffens the palate using a 
low power Nd:YAG laser of 1.44 micrometer as an alternative treatment to the UPPP 
surgery. This procedure is less invasive than the UPPP because it is a form of 
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“electrosurgery” that works by visibly shrinking the soft palate by breaking intrinsic 
collagen crosslinking to shrink the collagenous matrix, with an average 3.0 mm 
immediate reduction in length [38].   Histopathology results show no inflammation or 
necrosis, with submucosal fibrosis and scarring produced about 1-1.5 mm deep [38].  
The immediate response is mucosal shrinking, followed by a gradual tissue stiffening 
over time with the formation of tissue fibrosis [38].   Long-term effectiveness for this 
particular treatment have not been studied fully, but similar to other methods that stiffen 
the palate through scar tissue formation, it can be assumed that the effectiveness will 
decrease over time due to mechanical degradation in the soft palate.  
Other treatments for snoring and OSA include skeletal facial corrections and 
tracheotomy surgeries.   The maxillomandibular advancement is a type of skeletal facial 
correction that works by repositioning the jaw to allow for more airflow to prevent 
obstruction [36].  A tracheotomy is an opening in the windpipe that alleviates breathing 
obstructions [4,39]. Tracheotomy surgeries are generally viewed to be a mutilating 
intervention because it creates an unsightly hole in the trachea [4].  In general, these two 
treatments are the only treatments considered to be 100% effective at preventing OSA, 
and are reserved for patients with severe OSA that are unsuitable for CPAP or other 
surgical options due to severe life-threatening conditions or failure of previous surgical 
approaches [4].  
2.1.3 Acoustic Analyses of Snoring and Sleep Apnea 
A review of the literature was conducted to determine common techniques for 
detecting and analyzing snoring and OSA sounds.  Relevant techniques could then be 
applied to the equine in vivo study to record and analyze snoring sounds.   Beck et al. 
characterized snoring in the article title, “The acoustic properties of snoring.”  In Beck’s 
study, snoring was simulated in a canine model by placing a balloon above the larynx 
and inflating it to create various levels of obstruction to simulate OSA [40].  Beck then 
analyzed the snoring sounds from 75-2000 Hz in the time domain and frequency 
domain. The canine snoring sounds resulted in complex waveforms in the low frequency 
range associated with intermittent airway closure.  The biggest difference between 
Beck’s study and the current study is the animal model.  Beck’s study used a canine 
model that had an induced airway obstruction, whereas the equine model used in the 
present study experienced a naturally occurring form of OSA and snoring.  Regardless 
of the animal model, Beck’s study reiterated the idea that complex snoring waveforms in 
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the low frequency range are associated with airway obstruction, meaning that respiratory 
recordings and analysis in the low frequency range are a viable way to determine 
differences in snoring patterns.  
Another article titled, “Is there a relationship between sound intensity and 
frequency and OSAS severity?” by Acar et. al. explored the correlation between snoring 
loudness and OSA severity through snoring analysis.  Acar’s study consisted of patients 
with various degrees of OSA, ranging from mild to severe [41].  This study analyzed the 
snoring sounds using the fast Fourier transform function (FFT), and snoring was 
quantified using average snoring sound intensity level (SSIL) and the maximal frequency 
(Fmax).  Acar determined that SSIL and Fmax increased with age, in females, and in 
patients with severe OSA.  Additionally, Acar concluded that SSIL and Fmax are strongly 
correlated with AHI, and thus the severity of OSA.  Acar’s study showed that the FFT is 
a preferred way to analyze snoring sounds because it allows various peaks to be 
determined.  Acar also indicated that higher frequency peaks are characteristic of OSA 
snoring, which can be carried over for the equine snoring analysis used in the present 
study.   In contrast, Acar’s study focused on determining specific parameters associated 
with OSA, while the present study focused more on comparing a pre treatment 
frequency domain curve against a post treatment frequency domain curve.   
Another article by Azarbarzin and Moussavi, titled, “Snoring sounds variability as 
a signature of obstructive sleep apnea,” worked to determine an association between 
snoring sounds and the degree of OSA.   Azarbarzin and Moussavi recorded snoring 
sounds from patients with varying degrees of OSA and analyzed them using the time 
domain and frequency domain [42].  In their study, the apneic events had a pattern of 
high amplitude bands followed by apneic gaps without breathing in the time domain 
graphs.  These concepts can be used in the present equine in vivo study to determine 
the location of an obstruction caused by DDSP in the time domain.    
2.2 Dorsal Displacement of the Soft Palate 
2.2.1 Overview 
Equine soft palates were used as a relevant model to represent the multi-faceted 
conditions leading to soft palate degradation, tissue vibration and air passage 
obstruction in snoring and OSA due to a high incidence of a pathology involving awake 
snoring and apnea, known as dorsal displacement of the soft palate, or DDSP.  This 
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disease is a naturally occurring soft palate disorder caused by the displacement of the 
caudal edge of the soft palate, which interferes with normal airflow through the 
nasopharynx.  The disorder most commonly occurs when the head is in a flexed 
position, or when the horse is fatigued during hard exercise [43].  The displacement can 
usually be self-corrected by the animal by swallowing or by readjusting the head 
position, however, it can occur several times during a single race or training session, 
causing interruptions to normal breathing and consequently a significant decrease in 
performance.  
Horses breathe completely through their nostrils, meaning that they cannot 
breathe through their mouths [43].  The soft palate is a musculomembranous tissue that 
extends from the hard palate to the esophageal pharynx, separating the oral cavity from 
the nasopharynx [44].  The epiglottis projects through the caudal notch, or free border, of 
the palate [44].  Together, the soft palate and epiglottis form a seal to block off the nasal 
cavity from the oral cavity.  The free border of the palate should remain beneath the 
epiglottis at all times, except during swallowing or coughing [44]. DDSP occurs when the 
caudal edge of the soft palate displaces dorsally relative to the epiglottis, partially 
blocking the nasal passage and creating air turbulence during inspiration and, primarily, 
expiration, as demonstrated in Figure 2.2 [44].  When displaced, the soft palate reduces 
the cross-sectional area of the nasopharnyx, causing an obstruction.  The caudal edge 
of the palate vibrates as air flows past it, producing a “gurgling” or “snoring” noise in 50-
80% of affected horses [29-33,44-46].  When the soft palate is displaced, minute 
ventilation decreases by 13%, and maximal oxygen consumption decreases by 10% 
[45]. Swallowing or head movements can return the palate to the normal position after 
displacement [44].  In permanent cases, the palate is continuously displaced [27].   
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DDSP occurs in 10-40% of competitive horses, especially Thoroughbreds and 
Standardbred racehorses [27-33].  There is no known correlation between age of the 
horse and predisposition to DDSP, although younger horses seem more prone to the 
malady [27,32].  Since the soft palate acts as a seal for the larynx, any factor that 
disrupts the seal can cause the soft palate to displace.  Therefore, retraction of the 
Epiglottis 
Soft Palate 
Normal Anatomy 
Soft Palate DDSP Anatomy 
Epiglottis 
Figure	2.2:	The	normal	airway	anatomy	(top)	of	a	horse	allows	air	to	pass	freely	past	the	soft	palate,	
which	is	tucked	underneath	the	epiglottis.		In	DDSP	(bottom),	the	soft	palate	is	displaced	above	the	
epiglottis,	blocking	the	airway	as	the	horse	exhales.	
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tongue can cause caudal displacement of the larynx, forcing the soft palate above the 
epiglottis [24].  Structural abnormalities or physical obstruction due to masses, 
granulomas or cysts can also interfere with soft palate position, causing DDSP [27,46]. 
In certain cases, hyper activation of the muscles responsible for the movement of the 
larynx can cause the larynx to retract, thus displacing the palate.  This condition 
manifests in horses that are overly excitable or nervous [46].   
DDSP is diagnosed through clinical observations and dynamic endoscopic 
examinations.  A loud “gurgling” or “snoring” noise, as well as the fluttering of the cheeks 
as air is diverted beneath the displaced palate, are common symptoms of DDSP.  
Additionally, affected horses demonstrate exercise intolerance, often described by 
trainers as “choking down” or “swallowing their tongue” due to the temporary airway 
obstruction [27]. 
  Resting endoscopic evaluations are not useful in detecting DDSP because the 
soft palate rarely displaces at rest; however, resting endoscopic evaluations are utilized 
to assess the nasopharyngeal function and to rule out other upper airway disorders [27]. 
DDSP is diagnosed with a dynamic endoscopic examination performed on a treadmill or 
over ground.  The dynamic endoscope mimics showing or racing conditions that induce 
the displacement as close as possible.  For example, the horse is equipped with the 
typical tack and/or devices utilized during showing or racing.  An endoscope is advanced 
through the nostril to the pharynx, then the horse is exercised at various speeds and 
intensities until fatigue to induce DDSP conditions [27]. In some instances, the frequency 
of swallowing increases immediately prior to displacement [27]. Additionally, some 
horses experience a billowing of the caudal portion of the soft palate, causing palatal 
instability, preceding displacement [27]. DDSP is diagnosed if the soft palate displaces 
dorsally to the epiglottis for longer than eight seconds during the dynamic endoscopic 
evaluations [27].   
2.2.2 Current Treatments 
Because there are a variety of conditions that lead to DDSP, potential treatments 
vary significantly, from simple external devices or tack adjustments to complex surgical 
procedures.  The simplest treatment for DDSP is a tongue-tie during exercise, in which 
the tongue is physically tied to the lower jaw using a leather strap or fabric strip.  The 
tongue is indirectly connected to the larynx, so tying it prevents caudal retraction of the 
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larynx, and thus applying dorsal pressure to the soft palate in order to prevent 
displacement  [44,46,47].  Tying the tongue does not always prevent displacement, and 
in some cases, multiple tongue-ties are required to prevent displacement.   Similarly, 
changing the tack can help with the management of DDSP.  Commonly used tack 
options include a Z-bit or a leverage bit to hold the head and neck in certain positions to 
decrease the possibility of displacement [27,44]. Also, figure 8 nosebands are often used 
to prevent air from flowing into the orthopharynx by applying ventral pressure to the soft 
palate [46].  Finally, an external device can be added to assist in prevention of DDSP.  
As shown in Figure 2.3, the Cornell Collar applies pressure to the caudal aspect of the 
basihyoid bone and ventral aspect of the thyroid cartilage to pull the larynx more rostral, 
reducing the possibility of soft palate displacement [47].   
 
Figure 2.3: The Cornell Collar is an external device that applies pressure to the basihyoid bone to 
elevate the larynx and reduce potential soft palate displacements. 
When conservative treatments fail at preventing DDSP, more invasive surgical 
procedures are sometimes attempted.  Surgical treatments range from muscle 
transection to soft palate shortening to soft palate stiffening.  Overall, surgical treatments 
have a 58-78% success rate [48].    
A sternothyrohyoid myectomy transects the “strap” muscles via a bilateral partial 
tenomyectomy to increase upper airway pressure and to provide stability to the 
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nasopharyngeal structures. The “strap” muscles, which are responsible for caudal 
retraction of the larynx, include the sternohyoideus, sternothyroideus and omohyoideus 
muscles, commonly referred to as sternothyrohyoid muscles [44,47].   One potential 
benefit of this procedure is that it can be performed under light anesthesia with the horse 
remaining standing.  Similarly, there is a relatively short recovery period of about 14 
days with minimal complications [27,44,46]. Overall, the sternothyrohyoid myectomy has 
a reported 58-73% success rate [27,46,49,50].  
A staphylectomy consists of removing a portion of the caudal margin of the soft 
palate to prevent airway obstruction [44].  Although the staphylectomy is a relatively 
straightforward procedure, it can have severe complications and a 4-6 week recovery 
period.  If the soft palate is cut too short, it may allow food and water contents to enter 
the nasopharynx during swallowing, leading to coughing, sneezing, or aspiration 
pneumonia [46].   The success rate of 40-60% is based on the reduction of the amount 
of tissue blocking the airway when the soft palate displaces [46,49].   
The laryngeal tie-forward procedure mimics the effects of the Cornell Collar by 
permanently positioning the larynx dorsally to the basihyoid bone by suturing the larynx 
to the bone [27].   This procedure attempts to correct DDSP by reducing caudal 
movement of the larynx [50].  Post-operatively, there are minimal complications, and 
horses can return to work within 10-14 days [27].   Overall, there is about a 60-80% 
success rate, with failure typically being the result of breakdown of the suture [49,50].   
Similar to treatment in human snoring and OSA, one common treatment for 
DDSP is stiffening the soft palate through laser treatments or palatal sclerotherapy.   In 
laser palatoplasty, the caudal edge of the soft palate is stiffened though laser induced 
fibrosis during an outpatient procedure [27].   Minimal inflammatory complications occur 
post-operatively, and most horses can return to work within one month [27].   Similarly, 
caudal soft palate photothermoplasty stiffens the caudal edge of the soft palate by 
creating a large area of fibrosis through laser ablation of strips of the oral mucosa and 
submucosa [48].  Overall, stiffening the soft palate through various laser treatments had 
an immediate success rate of 60-92% to prevent DDSP [48-50].  Likewise, to stiffen the 
palate using sclerotherapy, a sclerosing agent, such as sodium tetradecyl sulfate, is 
injected into the submucosal layer of the soft palate to induce fibrosis [49].  Overall, a 
small study showed that sclerotherapy is a relatively simple procedure with minimal side 
effects and a short-term success rate of about 75% [49].  In general, the short-term 
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results show that stiffening the soft palate through the formation of scar tissue can 
prevent displacement and vibration of the palate; however, long-term results show that 
fibrous formation degrades the soft palate and is mechanically insufficient compared to 
healthy tissue, leading to treatment failure [48-50]. 
A common approach to DDSP treatment is a combination of two or more 
procedures.  Composite surgeries offer the benefit of minimizing anesthesia and 
surgery, while increasing the chances for DDSP prevention [51].   One common 
composite surgery is the Llewellyn procedure, which combines the myectomy with a 
staphlectomy to transect the sternothyrohoid muscles and shorten the caudal edge of 
the soft palate.  The Llewellyn procedure has an initial 60-92% success rate, but similar 
to the previous procedures, it becomes less effective over time due to degradation of the 
soft palate [49,50].  
2.2.3 Review of Equine Soft Palate Stiffening, Testing, and Sound Analysis 
A review was completed of literature associated with stiffening the equine soft 
palate for prevention of DDSP to compare and contrast the procedure and results with 
the present study.   One study, completed by Munoz et al, was titled, “Histological and 
biomechanical effects of palatal sclerotherapy in the horse using sodium tetradecyl 
sulfate.”  Munoz et al. used healthy horses to inject tetradecyl sulfate into the distal 
portion of the soft palate to stiffen it [52].  During the injections, a bubble was created at 
the injection site, leading to hard nodule formation in at least one of the horses [52].   A 
study by Alkabes et al. titled, “Evaluation of the effects of transendoscopic diode laser 
palatoplasty on clinical, histologic, magnetic resonance imaging, and biomechanical 
findings,” was also reviewed. Alkabes’ study, which used healthy horses, stiffened the 
soft palate through scar tissue formation via the laser palatoplasty procedure [53].   
Alkabes treated the horses with either a low-dose or a high-dose laser treatment, with 
edemas forming initially in each horse.  Over time, the edema decreased, and scarring 
of the soft palate increased [53].   Similar to the present study, both reviewed studies 
aimed to stiffen the soft palate to prevent DDSP.  However, both of these studies relied 
to some extent on scar tissue formation, whereas the current study relies on 
crosslinking.  Another major difference between the present study and these two studies 
is that the horses used in these studies were not diagnosed with DDSP and had normal 
soft palates.  Using horses with normal soft palates could lead to very different results 
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when compared to using horses with abnormal soft palates, due the pre-existing 
degradation and instability of the DDSP afflicted soft palate.   
Both of the studies in the literature analyzed the soft palate tissue through 
histological analysis and biomechanical testing.  Munoz evaluated the tissue using H&E 
staining, and did not find any significant necrosis, inflammation, or fibrosis in the treated 
or control palates [52].  Alkabes analyzed the tissue using H&E staining, and discovered 
inflammation caused by infiltration of lymphocytes and plasma cells.  The high-dose 
laser treated horses also had multiple fibrotic bands present [53]. Similar to the present 
study, both of these studies used H&E staining for the histological analysis.  As 
predicted, Alkabes’ study showed presence of fibrotic tissue formation, which is not the 
intended target in the current study that aims to stiffen and to strengthen the soft palate 
through crosslinking. 
The studies in the literature also biomechanically evaluated the treated tissues.  
Munoz tested each sample in tension until failure at a rate of 10 mm/s to determine the 
slope of the deformation curve, tensile stress and tensile strain [52].   In Munoz’s study, 
80% of the samples failed near the grips with no significant differences in stiffness, 
tensile strain or stress between the treated and control samples [52].   Alkabes 
examined the samples in compression using a deformation rod connected to a 100-g 
load cell at a rate of 3 mm/s [53].  Alkabes’ study showed a decrease in the elastic 
modulus of the high-dose laser treated horses compared to the control horses [53].   For 
the present study, compression testing was not used because the equine soft palate 
experiences minimal compressive loads; therefore, Alkabes’ biomechanical testing was 
not relevant to the present study.  On the other hand, Munoz’s biomechanical testing 
was similar to the present study because they tested the samples in tension to find 
Young’s Modulus, tensile stress and tensile strain.  However, the current study loaded 
the samples at a slower rate of 1 mm/s as described in the procedure in Section 3.3.4, 
rather than the rate of 10 mm/s used in Munoz’s study.  One major issue with Munoz’s 
biomechanical testing was that a majority of the samples failed near the grips rather than 
in the middle; consequently, steps were taken in the current study to neck down the 
samples to half of their original width to ensure failure in the middle of the sample.  
Three articles were reviewed to compare techniques for recording and analyzing 
respiratory sounds in horses.   The first paper by Derksen et al was titled, “Spectrum 
analysis of respiratory sounds in exercising horses with experimentally induced laryngeal 
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hemiplegia or dorsal displacement of the soft palate.”  Derksen induced DDSP in horses 
and recorded the respiratory sounds using a tape recorder positioned 4 cm from the 
horse’s nostril [53].   Abnormal respiratory noises were easily recorded in exercising 
horses in Derksen’s study, proving that it would be possible to record respiratory noises 
in the present study to determine differences in snoring before and after treatment.  
Two articles by Franklin et al. were reviewed because they analyzed respiratory 
noises in horses with breathing disorders.   These articles were titled, “Spectral analysis 
of respiratory noise in horses with upper airway disorders,” and “The displaced equine 
soft palate as a source of abnormal respiratory noise during expiration.”   Franklin’s 
studies recorded abnormal respiratory noises through an in vivo study with exercising 
horses diagnosed with DDSP and through an in situ study using cadaveric equine heads 
to simulate DDSP conditions [55,56].   In each of Franklin’s studies, the respiratory audio 
was recorded using a microphone placed halfway between the horse’s nostrils to avoid 
interference noises at a sampling rate of 10 kHz [55,56].   Both of these studies analyzed 
respiratory recordings by breaking the signals into individual inspiratory and expiratory 
segments and transforming them into the frequency domain using the fast Fourier 
transform (FFT) to determine an expiration to inspiration ratio for comparison with control 
horse respiratory audio [55,56]. One of the biggest differences was that Franklin 
compared the control horse respiratory audio to the DDSP horse respiratory audio using 
the expiration to inspiration ratio.  In the present study, the amplitude peaks were 
compared in the pre treatment and post treatment frequency domain graphs instead.  
For both the in vivo and in situ study, the snoring frequencies occurred in a low 
frequency range from 50-150 Hz, while a common ‘DDSP peak’ existed in the range 
from 20 to 80 Hz that could be potentially used to diagnose DDSP [55,56]. A very 
important finding from the Franklin studies was the existence of a ‘DDSP peak’ seen in 
all horses with DDSP, as well as in the cadaveric horse heads.  This finding provided a 
potential metric to use in the current study to determine the success of the genipin 
treatments based on the appearance or disappearance of the ‘DDSP peak’ in the 20-80 
Hz range. 
2.3 Genipin Crosslinking 
2.3.1 Overview  
Protein crosslinking is used to modify mechanical properties of biomaterials by 
augmenting the native collagenous crosslinks by adding additional crosslinking bonds 
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through direct injection of crosslinking agents [57,58].  Native collagenous crosslinks 
connect lysine or hydroxylysine residues within tropocollagen molecules or between 
different molecules [58].   Exogenous crosslinks can be added to create intrahelical 
crosslinks between the tropocollagen molecules within individual helical strands or to 
create interhelical crosslinks between adjacent molecules.  Additionally, intermicrofibrillar 
crosslinks can be formed between two adjacent microfibrils if the distance between the 
microfibrils is smaller than the length of the crosslinking agent [58], or in the case of self-
polymerizing crosslinkers such as glutaraldehyde and genipin, if the distance between 
potential binding sites is smaller than the chain length of the crosslinker.  
One of the most commonly used crosslinkers is glutaraldehyde, but it has many 
adverse side effects, including acute toxicity and calcification of the treated collagen [59].  
Therefore, other alternatives are being used as crosslinking reagents.  Genipin is a 
naturally occurring, minimally toxic crosslinker extracted from geniposide, a major 
ingredient in the fruit from the Gardenia jasminoides plant, which grows in Central Asia 
[57].  Genipin is commonly used with a phosphate buffered saline (PBS) solution to 
crosslink biomaterials and implants [57].   Genipin reacts with the free amino groups of 
lysine, hydroxylysine or arginine within biological tissue to produce a covalent bond, and 
a blue coloration with the simplest primary amine, methylamine.  The genipin-
methylamine monomer is formed through a nucleophilic attack by methylamine on the 
olefinic carbon at C-3 of genipin, followed by the opening of the dihydropyran ring and 
attack of the resulting aldehyde group by the secondary amino group.  The blue 
pigments are formed through oxygen radical-induced polymerization and 
dehydrogenation of several intermediary pigments [60].  As a result, after crosslink 
fixation, the tissue turns a dark blue, with the darkness of the blue coloration reflecting 
the density of the genipin crosslink bonds in the tissue [61].  Genipin crosslinking forms 
intrahelical, interhelical crosslinks, or intermicrofibrillar crosslinks [58].   Fixation by 
genipin crosslinking depends on the amount of genipin and the type of tissue.  As the 
genipin diffuses through the tissue, the fixation reaction occurs immediately.  If a limited 
amount of genipin is present, complete fixation can occur in a few minutes, but if a larger 
amount of genipin is present, unreacted genipin can continue to diffuse and react with 
available amines throughout the adjacent tissue such that complete fixation can take 
hours.  In general, fixation is usually complete within 24 hours [61].  
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Figure 2.4: Molecular structure of genipin. 
Using genipin as a crosslinking agent creates stable collagenous matrices, 
making the tissue less susceptible to enzymatic degradation [57,59-62].  Similarly, 
genipin treatment causes a three-fold reduction in fatigue induced mechanical 
degradation of the tissue [62].  Additionally, compared to glutaraldehyde, genipin 
crosslinking induces a smaller inflammatory reaction and calcium concentration in the 
fixed tissue [60,61,64].  
2.3.2 Mechanical Properties and Biocompatibility 
Crosslinking a tissue with genipin alters the strength, stiffness, and other 
mechanical properties of the tissue.  Genipin treated tissues sometimes experience an 
increase in tensile strength and modulus caused by an increase in crosslinking density 
[59,63]. Additionally, genipin crosslinking produces inter-fibrillar crosslinks, which may 
reduce the ability of the collagen fibers to slide past each other.  Therefore, the tissue 
can be less extensible, which could decrease the overall strain and increase the stiffness 
of the tissue, depending on the degree of crosslinking and the structure of the tissue 
[58,59,65]. Finally, genipin crosslinking also increases the tear resistance by 40% and 
the number of fatigue cycles to achieve failure [62].  
Biocompatibility studies have shown that genipin crosslinking is 2000-3000 times 
less cytotoxic than glutaraldehyde [60,64].  Additionally, genipin exposure is not 
associated with any abnormal symptoms in the liver or kidney, or in hematological or 
histological analysis [64].  However, genipin crosslinking is sensitive to pH changes, with 
the degree of genipin crosslinking concentrations varying at different pH values.   
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Genipin crosslinking at a basic pH is greater than crosslinking at a neutral pH, which is 
greater than crosslinking at an acidic pH [61].  In general, the higher the pH, the more 
reactive the genipin is for crosslinking [61].  
2.3.3 Other uses 
Genipin has successfully crosslinked many other collagenous tissues.  It is being 
investigated for the treatment of osteoarthritis by preventing chemical degradation and 
mechanical wear of articular cartilage [65].  Also, it has been used to treat injuries to the 
tendon and ligaments of horses [62].  Likewise, genipin crosslinking has been 
investigated for treatment of the pericardium, aortic valves, spinal discs, cellular 
scaffolds, knee meniscus injuries, tendons, and ligaments [57,62]. Traditionally, genipin 
has been used for herbal medications, Chinese medicine, treatments of jaundice, and 
various inflammatory and hepatic diseases [63].  Also, the dark blue pigment can be 
derived through the reaction of genipin with an amino acid and used in the fabrication of 
food dyes [60,61]. 
3. Methods 
3.1 Pilot in vivo Study Preparation 
 3.1.1 Study Design 
 The purpose of the in vivo study was to determine the safety and efficacy of 
injecting the equine soft palate with a genipin reagent.  The study was broken down into 
two parts: a safety phase and an efficacy phase.  The safety phase utilized three control 
horses to test the biological effects of the genipin reagent injections, while the efficacy 
phase utilized three DDSP horses to test the success of reducing soft palate vibrations 
and displacements with the genipin reagent injections.  
 To set up the experiment, Dr. Kimberly Sprayberry, DVM from Cal Poly San Luis 
Obispo, provided expert advice for the in vivo study.  Dr. Sprayberry helped by 
answering specific questions about the injection method, finding the DDSP horses, and 
quantifying the snoring sounds.  Working with Dr. Sprayberry, the requirements for the 
pre treatment examinations were set to include both a dynamic endoscope examination 
and a breathing audio recording to confirm DDSP diagnoses and to record the abnormal 
breathing patterns, respectively.   To view the questions and answers in full, see 
Appendix A1.  
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 Dr. Brett Woodie, DVM, MS, Dipl. ACVS from Rood and Riddle Equine Hospital, 
assisted with diagnosing the DDSP horses through dynamic endoscope examinations.  
Dr. Woodie also recommended enrolling horses older than two years old to ensure full 
development of the soft palate.  
 For the sound analysis portion of the study, Dr. Abhijit Patwardhan, Ph.D., a 
professor from the Department of Biomedical Engineering at the University of Kentucky 
with considerable signal-processing expertise, helped guide the appropriate steps.  Dr. 
Patwardhan advised to record all respiratory audio in a non lossy format, such as 
Windows Media Audio (WMA), to avoid automatic data compression of the audio signal 
by the digital voice recorder, which was important because the distinguishing parameters 
between the pre-treatment recordings and the post-treatment recordings were unknown 
at the start of the study. The goals for the sound analysis, outlined with Dr. Patwardhan’s 
assistance, were to objectively measure the snoring volume and to differentiate between 
low frequency and high frequency amplitudes in order to determine shifts in the post-
treatment audio amplitudes from the pre-treatment audio amplitudes.   
 3.1.2 Voice Recorder Design 
 In order to quantify the DDSP snoring noise, a digital voice recorder was utilized 
to record the horses while exercising.  The recordings were then analyzed using the time 
domain and the frequency domain in Matlab to determine any irregular breathing 
patterns and any changes in loudness or frequency of the snoring sounds.  The audio 
recording mechanism consisted of a digital voice recorder, a microphone, and a sturdy 
base. 
 The digital voice recorder had a few specific requirements.  First, it had to pick up 
sounds in a difficult environment with background noise and wind present.  It was crucial 
that voice activated recording (VAR) feature, which is common in most recording 
devices, could be disabled.  This feature causes the recorder to only record when it 
detects frequencies associated with human speech, and since the recorder needed to 
pick up breathing noise, the VAR feature had to be disabled.  Likewise, the recorder had 
to record in WMA or a similar non lossy recording format. Finally, the ideal recorder 
needed to have a microphone jack, a rechargeable battery, and an USB import jack.  
The RCA VR5330R digital voice recorder was chosen because it fit all of the 
aforementioned requirements.  The recorder was set to record in the high quality (HQ) 
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setting at a sampling rate of 8000 Hz.   The specifications for the digital voice recorder 
are in Appendix A2. 
The original recording device design consisted of a headstall with a wire attached 
to support the microphone as shown in Figure 3.1.  The actual device was created using 
wooden shims, duct tape and vet wrap.  Two wooden shims were secured together with 
duct tape to create a sturdy base for the recorder.  Then, the microphone wire was run 
along the length of the wooden shims with the microphone secured at one end.  The 
wooden shims and microphone cord were fully wrapped in vet wrap to cover all rough 
edges of the wood and to protect the microphone cord.  The voice recorder was 
attached on the opposite end of the microphone by wrapping vet wrap around the 
carrying case, ensuring to leave enough room to insert the recorder.  The entire device 
was attached to the halter or bridle using zip ties.  Two to three zip ties were secured on 
either end of the recorder, making sure it was securely attached. The recorder was firmly 
attached on the front of the head or side of the head depending on the horse’s tack with 
the microphone as close to one nostril as possible to minimize background noise as 
shown in Figure 3.2.  The microphone placement was uniform for each individual horse 
throughout the study. 
 
Figure 3.1: The recording device schematic consisted of a headstall or halter with a sturdy wire to 
support the microphone, which was placed near the horse’s nostril.  The digital recorder was 
attached to the horse’s neck or further up the halter.  
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 The recorder’s design integrity was tested using eight non-study horses.  These 
horses were exercised at a variety of speeds with numerous outdoor situations, including 
windy and calm days, to test the effectiveness of the device to record all breathing 
noises.  For all of the test horses, the recorder was attached to the halter on the side of 
the head with the microphone near the nostril, and the horse was exercised at a walk, 
trot and canter. The recordings were then studied to ensure that a variety of breathing 
noises could be heard.   
 3.1.3 Study Enrollment 
Before enrolling any horses in the study, a consent form and a donation form 
were created.  The consent form was used for the efficacy phase horses because the 
original owner maintained ownership throughout the study.  The donation form was used 
for the safety phase horses because the owner relinquished ownership to Orthopeutics, 
LP for the study.  Both forms described the study in detail, including the background of 
genipin, the procedure, and the associated risks.  Additionally, the forms requested 
information about the owner, the horse, and the horse’s veterinary history.  The consent 
form required further information describing the horse’s DDSP history, including the date 
of DDSP onset, the frequency of displacement, the loudness of DDSP snoring, and 
previous surgeries related to DDSP.  It was required that all horses had a completed 
Figure 3.2: The recording device was created with wooden shims and vet wrap and attached to either 
the side or front of the horse’s tack using zip ties to hold it firmly in place.  The microphone 
placement was consistent for each individual horse throughout the study.  
Microphone	 Microphone	
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consent or donation form on file prior to starting the study.  See Appendix A3 for the 
consent form and Appendix A4 for the donation form.  
The efficacy phase horses were located by calling or emailing a list of over 300 
qualified equine veterinarians in Kentucky provided by Dr. Sprayberry to help locate 
three horses diagnosed with DDSP.  The requirements for the DDSP horses were that 
they must be at least two years old, be either thoroughbreds or Standardbred 
racehorses, and be free of any breathing abnormalities except for DDSP.  Ideally, the 
DDSP horses would not have any previous surgeries or treatments for DDSP that would 
affect the structural or biological composition of the soft palate.  See Appendix A5 for the 
sample transcript of the emails and phone calls made to the veterinarians.  
 The safety phase control horse requirements included having no breathing 
issues, being older than two years old, and being thoroughbreds, Standardbred 
racehorses, or similar breeds. Originally, the plan was to purchase cheap yearling 
thoroughbreds that were not eligible to enter the thoroughbred sale for racing, and that 
were designated for euthanasia by their owners.  However, per Dr. Woodie’s 
recommendation, horses younger than two years old were not enrolled in the study 
because their soft palates may not be fully developed at an immature age.  Therefore, 
donated horses or purchased horses meeting the requirements were accepted as 
control horses.  
 Once all of the horses were enrolled, pre treatment examinations were 
completed.  First, each efficacy phase horse underwent either a dynamic endoscope 
examination or provided previous documentation of a DDSP diagnosis from within one 
calendar year of the projected study start date.  Dr. Woodie completed the dynamic 
endoscopic examinations using either a treadmill located at Rood and Riddle Equine 
Hospital or using a portable dynamic endoscope at a remote location.  
 The second stage of the pre treatment testing was to record each DDSP horse 
while exercising to document abnormal respiratory noises.  The goal was to record any 
roars, snores, vibrations, or breathing gaps associated with soft palate displacement.  
Each horse was recorded for 20 minutes at a walk, trot, and canter to ensure adequate 
snoring and palate displacements.   
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 3.1.4 Reagent Preparation 
 The genipin reagent used in the treatment consisted of two parts contained in 
two different vials: the genipin powder and the buffer solution.  The reagent was a 100 
mM concentration of genipin powder in a 10% Dimethyl sulfoxide (DMSO), 45 mM 3-[4-
(2-Hydroxyethyl)-1-piperazyl]propane sulfonic acid phosphate (EPPS-P) buffered 
solution.  Assistance in preparing the reagent components was received from Dr. 
Matthew Brown of Orthopeutics, LP/Crosscoat Medical, LLC in Lexington, KY. 
 To prepare the genipin vials, the vials, caps and lids were sterilized using 
autoclave sterilization.  Then, 45.24 ± 0.05 mg of cGMP genipin powder (CAS# 6902-77-
8) from Wilshire Technologies was placed into each vial with a disposable scoop to 
create a 100 mM buffer solution.  The rubber cap was placed in the bottle and crimped 
shut.  A total of 12 vials of genipin powder were prepared and shipped to STERIS 
Isomedix Services for terminal gamma irradiation for sterilization.  
To prepare the 45 mM EPPS-P buffer solution with 10% DMSO added, the vials, 
caps and lids were sterilized using autoclave sterilization.  Then 22.5 mL of 100 mM 
EPPS-P buffer, 22.5 mL of deionized water, and 5 mL of DMSO were combined into a 
bottle, through a 0.2µm sterile filter in a sterile hood.  Then, 2 mL of the buffer solution 
was distributed into 12 sterile vials. The DMSO was added to the buffer to increase 
solubility of the genipin.  Phosphate was added to the EPPS solution initially to catalyze 
the genipin crosslinking reaction.  
 Adding 2 mL from one buffer vial to one genipin power vial would produce 2 mL 
of the 100 mM buffered genipin reagent.  One reagent vial was sufficient for two 1 mL 
injections for the soft palate. Appendix A6 shows the calculations for the genipin powder 
and buffer solution. 
3.2 Pilot in vivo Study 
 3.2.1 Study Logistics 
 Due to grant requirements, the pilot in vivo study had to be completed in an 
Association for Assessment and Accreditation of Laboratory Animal Care International 
(AALAC) and Office of Laboratory Animal Welfare (OLAW) approved facility.  Therefore, 
the in vivo study was conducted at Sinclair Research Center (SRC), in Columbia 
Missouri.  All of the study horses had to be shipped to SRC, and the efficacy phase 
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horses had to be shipped back from SRC upon study completion. All six horses arrived 
to SRC by September 15, 2014, allowing for a one-week acclimation phase. Overall, the 
study lasted three weeks, with one week of acclimation, one injection day, three 
observation recovery days, and one week of post study recovery.   
3.2.2 Equine Arrival and Acclimation 
 Upon arrival at SRC, SRC personnel performed full veterinary examinations on 
each horse.  During the one-week acclimation phase, the horses were individually 
housed in appropriately sized box stalls within an enclosed large animal facility 
according to floor space criteria provided by the USDA animal welfare requirements.  
Horses were fed grain supplied by their owners as directed, and given unlimited access 
to fresh water and hay ad libitum.  The horses were hand walked twice per day for 
exercise.  Generalized exams and observations were completed twice a day throughout 
the course of the study.   
3.2.3 Soft Palate Treatment  
 Dr. Fabio Aristizabal, DVM from UC Davis, completed all soft palate injections.  
SRC veterinarians monitored the horses throughout the injection process.  Dr. Thomas 
Hedman, Ph.D. of Orthopeutics, LP/Crosscoat Medical, LLC and SRC personnel were 
also present to assist and to observe the procedures.  
 To begin the injections, a SRC veterinarian examined each horse.   After receiving 
a clean bill of health, the horse was sedated with the appropriate dose of intravenous 
detomidine and butorphanol according to the animal’s weight.  The horse was then led 
into a stockade and given ample time to ensure full sedation. Then, a 1-meter long, 9 
mm-outer diameter fiberoptic endoscope was inserted into one nostril and advanced into 
the larynx.  Dr. Aristizabal examined the soft palate to ensure there were no 
abnormalities.  Approximately 10 to 20 mL of 2% lidocaine was then sprayed onto the 
surface of the caudal margin of the soft palate through the injection port of the 
endoscope to induce topical local anesthesia.  
 Concurrently, the genipin buffered reagent was prepared.  For each injection, 2 
mL of the 45 mM EPPS-P buffer solution with 10% DMSO was injected into one vial of 
the genipin powder.  The solution was then shaken vigorously for about ten minutes until 
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all of the particles were fully dissolved.  Throughout the procedure, the buffer and 
genipin vials were stored at room temperature.  
 After allowing several minutes for the lidocaine to take effect, the soft palate 
injections were completed.  The endoscope was advanced through one nostril to the soft 
palate, and a transendoscopic injection needle was passed through the endoscope’s 
biopsy port and positioned over the area on the opposite side of the soft palate to inject 
the reagent.  Each horse was injected with two 1 mL injections of the genipin buffered 
reagent in the 5:00 and 7:00 positions on the soft palate, with the epiglottis occupying 
the 6:00 position, as shown in Figure 3.3.  The first horse received two 1.5 mL injections 
of the genipin buffered reagent due to accidentally injecting too much reagent.  After 
ensuring the needle was in the correct position, 1.5 mL of the reagent was drawn up into 
the syringe, and the needle was primed.  The transendoscopic needle maintained a 
loading volume of 0.5 mL in the tube, so it was crucial to load 1.5 mL of the reagent 
solution into the syringe to ensure the desired 1 ml of the reagent was injected into the 
soft palate. The needle was then pushed forward into the tissue with a quick, controlled 
thrust in order to penetrate the epidermal covering of the palate.  Once the needle was 
placed in the proper location in the soft palate, the reagent was injected using 1 mL of 
air.  The endoscope was then removed and reinserted through the other nostril for the 
second injection.  After both injections were complete, the horse was led back into the 
stall for recovery.  This procedure was repeated for all six horses. 
 
Figure 3.3: The 5:00 and 7:00 injection positions are represented by the black dots on the soft palate 
when viewed through an endoscope inserted from the nasal cavity of the horse. 
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 For the first 72 hours post treatment, the horses were monitored around the clock 
with veterinary examinations every hour.  Food and water were withheld until the horse 
was fully recovered from the sedation. The horses remained at SRC for one-week post 
treatment to allow for full recovery before traveling.  
 The three safety phase horses were euthanized seven days post treatment, and 
their soft palates were harvested. The horses were sedated with Detomidine (0.02 
mg/kg) and Butorphanol (0.03 mg/kg) intravenously.  Fatal Plus (1mL/4.5 kg) was 
injected for final euthanasia.  The soft palates were harvested, stored on dry ice, and 
shipped to Orthopeutics, LP in Lexington, KY for further analysis.  The horses were 
properly disposed of by SRC.  
 The three efficacy phase horses were returned to their owners 12 days post-
treatment for post-treatment examinations.   
3.2.4 Post Treatment Examinations 
 Two weeks post treatment, the efficacy phase horse owners reported on the 
exercise tolerance, breathing sounds, and general well-being of each horse compared to 
pre treatment conditions.  
 Post treatment dynamic endoscope examinations were conducted on the efficacy 
phase horses. Additionally, respiratory recordings were completed post treatment for 20 
minutes at full speed for each individual horse.  The dynamic endoscope examinations 
and the breathing recordings were delayed until approximately six weeks post treatment 
to allow the horses to be trained back into the same exercise condition as demonstrated 
in the pre treatment examinations   
3.2.5 Respiratory Audio Analysis 
  The sound analysis was completed using MATLAB.  As per Dr. Patwardhan’s 
suggestions, the sound analysis was broken down into the time domain and frequency 
domain in low frequency ranges and high frequency ranges.  The specific steps to 
analyze the breathing audio were determined as follows.  First, have a DDSP 
professional classify the snoring sound for validation.  Then, create a data set with 
control and DDSP horse breathing.  Next, analyze the audio in the time domain and 
frequency domain.  Finally, complete blind testing to determine the results of the 
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program.   Figure 3.4 represents the respiratory audio analysis steps completed using 
Matlab.  
 
Figure 3.4: Each sound file was broken down into 1, 3 and 20 exhale groups for analysis in the time 
domain and frequency domain in Matlab. 
 The audio samples were about 20 minutes long, recording from the time when the 
recorder was attached until it was removed.  Therefore, the samples were cut down 
using Audacity 2.1.1 (Computer Program, 2015), an audio editor and recording program, 
to remove the excess audio that was not required, leaving only the audio from the horse 
exercising at full speed.  Each recording was approximately five minutes long after 
removing the excess audio.  Then, the time locations of palate displacements were 
determined by noting where loud snores or where gaps in breathing occurred.  The loud 
snores and breathing gaps indicated a palate displacement because the wind pipe was 
obstructed.  Using the palate displacement time locations, the samples were further 
broken down into 1, 3, and 20 exhale recordings for various analyses. The one exhale 
(1E) recordings were analyzed using the frequency domain only.  The three exhales (3E) 
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recordings were analyzed using the time domain, spectrograms, and the frequency 
domain.  The 20 exhales (20E) recordings were analyzed using the time domain.  
 Individual programs were created in Matlab (Mathworks Matlab, R2014a Student 
Version) to analyze 1E, 3E, and 20E recordings, with the 3E program shown as an 
example in Appendix A7.  After the programs were finalized and validated using control 
respiratory recordings, the pre treatment and post treatment sound recordings for each 
horse in the efficacy phase of the pilot in vivo study were analyzed. For all programs, the 
first step was to import the desired files.  Then, the length and time of the files were 
determined.  
 Next, the 3E and 20E programs analyzed the files in the time domain.  The time 
domain was used to locate any gaps in the breathing pattern caused by a soft palate 
obstruction.  Additionally, the pattern and amplitudes of each exhale was compared for 
pre and post-treatment recordings.  To do this, the moving average was used to filter the 
data, which is done by creating a series of averages for different divisions and shifting it 
along the full data set to filter the file.  For each audio file, the divisions used for 
averaging were one-fourth of the entire data set, with a=1 and b= [¼ ¼ ¼ ¼ ] for the 
filter function in Matlab. Then, the time domain for pre treatment recordings and post 
treatment recordings were plotted in one window for easy comparisons with time on the 
x-axis and amplitude on the y-axis.  
 Then, the 3E programs plotted spectrogram graphs to visually determine changes 
in sound amplitude across all frequency ranges.  Spectrogram graphs were not plotted 
for the 1E programs because there was insufficient data with only a single exhale shown 
in the spectrogram.  Additionally, the 20E spectrogram graphs were not plotted because 
they did not provide any additional information compared to the 3E spectrogram graphs. 
The spectrograms were plotted using the spectrogram function with a window (nwin) of 
1024 samples and an overlap (noverlap) of 768 samples.  For each graph, the x-axis 
represented time, the y-axis represented frequency, and the color intensity represented 
amplitude from -40 to -120 V as demonstrated in Figure 3.5.   The spectrogram graphs 
for pre treatment and post treatment recordings were plotted in one window for 
comparison. 
 After creating the spectrogram graphs in Matlab, the total red area representing 
high amplitudes was analyzed using ImageJ software to determine the percent 
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difference between pre and post treatment recordings.  To do this, the Matlab 
spectrogram was saved as a JPEG and imported into ImageJ.  Once imported, the 
graph was split into three 8-bit images representing the red, green and blue color 
channels.  When separating color channels, a filter is applied to the image to 
differentiate red, green and blue colors.  For example, for the green color channel, a filter 
is applied that blocks any green pixel from passing through, causing it to appear white in 
the final picture.   The filter allows any pixel that is not green to pass through, 
representing it as black or as a shade of gray. Therefore, the green channel best 
mapped the red high amplitude pixels in the spectrogram graph because the red area 
appeared as black after the channel filter was applied as illustrated in Figure 3.6.  Then, 
the threshold was adjusted using the default values to intensify the pixels, which fall into 
the intensity range from 0 to 160.  Pixels with an intensity of 0 represented black and an 
intensity of 255 represented white [65]. Finally, the total area and percent area of the 
number of pixels were calculated through the analyze particles feature in ImageJ.  These 
steps were completed for all the pre treatment and post treatment spectrograms, and a 
detailed protocol is shown in Appendix A8.  The percent difference was calculated to 
determine the change in the total area of the high amplitude red squares in the 
spectrogram graphs using Equation 1. 
%𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =
𝑃𝑜𝑠𝑡 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝐴𝑟𝑒𝑎 − 𝑃𝑟𝑒 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝐴𝑟𝑒𝑎
𝑃𝑟𝑒 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝐴𝑟𝑒𝑎
 𝑥 100%    (𝐸𝑞. 1) 
 
Figure 3.5: An example spectrogram graph shows the various colors present with red representing 
the high amplitude noises and blue representing the low amplitude noises.  
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Figure 3.6: The red (left), blue (middle), and green (right) channel graphs produced by ImageJ 
display the different color pixels depending on which filter is applied to the original image.  In this 
case, the green channel best represents the shape of red squares in the original spectrogram graph. 
 Finally, the 1E and 3E programs were analyzed using the frequency domain.   
First, the recordings were transformed into the frequency domain using the fast Fourier 
transform (FFT).  Once in the frequency domain, the entire pre treatment and post 
treatment graphs were plotted with frequency on the x-axis and amplitude on the y-axis.   
Then, the frequency domain signals were filtered using the moving average to remove 
noise.  The original frequency domain graph and the filtered graph were plotted on a 
single graph for comparison for both the pre treatment and post treatment files.   
 The high amplitude frequency range was analyzed in relation to palatal 
displacement “whistling” noises.  The filtered signals for the pre and post treatment audio 
was plotted from 500 to 4000 Hz.  The low-end frequency was set to 500 Hz because 
that was the cutoff frequency for the laser non-contact displacement measuring system 
used in the wind tunnel study.  With a data collection rate of 8 kHz, the Nyquist 
frequency for the samples was 4000 Hz, so that was used as the maximum point in the 
graph.  
 The low amplitude frequency range was analyzed in relation to snoring loudness 
because typical snoring sounds occur below 200 Hz.  First, frequency domain graphs 
were created from 0 to 500 Hz because frequencies less than 500 Hz would contain the 
sounds related to snoring caused by vibration of the soft palate according to Dr. 
Patwardhan.   Also, 500 Hz was the cutoff frequency for the laser system used during 
the wind tunnel study.   Next, the frequency domain graphs were plotted from 0 to 200 
Hz because 200 Hz is the typical maximum frequency used for human snoring analysis 
[39,40].  Then, the frequency domain graphs were plotted form 0 to 100 Hz to 
correspond with palatal vibrations.   For the low frequency domain graphs, the area 
under the curve was used to determine the percent difference between the pre-treatment 
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and post-treatment audio recordings.  The area under the curve was calculated using 
the trapz function in Matlab and plotted on the corresponding graph as demonstrated by 
Figure 3.7.  Percent difference was calculated using Equation 1. 
 
Figure 3.7: For each pre treatment and post treatment frequency domain graph, the area under the 
curve was calculated and highlighted as demonstrated in the graph above. 
 Finally, as previously mentioned, a study completed by Franklin et al. discovered 
a peak in the frequency domain corresponding to DDSP.  Based on their results, the 
peak appeared at 41±21Hz for the in vitro horses and 53±24 Hz for in vivo study horses 
with DDSP, as shown in Figure 3.8 [55].  Therefore, the 1E frequency domain graphs 
were analyzed from 20 Hz to 80 Hz to include the average ‘DDSP Peak’ location plus 
one standard deviation on either side.  Only 1E was analyzed in this range to best 
compare to the results from the previous study, which only analyzed one exhale at a 
time.  These graphs were used to determine if the ‘DDSP Peak’ existed before or after 
treatment with the genipin injections in relation to the study completed by Franklin et al.  
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Figure 3.8: The DDSP peak occurs in the 20-80 Hz range in the frequency domain as demonstrated 
by the peaks from the cadaveric in vitro DDSP study results (top) and the in vivo study results 
(bottom) [55]. 
3.2.6 Histological Analysis 
 The three soft palates harvested from the safety phase horses were thawed for 24 
hours and sectioned for histological analysis.  Each palate was cut in half along the 
median, and then three sections were cut perpendicular to the median from each lateral 
half palate, producing six samples for each palate for a total of 18 samples.  Two 
samples from treated regions of tissue as determined by the visual observation of the 
blue coloration due to genipin crosslinking, and one sample from an apparently 
untreated region of tissue were sectioned from each soft palate half.  Figure 3.9 shows 
the specific sections used for each palate.  Samples were taken from the internal portion 
of the sample along the sagittal plane so that each histology slice would contain both the 
oral and respiratory mucosal layer.  A suture was placed in each sample on the opposite 
side of the cutting plane. The samples were labeled according to the original location on 
the soft palate and placed in beakers with 100 mL of 10% formalin for six days.  Then, 
the samples were packaged into separate 50 mL tubes of 70% ethanol and shipped via 
FedEx ground to IDEXX BioResearch Pathology Services (IDEXX) in Columbia, MO for 
histological analysis.    
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Figure 3.9: Each soft palate was divided in half and then three sections were cut from each half in 
the general areas shown in the figure.  At least one of the samples from each side was cut from a 
perceived untreated section of the palate. 
 Dr. Cynthia Besch-Williford, a licensed veterinary pathologist, at IDEXX completed 
the histological analysis.  All biopsies were sectioned in the sagittal plane such that both 
mucosal surfaces along with the submucosal and muscular components were 
represented.   Tissues were processed for paraffin infiltration, blocked, sectioned, 
stained with H&E and examined microscopically.  Observed microscopic changes were 
described as to the extent and grade of inflammation and fibroplasia using terms 
including minimal, mild, moderate, and marked.  
3.3 Soft Palate Mechanical Testing  
 3.3.1 Study Preparation 
 The soft palate mechanical testing study was completed to determine any 
mechanical property changes in the soft palate after injecting it with 50 mM genipin 
solution. The genipin was mixed with a saline solution that would be available in most 
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hospital or laboratory settings. Phosphate was added to the solution to catalyze the 
reaction.  
 A total of 12 cadaveric equine soft palates were separated into four sections and 
put into three testing groups: control (no injection), buffer-only injection or genipin 
injection. The samples were mechanically tested to compare the hysteresis, stress 
relaxation and tensile properties of each sample.  
 3.3.2 Reagent Preparation 
 The genipin powder was premeasured and placed into individual glass vials.  
Each vial contained 22.6 ± 0.5 mg of genipin (CAS#6902-77-8) from Wilshire 
Technologies in order to create a concentration of 50 mM when mixed with 2 mL of the 
buffer solution. A total of 10 vials were created.  
 To make the buffer solution, saline was combined with phosphate to create a 50 
mM phosphate solution.  First, the 0.9% saline was made by adding 9.0 grams of NaCl 
(CAS#7647-14-5) to 1000 mL of deionized water and shaking vigorously until fully 
dissolved.  Then, 19.0 grams of sodium phosphate tribasic dodecahydrate (CAS# 
10101-89-0) was added to the 1000 mL saline solution, creating saline with a 50 mM 
phosphate concentration.  See Appendix B1 for full calculations for the genipin and 
buffer solution. 
 3.3.3 Sample Preparation 
 Twelve frozen cadaveric equine soft palates were received from Conboy 
Enterprises, Inc. in Lexington, KY. The soft palates included the entire upper respiratory 
tract, including the trachea, larynx, epiglottis, soft palate, and the surrounding bones, 
muscles, tendons and ligaments.  The palates were thawed for 24 hours.  After thawing, 
the soft palates were excised from the surrounding tissue.  To remove, the tissue above 
the palate was cut in half along the median to expose the epiglottis and soft palate.  The 
epiglottis was placed below the notch in the soft palate.  Then, the palate was removed 
by cutting along the outside edge of the palate.  The edges of the V-notch of the palate 
were removed by cutting along the bones. Once the palate was removed, it was 
examined and trimmed to ensure only the soft palate was present. The other tissue was 
discarded appropriately.  See Appendix B2 for the soft palate extraction protocol 
supplemented with pictures. 
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 The soft palate was then divided into four samples, cut along the V-notch of the 
palate.  First, the soft palate was divided along the midline, and then two samples, 
approximately 2 cm wide, were cut along the V-notch, or free edge, of the palate. The 
samples cut from the first spot next to the free edge of the palate were labeled as tops, 
and the samples cut closer to the hard palate were labeled as bottoms, as demonstrated 
in Figure 3.10. The samples were divided among the three groups according to the chart 
in Figure 3.11. 
 
Figure 3.10: The two samples, #1 and #2, sectioned from the free edge of the palate were labeled as 
tops.  Section #3 and #4 were labeled as bottoms.  The excess tissue near the hard palate was 
discarded. 
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Figure 3.11: Each soft palate sample was divided into a test category based on the schematic above.  
The test categories were rotated among the palates to randomize the groupings. 
 Samples in the control group were wrapped in a saline soaked paper towel, 
sealed in a plastic bag filled halfway with saline to maintain tissue moisture, and put on a 
shaker plate at room temperature. Samples in the buffer group were injected with 0.5 mL 
of the buffer solution using a 22 g, 1” needle. The injections were administered about 
halfway down the length of the sample.  The needle was inserted at an angle of 
approximately 30 degrees from the horizontal.  The reagent was delivered with uniform 
pressure over five seconds.  The sample was wrapped in a saline soaked paper towel, 
placed in a sealable plastic bag halfway filled with saline, and put on a shaker plate at 
room temperature.  Samples in the genipin group were injected with 0.5 mL of the 
genipin reagent using a 22 g, 1” needle. The injections were administered about halfway 
down the length of the sample.  The needle was inserted at an angle of approximately 
30 degrees from the horizontal as demonstrated in Figure 3.12.  The reagent was 
delivered with uniform pressure over five seconds.  The sample was wrapped in a saline 
soaked paper towel, placed in a sealable plastic bag halfway filled with saline, and put 
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on a shaker plate at room temperature.  Pre-treatment sample height, length, and width, 
as well as injection time were recorded.  
 
Figure 3.12: The needle was placed about halfway down the length of the sample.  The reagent was 
uniformly injected as the needle was pulled back out of the sample to ensure even coverage and to 
prevent pillowing of the palate. 
 All samples remained on the shaker plate overnight for 12-15 hours at room 
temperature to allow the genipin plenty of time to diffuse.  After incubation, all samples 
were necked down to approximately 1 cm wide by 1 cm long in the middle using a 
circular metal punch as seen in Figure 3.13.  Necking height, length, and width were 
recorded.  
 
 
 
Figure 3.13: After incubating overnight, the soft palate samples were necked down to ensure failure 
in the middle during the tensile test. 
 3.3.4 Mechanical Testing Protocol 
 All samples were mechanically tested using a materials test system (Test 
Resources 100R1000) via a protocol including hysteresis, stress relaxation and tensile 
loading to failure tests, as shown in Appendix B3.  The sample was loaded into the 
tensile testing machine and secured using the grips at a gauge length of 42 mm.  To 
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prevent slippage, both ends of the tissue were wrapped in a Chem-Wipe to reduce 
wetness and increase grip.  
 The hysteresis test was performed first.  A force of 10 N was loaded onto the 
sample.  The test resources machine was then set up to perform a hysteresis test of 20 
cycles with a displacement of +/- 3mm from the starting point at a rate of 5 mm/s.  The 
time (s), stroke (mm), load (N), torque (N-mm) and angle (deg) were recorded at a 
sampling rate of 50 Hz.  
 The stress relaxation test was performed next.  Again, a force of 10 N was applied 
to the sample.  The sample was then held at that constant displacement for five minutes. 
Upon completion of the five minutes, the force was reduced to zero, and the sample 
rested for one minute. Again, the time (s), stroke (mm), load (N), torque (N-mm) and 
angle (deg) were recorded at a sampling rate of 25 Hz.  
 Finally, the tensile test to failure was performed.  Starting from 0 N, the machine 
loaded the tissue in tension until failure at 1 mm per second. The time (s), stroke (mm), 
load (N), torque (N-mm) and angle (deg) were recorded at a sampling rate of 50 Hz.  
After the genipin samples failed, the approximate percent of blue fibers in the failure 
region was noted by looking at the surface fibers of the torn region.  
 3.3.5 Mechanical Testing Analysis 
 Hysteresis was calculated as the area between the loading up and loading down 
curves for each sample. To determine the change in hysteresis and the hysteresis ratio, 
the time (s), stroke (mm) and load (N) data from the mechanical test was utilized.  The 
starting point was used to offset the stroke data to find the absolute displacements.  For 
example, if the starting point was -42 mm, the stroke data was offset by 42 mm.  Then, 
strain was determined by dividing the displacement by gauge length.  Finally, stress in 
MPa was calculated by dividing the load by the cross-sectional area of the tissue.  
 To determine the 1st and 20th cycles of the hysteresis plot, the cyclical loading was 
plotted with load in Newton on the y-axis and time in seconds on the x-axis as shown in 
Figure 3.14.  The first cycle was determined to be from the first local minimum to the 
second local minimum as shown in red.  The last cycle was determined to be from the 
19th local minimum to the 20th local minimum as shown in black.   Then, the 
corresponding local minimum points were extracted and graphed to create the individual 
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cycle hysteresis curves with stress on the y-axis and strain on the x-axis.  For the first 
cycle, the stress and strain were plotted from corresponding values at the 1st local 
minimum point to the 2nd local minimum point as shown in Figure 3.15.  For the last 
cycle, the stress and strain were plotted from corresponding values at the 19th local 
minimum point to the 20th local minimum point as shown in Figure 3.15, as well.  Finally, 
the entire hysteresis curve was plotted with strain on the x-axis and stress on the y-axis 
as shown in Figure 3.17.  The 1st and 20th cycles were highlight in red and black 
respectively.  
 
Figure 3.14: To determine the location of the 1st and 20th cycles of the hysteresis curve, the loading 
cycles versus time were plotted.  The 1st cycle was taken from the 1st local minimum to the 2nd local 
minimum, and the 20th cycle was calculated form the 19th local minimum to the 20th local minimum. 
 
Figure 3.15: The 1st and 20th cycles were plotted in relation to stress and strain to determine the 
hysteresis. 
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Figure 3.16: The entire hysteresis curve was plotted with the 1st and 20th cycles highlighted to see 
their relation to the rest of the cycles. 
 Finally, the contribution toward the hysteresis calculation for each individual set of 
adjacent data points was calculated using Equation 2, with stress point 1 and stress 
point 2 representing the individual stress points throughout the hysteresis cycling.  
𝐼𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝐻𝑦𝑠𝑡𝑒𝑟𝑒𝑠𝑖𝑠 = !"#$%% !"#$% !!!"#$%% !"#$% !
!
∗ (𝑆𝑡𝑟𝑎𝑖𝑛 2 − 𝑆𝑡𝑟𝑎𝑖𝑛 1)   (Eq. 2) 
Once all of the individual hysteresis values were calculated, the total hysteresis for the 
loading curve and the total hysteresis for the unloading curve were calculated for the 1st 
load-unload cycle.   The total hysteresis for the loading curve was calculated by adding 
together all of the individual hysteresis values from the 1st local minimum to the 1st cycle 
maximum.  The total hysteresis for the unloading curve was calculated by adding 
together all of the individual hysteresis values form the 1st cycle maximum to the 2nd local 
minimum.  Then, the difference between the loading curve total hysteresis and the 
unloading curve hysteresis was calculated to determine the area between the curves.  
This was repeated for the 20th cycle.  Finally, the change in hysteresis between the 1st 
and 20th cycles was calculated by subtracting the 20th cycle hysteresis from the 1st cycle 
hysteresis.  Additionally, the hysteresis ratio was calculated by dividing the 20th cycle 
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hysteresis by the 1st cycle hysteresis.  Examples of hysteresis calculations are shown in 
Appendix B4.  
  Using the load (N), time (s), and stroke (mm) data from the stress relaxation test, 
the stress relaxation was calculated as the decrease in stress over a five-minute period.  
First, the offset displacement was added to the stroke to find total displacement, and 
then the displacement divided by the gauge length was used to determine the strain.  
Next, stress in MPa was calculated by dividing the load by the cross-sectional area.   
Using the stress in MPa and time in seconds, the stress relaxation curve was plotted as 
demonstrated in Figure 3.17. Then, stress relaxation was calculated by subtracting the 
minimum stress value from the maximum stress value.  Next, relaxation modulus was 
calculated by dividing the stress by the constant strain according to Equation 3, and then 
the overall relaxation modulus was determined by subtracting the minimum modulus 
value from the maximum modulus value.  Finally, normalized relaxation modulus was 
calculated by normalizing the strain used in Equation 3 by dividing the individual sample 
strain by the average strain for each test group.   
𝑅𝑒𝑙𝑎𝑥𝑎𝑡𝑖𝑜𝑛 𝑀𝑜𝑑𝑢𝑙𝑢𝑠 (𝑡) =  !(!)
!
  (Eq. 3) 
 Examples of the stress relaxation test calculations are shown in Appendix B5.  
 
Figure 3.17: The stress relaxation graph for each sample was plotted to demonstrate the relaxation 
of the specimen over time. 
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 The tensile test to failure data was utilized to calculate a variety of elastic-plastic 
parameters using stroke (mm) and load (N), including ultimate tensile stress, ultimate 
tensile strain, Young’s modulus, toe region slope, yield point stress, yield point strain, 
toughness and resilience.  Using the stroke (mm) from the mechanical testing data, the 
values were offset based on the starting stroke.  For example, if the test begins at -42 
mm, the stroke values were offset by 42 mm to get the actual deformation of the 
specimen.  Then the strain was calculated by dividing the deformation by the gauge 
length.  Using the load (N) data from the mechanical test, stress was calculated by 
dividing it by the smallest cross-sectional area of the specimen.  The maximum stress 
was used to determine the ultimate tensile stress. The ultimate tensile strain was the 
strain at the maximum stress point.   The ultimate tensile stress and strain occurred at 
the maximum point in the graph as illustrated in Figure 3.18 by the black arrow. 
Next, the stress versus strain graph was plotted with stress on the y-axis and 
strain on the x-axis to find the next parameters as demonstrated in Figure 3.18.  First, 
the toe region was calculated by plotting the points from the first non-zero stress value to 
0.05 MPa and adding a polynomial trend line raised to the 2nd power.  The toe region 
slope, which measured the straightening of the collagen fibers as they began to 
experience load, was the slope of the toe region trend line as shown in purple.  Next, the 
start of the linear region was determined by moving 50 values past the last value of the 
toe region.  The linear region was determined to be the next 150-200 values past the 
starting point, as long as there was no obvious break in linearity in the graph as shown in 
green.  A linear trend line was plotted for this region. Young’s modulus, which measured 
the stiffness of the tissue, was considered to be the slope of the linear region trend line.   
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Figure 3.18: The ultimate tensile stress and strain were determined by the maximum location on the 
graph as illustrated by the black arrow.  The toe region slope and Young's modulus were also 
determined from the toe region and linear region, respectively. 
Then, the linear region trend line was offset by 0.2% strain, and the resulting line 
was plotted.  From the intersection of the offset strain line and the stress-strain curve, 
the yield point was calculated as the point that the tissue begins to plastically deform 
leading to permanent tissue damage as shown in Figure 3.19.  The x and y values at the 
yield point were the yield strain and yield stress as demonstrated by the black arrow.  
The toughness was defined as the ability to deform the tissue up to the fracture point, 
and the area under the entire stress-strain curve calculated it as demonstrated by the 
orange highlighting in Figure 3.20.  From the toughness value, the energy required to 
deform the tissue was calculated by multiplying the toughness by the cross-sectional 
area.  Likewise, the resilience was defined as the ability of a material to absorb energy 
when it is deformed elastically, and it was calculated by determining the area under the 
stress-strain curve up to the yield point as shown by the red highlighting in Figure 3.21 
[66-68].  Examples of the tensile test to failure calculations are shown in Appendix B6. 
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Figure 3.19: The yield point was determined by offsetting the linear region line by 0.2% strain and 
calculating the intersection point of the two lines, as demonstrated by the arrow in the graph. 
 
Figure 3.20: Toughness was calculated by the area under the stress-strain curve as represented in 
orange. 
	 50	
 
Figure 3.21: Resilience was calculated as the area under the stress strain curve up to the yield point 
as highlighted in red.  
 After all of the parameters were calculated for each sample, the outliers, 
determined by the three-sigma rule, were removed from the data set.  Any samples that 
had results more than three standard deviations away from the mean were noted as 
outliers in that category.  If a sample had more than five total outliers across all 
categories, the sample was determined to be an overall outlier and removed from the 
analysis.  
 The averages and standard deviations for each parameter were calculated for 
individual control, buffer, and genipin groups.  Likewise, each group was broken down 
into the tops group and the bottoms group, corresponding to the position of the sample 
relative to the soft palate as previously demonstrated in Figure 3.10, and the averages 
and standard deviations for each parameter were also calculated.  Percent differences 
between the parameters of the different groups were computed using Equation 4.  
%𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 = (!"#$!%# !"#$%! !"#"$%&%#!!"#$!%# !"#$%! !!"!#$%$")
!"#$!%# !"#$%! !"#"$%&%#
∗ 100 (Eq. 4) 
Any parameters with a percent difference greater than 30% were noted.  
 Statistical analysis was completed to determine if the means of the different 
groups were statistically significant.  The first group compared was the control samples 
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versus the buffer treated samples, comparing the top samples only, the bottom samples 
only, and all of the samples combined.  This was used to verify that there was no 
significant difference in the mechanical properties caused by the buffer treatment alone.  
The same statistical comparisons were compared for the buffer samples versus the 
genipin treated samples.  This comparison was used to determine any significant 
differences in the mechanical properties as a result of the genipin treatment.    Either a 
two-sample t-test with independent sample groups or a non-parametric Mann-Whitney 
test was completed based on the results of the F test.  
The two-sample t-test with independent groups determined whether the means of 
two groups were different.  To complete a two-sample t-test, the following assumptions 
were made [70]: 
• The two groups were independent variables.   
• Each observation within the group was independent of the other 
observations in the group.  
• The variables followed a normal distribution with the same variance.  
The Mann-Whitney test compared the median differences between the two 
groups.  The assumptions followed for the Mann-Whitney were [70]: 
• The two groups were independent of one another.  
• The results were ordinal.  
• The samples within each group were independent. 
• The variables did not have to be normally distributed.  
To decide the appropriate statistical analysis test for each group, the F-test was 
completed to determine if the sample variances of the two populations were equal.   
Equation 5 was used to calculate the F statistic [70].  
𝐹 =
(𝑑𝑓! ∗ 𝑆!
!
𝜎!!
) 𝑑𝑓!
(𝑑𝑓!" ∗ 𝑆!
!
𝜎!!
) 𝑑𝑓!
     (𝐸𝑞. 5) 
Then, the Fcrit value was determined using an F-table.   If the F value was greater than 
the Fcrit value, the variances were considered to be different.  If the F value was less than 
the Fcrit value, the variances were considered to be the same.  For the comparisons that 
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passed the F-test, a t-test was completed because all assumptions of the t-test could be 
met.  For comparisons that failed the F-test, a Mann-Whitney test was completed 
because the sample variances were determined to be different resulting in not being 
able to meet all of the t-test assumptions.    
4. Results and Discussion 
 This section discusses the results of the pilot equine in vivo study and the soft 
palate mechanical testing study.  Throughout this chapter, the results from the wind 
tunnel study conducted previously by Dr. Kuo, as discussed in Chapter 1, are referenced 
in relation to the results of the in vivo and mechanical testing studies.  
4.1 Pilot in vivo Study Results 
This section goes into further detail about the results of the pilot equine in vivo 
study, including the outcomes of dynamic endoscope examinations and the respiratory 
audio recordings.   
4.1.1 Voice Recorder Design Testing 
Prior to conducting tests on the in vivo study horses, the recorder design integrity 
was tested using eight non-study horses to verify that the recorder could distinguish a 
variety of breathing noises in various exercising conditions.   All eight of the non-study 
horses were equipped with the recorder on the side of the halter and exercised at a 
walk, trot, and canter as shown in Figure 4.1.  The recordings took place in windy 
conditions and in calm conditions.  The recorder was able to pick up a variety of exhales, 
snorts, coughs, and other respiratory noises.   Additionally, the design of the recorder 
was sturdy enough to withstand being smacked against a gate by one of the horses.  
Overall, the recorder was determined to be successful because it could pick up a variety 
of noises in different environmental conditions, as well as withstand physical abuse by 
the horses throwing or moving their heads. 
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Figure 4.1: The recording device was tested on non-study horses to ensure the integrity of the 
device at a walk, trot and canter. 
4.1.2 Study Enrollment 
Despite DDSP being relatively prevalent in racehorses, most afflicted horses are 
quietly euthanized, making it difficult to find the three horses to enroll in the study.  Dr. 
Sprayberry provided a list of over 300 qualified equine veterinarians in Kentucky that 
were called or emailed to potentially help find horses with DDSP. From that list, only a 
handful of local veterinarians were willing to help locate horses with DDSP. Overall, the 
process took six months to find just three DDSP horses to enroll in the study.   
The first horse enrolled was a 7-year-old thoroughbred mare that was previously 
diagnosed with DDSP via a dynamic endoscope examination. She displaced frequently 
at a walk, trot, and canter.  She had no previous surgeries or treatments for DDSP.  She 
was a pet with no previous racing history.  This horse was withdrawn from the study, due 
to logistical issues and feasibility concerns about the study.   
The next horse enrolled was a 7-year-old thoroughbred gelding, BH.  At 2 years 
old, he underwent a preventative tieback surgery despite having a normal epiglottis and 
soft palate at the time.  At 3 years old, the tieback was released, and he began 
displacing a few months later.  At that point, he was diagnosed with DDSP and retired 
from racing.  A tie forward procedure was completed at 5 years old.  At 6 years old, the 
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edge of his soft palate was trimmed with a laser.  Currently, he has been turned out to 
pasture due to frequent displacement of his soft palate.  BH has no surgical or treatment 
options left for DDSP.   
The third horse was TH, a 3-year-old Standardbred gelding.  TH was not 
previously diagnosed with DDSP, but he exhibited all of the classic symptoms, including 
roaring, snoring, and exercise intolerance. During races, TH would produce a loud 
roaring noise and then stop, gasping for air.  TH did not undergo any surgeries, but he 
did unsuccessfully try the Cornell Collar.  TH was actively being raced in Standardbred 
harness races at the start of the study.   
The final horse was MV, a 2-year-old Standardbred mare. MV was never formally 
raced, but she was in training to be a Standardbred harness racehorse.  During training, 
MV often would roar and experience shortness of breath.   
One donated control was a 25-year-old quarter horse gelding with no history of 
breathing abnormalities.  The other donated control was a 17-year-old quarter horse 
gelding with no history of breathing abnormalities. The final control horse was purchased 
from a horse dealer in KY.  This control was a 6-year-old quarter horse mix gelding with 
no history of breathing abnormalities.  
After all six horses were enrolled in the study; horse identification numbers were 
assigned as shown in Table 4.1 
Table 4.1: Identification numbers assigned to safety and efficacy phase horses enrolled in the study. 
Horse 
ID 
Animal Name Gender Age Study Phase 
1 BH Gelding 8 Efficacy - DDSP 
2 TH Gelding 3 Efficacy - DDSP 
3 MV Filly 2 Efficacy - DDSP 
4 Donation #1 Gelding 16 Safety – Control 
5 Donation #2 Gelding 23 Safety – Control 
6 Purchased Horse Gelding 6 Safety - Control 
 
 
	 55	
4.1.3 Pre Treatment Examinations 
An outside veterinarian completed a dynamic endoscope examination on Horse 
#1 using a dynamic endoscope within the last year.  The report of the study concluded 
that Horse #1 had a completely paralyzed and thickened left arytenoid.  Also, the left 
arytenoid was partially scarred and located out of the way due to a previous tieback 
surgery that was released.  DDSP occurred readily, and the palate was displaced 
through 90% of the examination.  The epiglottis was moderately flaccid and normal 
sized.  See Appendix C1 for full pre treatment endoscopic examination for Horse #1.  
Horse #2 and Horse #3 were both examined for DDSP by Dr. Woodie using a 
dynamic endoscope as demonstrated in Figure 4.2.  Horse #2 was evaluated using the 
equine treadmill at Rood and Riddle Equine Hospital, in Lexington, KY. Horse #2 was 
diagnosed as having a normal upper airway at rest.  While pacing at high-speed 
exercise, Horse #2 displaced his palate and was diagnosed with DDSP.  Horse #3 was 
evaluated using a portable dynamic endoscope at Red Mile Racetrack, in Lexington, KY. 
See Appendix C2 for complete diagnosis from the pre treatment endoscopic examination 
for Horse #2. 
 
Figure 4.2: Dynamic endoscope examinations were completed using an equine treadmill for Horse 
#2 (left) and a portable dynamic endoscope at a remote location for Horse #3 (right). 
The pre treatment respiratory recording for Horse #1 was completed on a lunge 
line at a walk, trot, and canter for 20 minutes. The recorder was attached to the left side 
of his halter with the microphone placed near his nostril as shown in Figure 4.3.  During 
the recording, Horse #1 did not displace or make any abnormal breathing sounds at a 
walk or trot.  However, at a canter, Horse #1 snored frequently and experienced exercise 
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intolerance.   At least once, Horse #1 came to a complete stop and snorted loudly to 
correct his displaced palate.  The audio recordings for Horse #1 had excess wind noise 
because of slight movement of the halter during exercise.  
 
Horse #2 was recorded while exercise harness racing for 20 minutes. Per his 
owner, Horse #2 was pacing at his top racing capabilities.  Due to interference with the 
bridle and riding equipment, the recorder was attached to the front of his bridle with the 
microphone near his nostrils as shown in Figure 4.4.  During the recording, Horse #2 
snored loudly throughout the exercising, with increased snoring towards the end of the 
race. 
 
Horse #3 was recorded while exercise harness racing, as well.  The trainer 
completed a full practice race with Horse #3 for 20 minutes.  Again, due to potential 
Figure	4.4:	The	recording	device	was	attached	to	the	front	of	Horse	#2's	bridle	to	record	his	respiratory	
noises.	
Figure	4.3:	Attaching	the	recording	device	to	the	side	of	the	halter	allowed	the	audio	recordings	for	Horse	#1	to	
be	recorded.		During	the	recordings,	the	recorder	moved	slightly	with	the	movement	of	the	halter.	
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interference with the tack, the recorder was attached to the front of her bridle with the 
microphone near her nostrils as shown in Figure 4.5. During the pre treatment recording, 
Horse #3 snored while trotting at high speeds and had multiple occasions where her 
breathing was completely interrupted for about ten second intervals. 
 
Figure 4.5: For Horse #3, the recording device was attached to the front of the bridle to record any 
respiratory noises. 
4.1.4 Soft Palate Treatment 
Even for an experienced veterinarian, injecting the soft palate proved to be a 
difficult procedure.  The soft palate is a flimsy material, making it difficult to insert the 
needle and maintain the correct position to administer the reagent.  Therefore, the 
injections were completed so that the needle trajectory crossed the center of the soft 
palate to help maintain the correct needle position.  When the endoscope was inserted 
into the right nostril, the 7:00 palate injection was completed on the left side, and when 
the endoscope was inserted into the left nostril, the 5:00 palate injection was completed 
on the right side.  A digital display video endoscope was unable to be obtained for this 
study, so a simple endoscope with only a standard viewing port was used for the 
injections.  Dr. Aristizabal had to look through the 1-meter long viewing port, which is 
similar to looking through the body tube of a microscope, to see the injection location 
and needle placement.  As one would expect, looking through a 1-meter long tube made 
the injection area very small and challenging to see, thus increasing the difficulty of 
placing the needles in the correct position, as shown in Figure 4.6.  If a digital display 
video endoscope had been available, some of the difficulties associated with this type of 
injection would have been greatly reduced.   
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Also, the 1-meter long transendoscopic injection needle required a 0.5 mL 
loading dose to fill the needle tube plus an additional 1 mL of the reagent to advance the 
desired amount into the soft palate.  The 1 ml advancing substance was overlooked 
when preparing for the study and extra reagent was not available. Therefore, Dr. 
Aristizabal suggested to use a column of approximately 1 mL of air to push the entire 
reagent volume into the soft palate as demonstrated in Figure 4.7.   Dr. Aristizabal had 
previously used air to advance reagents for other equine applications in peripheral 
tissues, and he did not believe it would cause any issues.   Due to the compressibility of 
air under pressure, using 1 mL of air to advance the reagent would result in less than 1 
mL of reagent being injected.  During each of the soft palate injections the soft palate 
readily expanded to accommodate the extra volume, causing a ‘pillow’ filled with the 
reagent and perhaps a small volume of air to form at the injection site.   This was most 
likely due to the fact that the soft palate has insufficient elasticity to withstand the 
injection without incurring moderate tissue damage as further discussed in Section 4.1.7. 
 
Figure 4.6: The endoscope had a viewing window that allowed the soft palate to be viewed (left).  
However, because the endoscope was 1 meter long, the soft palate appeared very small (right). 
When viewing the soft palate in real time, it appeared clear and in focus.  The image on the right is 
only out of focus because it was taken with a camera through the endoscope port. 
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Figure 4.7: The reagent was advanced into the soft palate using a column of air after ensuring the 
needle was in the correct position. 
The protocol called for each horse to receive two 1 mL injections of the genipin 
buffered reagent into the 5:00 and 7:00 positions on the soft palate.  Five of the six 
horses received two 1 mL injections in these positions. Horse #5 was the first horse 
treated, and he received two 1.5 mL injections by mistake because the full amount was 
accidentally injected into the soft palate.   Also, during the first injection for Horse #1, the 
needle slipped out of the soft palate as the reagent was being delivered, causing it to be 
sprayed topically on the soft palate.  Horse #1 then received two more 1 mL injections 
into the 5:00 and 7:00 positions.  All individual horse injection details and notes are 
included in Table 4.2 
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Table 4.2: Notes from soft palate treatment and volume of reagent injected for each horse. 
Injection 
Order 
Horse 
ID 
Injection 
Spot 
Volume 
Injected (mL) 
Procedure Notes 
1 5 5:00 1.5 • Injected too much 
reagent by mistake 
 2 7:00 1.5 
3 4 5:00 1.0 • Very tough palate – 
difficult to insert needle 
 4 7:00 1.0 
5 1 5:00 1.0 • 1 mL of reagent sprayed 
topically on soft palate 
• Very flimsy soft palate 
• Palate displaced during 
injection 
 
6 7:00 1.0 
7 3 5:00 1.0 • Normal palate 
 8 7:00 1.0 
9 2 5:00 1.0 • Very soft and flimsy soft 
palate 
 10 7:00 1.0 
11 6 5:00 1.0 • Injected both 5:00 and 
7:00 locations from one 
nostril 
 
12 7:00 1.0 
 
Post treatment, the horses were examined every hour for 72 hours.   Initially, a 
few of the horses cleared their throat or coughed, but not excessively.  Horse #3 
experienced mild hypersalivation and a reduced appetite 24 hours post treatment as 
shown in Figure 4.8.  These symptoms subsided within 24 hours.  Otherwise, all of the 
horses recovered unremarkably.  Table 4.3 in Appendix C3 lists the post treatment 
clinical observations for each horse in more detail.  
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Figure 4.8: Horse #3 experienced hypersalivation for 24 hours post treatment, as noted by the white 
foam coming from the horse's mouth. 
Seven days after treatment, the safety phase control horses were sedated with 
Detomidine (0.02 mg/kg) and Butorphanol (0.03 mg/kg), and euthanized with Fatal Plus 
(1 mL/4.5 kg).  Their soft palates were then removed, stored on dry ice and shipped to 
Orthopeutics, LP for analysis.  The animal carcasses were appropriately disposed of by 
SRC.  Twelve days after treatment, the efficacy phase horses were returned to their 
owners for post treatment examinations.  
4.1.5 Post Treatment Examinations 
Immediately after returning home, follow up phone calls were made to the 
efficacy phase horse owners for updates on the well being, breathing sounds, and 
exercise tolerance.   Per Horse #1’s owner, Horse #1 was recovering well and showing 
no signs of abnormal noises.  Horse #1 had not been exercised, so the status of 
abnormal noises and exercise intolerance were unknown.  In general, Horse #2 was 
recovering well and showing no signs of abnormal noises at rest.  However, when 
exercising at high speeds, Horse #2 showed variable results.  Sometimes when 
exercised, he would breathe normally with no abnormal noises or noticeable 
displacements.  Other times, he would snore throughout his entire exercise session and 
displace his soft palate at the end during high speed exercising.  Overall, Horse #3 
	 62	
recovered well from the genipin treatment and demonstrated no abnormal breathing 
sounds or exercise intolerance.  
Approximately one month after treatment, the efficacy phase horses underwent 
post treatment dynamic endoscope examinations and respiratory audio recordings.  Post 
treatment, Horse #1 underwent a portable dynamic endoscope examination by Dr. 
Woodie at a walk, trot and canter on a lunge line.  At rest, Horse #1 had a paralyzed and 
thickened left arytenoid and evidence of a previous left ventriculocordectomy.  Horse #1 
did not displace his palate at rest.  While exercising, he did not displace his soft palate or 
make any abnormal respiratory noises at a walk, trot or canter.  He did experience 
intermittent epiglottic entrapment.  For the full post treatment diagnosis, see Appendix 
C1. 
The post treatment dynamic endoscopic examination was completed on Horse 
#2 while exercise harness racing using a portable dynamic endoscope.  At rest, the soft 
palate and upper airway were within normal limits.  During high-speed exercise, he 
displaced his soft palate.  For full post treatment diagnosis, see Appendix C2. 
Horse #3 did not have a post treatment dynamic endoscope examination 
completed due to logistical issues.  Horse #3 resides over two hours away and the 
owner was unable to make the round trip to bring the horse to Lexington, KY for the 
examination.  
Respiratory audio recordings were completed on all three horses post treatment.  
For the post treatment audio recording for Horse #1, the halter was again placed on the 
left side of the halter with the microphone near the nostril.  Horse #1 was lunged at a 
walk, trot and canter for 20 minutes.  During this time, the Horse #1 did not make any 
abnormal respiratory noises or snoring.  Also, Horse #1 did not show any exercise 
intolerance or stop exercising because of palatal displacements.  
Horse #2 had a post treatment audio recording completed while exercise harness 
racing with the recorder attached to the center of the bridle with the microphone near the 
nostril.  During the post treatment audio, Horse #2 did not displace his soft palate, 
however, audible snoring noises were still present towards the end of his race.  Per his 
owner, Horse #2 paced his fastest mile to date, showing an improvement in exercise 
intolerance.  
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The post treatment respiratory recording for Horse #3 was completed during an 
exercise harness race at full trotting speed.  The recorder was attached to the center of 
bridle with the microphone near the nostril.  During the post audio treatment, Horse #3 
did not make any abnormal respiratory noises or experience any breathing issues.  
Based on the breathing recording, Horse #3 did not displace her palate or show any 
exercise intolerance after the genipin treatment.  
Based on the dynamic endoscopic examinations and the audio respiratory 
recordings, two of the three horses have showed improvement in snoring loudness and 
palatal displacement.  Horse #1 and #3 both exercised post treatment with no abnormal 
breathing noises or exercise intolerance.  Horse #2 showed inconsistent results with 
limited improvement in snoring loudness.  Therefore, it appears that the genipin 
treatment reduced snoring loudness and palatal displacement; however, more research 
should be completed to determine the appropriate dosage and concentration to produce 
desirable results in all horses.  
4.1.6 Respiratory Audio Analysis 
In the pre treatment and post treatment respiratory recordings, the horses were 
exercised for the same amount of time and at the same exertion rate to remove as many 
discrepancies as possible between the recordings.  To analyze the respiratory audio 
files, the samples were cut down using Audacity 2.1.1 (Computer Program, 2015), an 
audio editor and recording program, to remove the extraneous noises associated with 
attaching and detaching the recorder and warming the horse up.  The resulting audio 
files consisted of about five minutes of the horses exercising at maximum speed. For 
Horse #1, full speed was cantering on a lunge line; for Horse #2, full speed was high-
speed pacing while harness racing; and for Horse #3, full speed was high-speed trotting 
while harness racing.  Then, the points of palatal displacements or snoring were noted 
for each sound file, as listed in Table 4.4.  For Horse #1, the clearest pre treatment 
snoring sounds occurred between 0:59-1:06 minutes.  For Horse #2, the clearest 
pretreatment snoring sounds appeared during the 5:05-5:50 minute range with snoring 
occurring with each exhale.  For Horse #3, the clearest pretreatment displacement 
locations were from 2:45-2:59 minutes because there was a time interval when the horse 
completely stopped breathing during this span.  Using the location of the palatal 
displacements, the audio files were further broken down into one exhale (1E), three 
	 64	
exhales (3E) and 20 exhales (20E) sections that contained the DDSP snoring or 
breathing gaps when present.   
Table 4.4: DDSP snoring locations for each horse with clear snores highlighted in bold 
Audio File Snoring Locations 
(in mins) 
Horse #1: Pre Treatment 0:59-1:06; 2:43-2:50; 4:27-4:33; 5:34-5:49 
Horse #1: Post Treatment None 
Horse #2: Pre Treatment 0:24; 0:56; 2:51; 3:54; 4:28; 4:53-4:59; 5:05-
5:50 
Horse #2: Post Treatment 1:10-1:12; 1:36-1:39; 4:17-4:24; 5:03-5:05 
Horse #3: Pre Treatment 0:19; 0:58-1:00; 2:30; 2:45-2:59; 5:32-5:34 
Horse #3: Post Treatment 2:32*; 3:09* 
*Possible snoring noises, but difficult to be 
conclusive with respiratory audio alone 
 
	 65	
Next, the 3E and 20E audio files were analyzed using custom program codes 
developed in Matlab in the time domain.  The 3E files were used to compare amplitudes 
between pre treatment and post treatment audio files.  For each graph, the pre treatment 
audio recordings are shown in red and the post treatment audio recordings are shown in 
blue.  As shown in Figure 4.9, Horse #1 has about the same amplitude peaks for the pre 
treatment and post treatment breathing, however, the breathing pattern is much more 
uniform post treatment.  This is also true for Horse #2 and Horse #3, who demonstrated 
smaller amplitude peaks in the post treatment graphs as shown in Figures 4.10 and 
4.11, respectively.  The reduction in amplitude for all three horses relates to a reduction 
in snoring loudness.  In all three time domain graphs, there is also evidence of an 
approximately 10 Hz oscillation in the pre treatment exhales.  For Horse #1 and Horse 
#3, this low frequency vibration is not present in the post treatment exhales, which 
corresponds to a decrease in palatal snoring.  Additionally, for Horse, #1, the breathing 
rate post treatment is twice as fast as the breathing rate pre treatment.  Since the audio 
files were taken at approximately the same time into the warm up routine, it could be 
assumed that the horse is able to work harder post treatment, thus increasing his 
breathing rate.  Overall, the time domain graphs for all three horses support the dynamic 
endoscope examination results because they show a decrease in snoring loudness and 
an increase in exercise tolerance based on the decrease in amplitude peaks and the 
increased breathing rates.  Horse #1 and Horse #3 no longer experience any DDSP 
symptoms, which is evident in their time domain graphs because there is a decrease in 
post treatment amplitude peaks and a decrease in the 10 Hz oscillations associated with 
palatal vibration.  For Horse #2, there was a decrease in amplitude peaks; however, the 
10 Hz oscillations are still present in the post treatment time domain graph, supporting 
the results of the dynamic endoscopic examination with a reduction in snoring loudness 
but the presence of palatal vibrations. 
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Figure 4.9: The time domain graph for Horse #1 for 3E shows a reduction in the 10 Hz oscillations, as 
well as an ability to work harder based on the faster breathing rate. 
 
Figure 4.10: Horse #2 demonstrates a reduction in the amplitudes in the post treatment time domain 
graph, relating to a reduction in snoring loudness. 
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Figure 4.11: The post treatment time domain graph for Horse #3demonstrated a decrease in both the 
amplitude peaks and the 10 Hz oscillations, relating to a reduction in snoring loudness and palatal 
vibrations. 
The 20E files were analyzed to determine any irregularities in the breathing 
pattern because the larger number of exhales allowed patterns to be easily noticed.   In 
general, for all three horses, the pre treatment time domain graphs were not uniform in 
amplitude peak heights.  Additionally, in the pre treatment graphs, there is evidence of 
irregular breathing patterns, with short inhales, long exhales, and gaps caused by airway 
obstruction, as demonstrated in particular by Horse #1 in Figure 4.12.  For all horses, 
each individual exhale in the pre treatment graphs is much longer, causing the breathing 
rate to be slower than in the post treatment graphs.  This is especially evident for Horse 
#2, as seen in Figure 4.13.  Horse #3 also shows evidence of a large breathing gap in 
the pre treatment audio between 10 and 12 seconds as shown in Figure 4.14.  Any gaps 
in the breathing pattern indicate apneic events, as previously described in the study by 
Azarbarzin and Moussvi [42].   In the post treatment graphs, breathing patterns are more 
regular with a uniform peak height for all three horses.   Also, any breathing gaps caused 
by airway obstruction are also non-existent.  Overall, the 20E time domain graphs are 
useful to determine the location of soft palate displacements as indicated by the gaps in 
the breathing pattern.  
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Figure 4.12: The 20E time domain graphs for Horse #1 show varying lengths of inhales and exhales 
in the pre treatment graph.  In the post treatment graph, the breathing rhythm is more uniform.  
 
Figure 4.13: For Horse #2, the 20E pre treatment time domain graph has a much slower breathing 
rate due to each exhale requiring more force to overcome palatal vibration.  The post treatment 
graph has a faster, more uniform, breathing rate.  
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Figure 4.14: The 20E pre treatment time domain graph for Horse #3 has a large gap from 10-12 
seconds, corresponding to an airway obstruction.  In the post treatment graph, there is no evidence 
of any palatal obstructions.  
Then, spectrogram graphs were created in Matlab using the 3E audio files.  The 
spectrograms showed changes in amplitude across a variety of frequencies.  For the 
spectrograms, the x-axis represented time, the y-axis represented frequency, and the 
red squares represented high amplitudes at -40 V while the blue squares represented 
low amplitudes at -120 V.   Horse #1 and Horse #3 both showed a noticeable reduction 
in the quantity of high amplitude red squares in the high frequency range in the post 
treatment spectrogram graph compared to the pre treatment graph as demonstrated in 
Figure 4.15 and Figure 4.17, respectively.   Additionally, Horse #3 had a reduction in the 
area of red squares in the low frequency range.  Horse #2 did not have an obvious 
decrease in the number of red squares representing high amplitudes for any frequency 
between the pre treatment and post treatment spectrogram graphs as shown in Figure 
4.16.  Based on the spectrogram graphs, the genipin treatment seemed to have caused 
a decrease in amplitude in the high frequency range, which corresponds to a decrease 
in palatal vibration and whistling.  This is supported by the results of the dynamic 
endoscope examinations and owner reports that had a reduction of DDSP symptoms for 
Horse #1 and Horse #3.  
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Figure 4.15: The spectrogram for Horse #1 shows a reduction in high amplitude red squares in the 
high frequency range in the post treatment graph (bottom) compared to the pre treatment graph 
(top). 
 
Figure 4.16: The pre treatment (top) and post treatment (bottom) spectrogram graphs for Horse #2 
did not show an obvious difference in the area of high amplitude red squares for any frequency 
range. 
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Figure 4.17: The pre treatment spectrogram graph (top) showed more high amplitude red squares 
than the post treatment spectrogram graph (bottom) across all frequency ranges for Horse #3. 
Using ImageJ image analysis software, the area of high amplitude red squares 
was calculated and compared pre and post treatment to determine the percent 
differences.  Each spectrogram graph was loaded into ImageJ and analyzed using the 
green color channel to count the number of red squares.   The green color channel was 
used because it best represented the area of the red squares due to the filter applied 
when separating the channels.  The green color channel graphs for each spectrogram 
are shown in Figures 4.18, 4.19 and 4.20 with the pre treatment and post treatment 
spectrogram graphs represented.   Using the color channel graphs, the area of red 
squares was calculated by counting the number of black particles in the green color 
channel graphs, as summarized in Table 4.5.  Figure 4.21 shows the differences for 
each horse in the area of red squares, representing high amplitude sounds across all 
frequencies.  Using these values, the percent difference between the area of red 
squares in the pre treatment spectrogram and the post treatment spectrogram was 
calculated for each horse and plotted in Figure 4.22.  On average, there was a 39% 
decrease in the number of red squares in the post treatment respiratory recordings 
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compared to the pre treatment respiratory recordings.  Horse #1 and #3 both had a 
reduction of greater than 50% in the number of high amplitude squares relating to a 
reduction in sounds associated with snoring an palatal displacement, which correlates 
with the observations made at the post treatment evaluations and with the horse owner 
post treatment assessments.  
 
Figure 4.18: The green color channel graphs from Image J representing the pre treatment 
spectrogram (left) and post treatment spectrogram (right) for Horse #1 showed a decrease in high 
frequency amplitudes. 
 
Figure 4.19: The green color channel graphs from Image J representing the pre treatment 
spectrogram (left) and post treatment spectrogram (right) for Horse #2 showed a slight decrease in 
the area of red squares. 
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Figure 4.20: The green color channel graphs from Image J representing the pre treatment 
spectrogram (left) and post treatment spectrogram (right) for Horse #3 showed a decrease in the 
area of red squares across all frequency ranges. 
	
Table 4.5: The ImageJ results included the total area of red squares as well as the percent area.  
Using these values, the percent difference was calculated for the pre treatment and post treatment 
spectrograms for each horse. 
Audio File Total 
Area 
Percent 
Area Red 
Percent Difference in 
area of red squares in 
post treatment 
spectrogram 
Horse #1: Pre Treatment 48605 32.33% 
60.20% decrease Horse #1: Post 
Treatment 
19400 12.87% 
Horse #2: Pre Treatment 45344 30.16% 
7.54% decrease  Horse #2: Post 
Treatment 
41612 27.89% 
Horse #3: Pre Treatment 54399 23.13% 
50.01% decrease Horse #3: Post 
Treatment 
27196 11.56% 
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Figure 4.21: For each horse, the percent area of red squares decreased after treating the soft palate 
with the genipin reagent as shown in the bar graph. 
 
Figure 4.22: Each horse had at least a 5% decrease in the area of red squares in the post treatment 
recording compared to the pre treatment recording. 
 Finally, the 1E and 3E audio files were analyzed using the frequency domain in 
the high frequency and low frequency ranges.  The one exhale (1E) and three exhale 
(3E) sections were chosen based on the location of DDSP snores and palatal 
displacements as described in Table 4.4.  The 1E sound files were used to see the 
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changes in the frequency domain between pre and post treatment audio files for just a 
single exhale at a time.  The 3E sound files were used to see the post treatment 
changes as an average of a few exhales at a time.  For both the 1E and 3E graphs, the 
entire frequency range between 0 Hz and 4000 Hz were evaluated first in order to see 
the general frequency distribution of each audio segment with the pre treatment audio 
recordings in red and the post treatment audio recordings in blue as shown in Figures 
4.23-4.28.  Comparing the 1E graphs to the 3E graphs for the pre treatment and post 
treatment files, the shapes of the graphs are generally the same for all three horses.  
Also, based on visual examination alone, it appeared that there was a reduction in 
higher frequency amplitudes for the post treatment audio files, as demonstrated in 
Figures 4.23 and 4.24.   Additionally, there seems to be a decrease in amplitudes in the 
lower frequency range as shown in Figures 4.25-4.28, corresponding to a reduction in 
snoring loudness. 
 
Figure 4.23: The frequency domain graphs for the pre treatment and post treatment audio recordings 
for Horse #1 show a general reduction in amplitudes, especially in the high frequency range, for the 
1E files. 
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Figure 4.24:  The frequency domain graphs for the pre treatment and post treatment audio 
recordings for Horse #1 show a large reduction in amplitudes, especially in the high frequency 
range, for the 3E files. 
 
 
Figure 4.25: For Horse #2, the pre and post treatment frequency domain graphs show a general 
decrease in amplitude for the 1E files, especially in the low frequency range. 
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Figure 4.26: In the 3E files, the frequency domain graphs also show a general reduction in amplitude 
for the post treatment files for Horse #2, especially in the low frequency domain. 
 
Figure 4.27: In general, Horse #3 had a reduction in amplitudes of the frequency domain graphs from 
pre treatment to post treatment for the 1E files, particularly in the low frequency range. 
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Figure 4.28: Again, the 3E file graphs for Horse #3 show a general reduction in amplitude for the post 
treatment frequency domain graph from the pre treatment graph, particularly in the low frequency 
range. 
The frequency domain graphs were filtered using the moving average to aid in 
the quantitative analysis by removing any background noise or outlier peaks.  The 
filtered frequency domain graphs, in pink, were plotted over top of the original data, in 
black, to display the changes in the graphs.  As predicted, the large outlier peaks were 
removed when filtered using the moving average for all 1E and 3E frequency domain 
graphs, as shown in Figures 4.29-4.34 below.   
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Figure 4.29: Using the moving average to filter the frequency domain graphs, the large outlier peaks 
were smoothed in the1E pre treatment and post treatment graphs for Horse #1.  
 
Figure 4.30: The moving average filter removed the large outlier peaks and background noise for 
Horse #1 in the 3E pre treatment and post treatment graphs. 
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Figure 4.31: For Horse #2, smoothing the frequency domain graphs using the moving average 
method diminished the large outlier peaks in the 1E pre treatment and post treatment graphs.  
 
Figure 4.32:  For the 3E pre treatment and post treatment graphs for Horse #2, the large outlier peaks 
were reduced after filtering. 
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Figure 4.33: Filtering the frequency domain graphs for Horse #3 using the moving average method 
removed the outlier peaks from the 1E pre treatment and post treatment audio files. 
 
Figure 4.34: For the 3E pre treatment and post treatment audio files, the moving average method 
removed the outlier peaks for Horse #3. 
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After filtering, the frequency domain graphs were broken down into the high 
frequency range from 500 to 4000 Hz for 1E files and 3E files.  The high frequency 
domain analysis started at 500 Hz because that was the cut off frequency for the laser 
used in the wind tunnel study.  The Nyquist frequency, which is the minimum rate that a 
signal can be sampled without introducing errors, was 4000 Hz, making that the 
maximum point in the frequency domain.  For all graphs, the pre treatment audio is 
shown in red and the post treatment audio is shown in blue.  Horse #1 showed a 
substantial decrease in amplitudes in the high frequency range as shown in Figure 4.35. 
Horse #2 did not have any obvious decreases in the high frequency range as 
demonstrated in Figure 4.36. Horse #3 exhibited a slight decrease in amplitudes in the 
high frequency range, but not nearly as drastic as the reduction for Horse #1 as seen in 
Figure 4.37. Since Horse #1 has been clinically evaluated to no longer having DDSP 
after the genipin treatment based on the dynamic endoscope testing, the reduction in the 
high frequency whistling noises could be associated with the elimination of palatal 
displacement in the equine model.  This is further supported by the high frequency range 
results for Horse #2 because that horse did not have any reduction in the high frequency 
range amplitude, and that horse still has clinically validated DDSP based on the post 
treatment dynamic endoscopic examination.  Horse #3 did not undergo a post treatment 
dynamic endoscope, but based on owner reports, the horse is not experiencing any 
DDSP symptoms, which supports that the decrease in high frequency amplitudes is 
associated with a reduction in palatal displacement.  
 
Figure 4.35: The frequency domain graphs from 500-4000 Hz for Horse #1 show a substantial 
decrease in amplitudes in the high frequency range after the genipin treatment for both the 1E graph 
(left) and 3E graph (right).  
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Figure 4.36: Horse #2 shows a slight reduction in the 1E graph (left) in the post treatment amplitudes 
in the high frequency range, but no reduction in the 3E graph (right), indicating that the selection of 
exhales can influence the outcome.  
 
 
Figure 4.37: Horse #3 had a slight decrease in amplitudes in the high frequency range as shown by 
the 1E graph (left) and the 3E graph (right).  
The filtered frequency domain files were examined in various low frequency 
ranges to determine the reduction in amplitude peaks correlating to a decrease in 
snoring loudness and soft palate vibrations.  The ranges used were 0-500 Hz, 0-200 Hz 
and 0-100 Hz, correlating to various frequency ranges commonly used to analyze 
snoring sounds.  The areas under the frequency domain curve were calculated as a 
representation of the spectral density of the audio file, and then the percent difference 
was determined to quantify a difference between the pre treatment and post treatment 
amplitude files. The trapz function in Matlab was used to determine the area under the 
curve for the 1E and 3E files, and the specific area used for each frequency range was 
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highlighted as shown in Figures 4.38-4.43.  The pre treatment graph is shown in red and 
the post treatment graph is shown in dark blue.  The area under the curve (AUC) from 0-
500 Hz is shaded in light blue, the AUC from 0 -200 Hz is highlighted in green, and the 
AUC from 0-100 is colored in yellow.  
 
Figure 4.38: The areas under the curve for the Horse #1 for the 1E pre treatment (top) and post 
treatment (bottom) files were calculated for the various frequency ranges. 
 
Figure 4.39: The areas under the curve for the Horse #1 for the 3E pre treatment (top) and post 
treatment (bottom) files were calculated for the various frequency ranges. 
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Figure 4.40: The areas under the curve for the Horse #2 for the 1E pre treatment (top) and post 
treatment (bottom) files were calculated for the various frequency ranges. 
 
Figure 4.41: The areas under the curve for the Horse #2 for the 3E pre treatment (top) and post 
treatment (bottom) files were calculated for the various frequency ranges. 
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Figure 4.42: The areas under the curve for the Horse #3 for the 1E pre treatment (top) and post 
treatment (bottom) files were calculated for the various frequency ranges. 
 
Figure 4.43: The areas under the curve for the Horse #3 for the 3E pre treatment (top) and post 
treatment (bottom) files were calculated for the various frequency ranges. 
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The filtered frequency domain files were examined in the low frequency range 
from 0 to 500 Hz.  A limit of 500 Hz was chosen because it was the cutoff frequency for 
the laser used in the wind tunnel study.  In the graphs, the pre treatment audio data is 
shown in red, and the post treatment data is shown in blue.  As demonstrated by all 
three horses, there is a reduction in the low frequency range amplitudes between 0-500 
Hz.  Horse #1 also shows a decrease in amplitudes, but it is less evident in the 3E graph 
than in the 1E graph as shown in Figure 4.44.   Horse #2 and Horse #3 show a definitive 
reduction that is evident in both the 1E graphs and 3E graphs, as demonstrated in 
Figures 4.45 and 4.46. The reduction in low frequency domain amplitudes supports the 
reduction in steady-state displacements, or vibration amplitudes, as seen in the wind 
tunnel study.  
As previously shown in Figures 4.38-4.43, the area under the frequency domain 
curves was determined for each audio file as a representation of the spectral density of 
the audio file.  Table 4.6 highlights the calculated areas under the curves, and the 
associated percent difference between the pre treatment values and post treatment 
values for each individual horse.  Figure 4.47 and 4.48 show the differences in the areas 
under the curve between the pre treatment and post treatment audio files for the 1E and 
3E files, respectively.  Finally, Figure 4.49 plots the percent differences between the 
area under the curve for the pre treatment file and post treatment file for each horse in 
the 1E and 3E files.  Overall, for the 1E files, there was an average 31.6% reduction in 
amplitudes from 0-500 Hz.  For the 3E files, there was an average 15.6% reduction in 
amplitudes form 0-500 Hz.  In the 3E files, Horse #1 had a slight increase in the area 
under the curve for the post treatment curve.  Based on clinical observations, Horse #1 
no longer experiences any DDSP related snoring, so the increase in area under the 
curve for the post treatment audio file could be the result of background noise that was 
not fully filtered out or due to increased airflow because of an elevated level of exercise 
available to the horse now that the breathing disorder has been corrected. The reduction 
in amplitudes in the low frequency range from 0-500 Hz relates to a decrease in snoring 
loudness, which further supports the wind tunnel study results that showed an average 
23% reduction in steady state soft palate vibration amplitudes for the 100 mM genipin 
concentration injections.  
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Figure 4.44: Horse #1 shows a post treatment reduction in amplitudes in the 1E graph (left) in the 
frequency domain graph from 0-500 Hz, with a less obvious reduction in amplitudes in the 3E graph 
(right).  A majority of the reduction in amplitudes occurs in the frequencies below 200 Hz. 
 
 
Figure 4.45: For Horse #2, there is a large reduction in amplitudes in both the 1E (left) and 3E (right) 
post treatment curves compared to the pre treatment curves, with the greatest amplitude decrease 
occurring below 200 Hz. 
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Figure 4.46: The 1E (left) and 3E (right) post treatment amplitudes demonstrated a slight reduction 
from the pre treatment amplitudes, especially below 150 Hz, for Horse #3. 
	
Table 4.6: This table shows the spectral density of the audio data represented by the areas under the 
curve in the frequency domain for the 1E and 3E audio files from 0-500 Hz and the percent 
differences calculated between the pre treatment and post treatment graphs. 
Audio File 
𝑨𝟏𝑬𝚫𝝎
𝝎!𝟓𝟎𝟎
𝝎!𝟎
 
A1E=Audio 
Amplitude for 1E 
1E 
%Difference 
between Pre 
and Post 
Treatment 
Audio 
𝑨𝟑𝑬𝚫𝝎
𝝎!𝟓𝟎𝟎
𝝎!𝟎
 
A3E=Audio 
Amplitude for 
3E 
3E 
%Difference 
between Pre 
and Post 
Treatment 
Audio 
Horse #1: Pre 
Treatment 
1.10E+04 
 12.46% 
decrease 
 
1.56E+04 
 
19.29% increase 
 Horse #1: Post 
Treatment 
9.62E+03 
 
1.86E+04 
 
Horse #2: Pre 
Treatment 
9.12E+03 
 48.74% 
decrease 
 
1.62E+04 
 35.15% 
decrease 
 Horse #2: Post 
Treatment 
4.68E+03 
 
1.05E+04 
 
Horse #3: Pre 
Treatment 
4.33E+03 
 33.46% 
decrease 
 
7.42E+03 
 30.90% 
decrease 
 Horse #3: Post 
Treatment 
2.88E+03 
 
5.13E+03 
 
	 90	
 
Figure 4.47:  The spectral density of the audio data represented by the areas under the frequency 
domain curve demonstrate a reduction in post treatment amplitudes for all horses from 0-500 Hz for 
the 1E files, relating to a reduction in snoring loudness and soft palate vibrations.  
 
Figure 4.48: The spectral density of the audio data represented by the areas under the frequency 
domain curve demonstrate a reduction in post treatment amplitudes for two horses from 0-500 Hz 
for the 3E files, relating to a reduction in snoring loudness and soft palate vibrations.  Although no 
longer experiencing DDSP symptoms, Horse #1 had an increase in amplitudes for the 3E file from 0-
500 Hz, which could be attributed to an increase in breathing rate post treatment. 
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Figure 4.49: Comparing the percent differences in the amplitudes of the pre treatment and post 
treatment spectral densities for the 1E and 3E files from 0-500 Hz, shows an average 31.6% decrease 
for the 1E file and 15.6% decrease for the 3E files. 
Similarly, the audio data was analyzed in the low frequency range from 0 to 200 
Hz for the 1E and 3E files. A cutoff of 200 Hz was used because the common frequency 
range to analyze human snoring sounds is from 0 to 200 Hz, which is associated with 
snoring and the soft palate vibrations, as previously stated.  In all graphs, the pre 
treatment audio files are represented in red and the post treatment audio files are 
represented in blue.  In general, all three horses experienced a decrease in the 
amplitudes of frequency domain graphs from 0 to 200 Hz in the 1E files.  For Horse #1 
the reduction in amplitudes was noticeable in the 1E graph, but less noticeable in the 3E 
graph, as shown in Figure 4.50.  Most of the reduction in amplitudes for Horse #1 
occurred below 100 Hz, which is associated specifically with a reduction in soft palate 
vibrations.  Horse #2 and Horse #3 both reflected large reductions in amplitude from 0 to 
200 Hz for the 1E and 3E files as demonstrated in Figures 4.51 and 4.52, relating to a 
reduction in snoring loudness and soft palate vibrations.  
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The areas under the pre treatment and post treatment frequency curves were 
calculated for each horse, as a representation of the spectral density of the audio data, 
and the percent difference between the two was determined.  As previously shown, 
Figures 4.38-4.43 highlight the areas under the curves that were calculated, and these 
results are displayed in Table 4.7.  Figure 4.53 and 4.54 show the areas under the curve 
for pre treatment and post treatment graphs for each horse for the 1E files and 3E files, 
respectively.  Finally, Figure 4.55 plotted the percent differences between the pre 
treatment and post treatment audio files for each horse for the 1E and 3E files.  Overall, 
there was an average 47.2% decrease in amplitude for the 1E post treatment audio files, 
and an average 25.4% decrease in amplitude for the 3E post treatment audio files.  
Again, Horse #1 experienced a slight increase in the post treatment area under the 
curve from 0-200 Hz for the 3E file, most likely due to an increase in breathing rate 
because of a reduction in exercise exertion after curing his breathing disorder.   Based 
on the reduction of the amplitudes in the 0-200 Hz frequency range, it can be concluded 
that all three horses experienced a decrease in snoring loudness due to the correlation 
with human snoring frequencies.  This conclusion is in agreement with the individual 
reports from the owners who stated that all three horses had a decrease in snoring 
loudness while exercising.  Also, it is supported by the dynamic endoscope results from 
Horse #1, who was diagnosed as no longer having DDSP after the genipin treatment.  
 
Figure 4.50: The areas under the pre treatment and post treatment curves for Horse #1 show a 
reduction in amplitude from 0-200 Hz for the 1E files (left) and for the 3E files (right), especially in the 
frequency range below 100 Hz relating to a reduction in soft palate vibration. 
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Figure 4.51: The areas under the pre treatment and post treatment curves for Horse #2 show a large 
reduction in amplitude for the 1E files (left) and 3E files (right) from 0-200 Hz, relating to a reduction 
in snoring loudness and soft palate vibration. 
 
Figure 4.52: The areas under the pre treatment and post treatment curves for Horse #3 demonstrate 
a reduction in amplitude for the 1E files (left) and 3E files (right) from 0-200 Hz, especially in the 
range from 0-100 Hz, representing a reduction in soft palate vibration. 
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Table 4.7: This table shows the spectral density of the audio data represented by the areas under the 
curve in the frequency domain for the 1E and 3E audio files from 0-200 Hz and the percent 
differences calculated between the pre treatment and post treatment graphs. 
Audio File 
𝑨𝟏𝑬𝚫𝝎
𝝎!𝟐𝟎𝟎
𝝎!𝟎
 
A1E=Audio 
Amplitude for 1E 
1E 
%Difference 
between Pre and 
Post Treatment 
Audio 
𝑨𝟑𝑬𝚫𝝎
𝝎!𝟐𝟎𝟎
𝝎!𝟎
 
A3E=Audio 
Amplitude for 3E 
3E 
%Difference 
between Pre and 
Post Treatment 
Audio 
Horse #1: Pre 
Treatment 
4.09E+03 
 
27.04% decrease 
 
5.06E+03 
18.11% increase 
 Horse #1: Post 
Treatment 
2.99E+03 
 
5.98E+03 
 
Horse #2: Pre 
Treatment 
4.01E+03 
 
62.11% decrease 
 
6.99E+03 
 
49.94% decrease 
 Horse #2: Post 
Treatment 
1.52E+03 
 
3.50E+03 
 
Horse #3: Pre 
Treatment 
2.17E+03 
 
52.36% decrease 
 
3.19E+03 
 
44.29% decrease 
 Horse #3: Post 
Treatment 
1.03E+03 
 
1.78E+03 
 
 
 
Figure 4.53: All three horses experienced a reduction in the amplitudes for the areas under the 
frequency domain curves, which represented spectral density, from 0-200 Hz for the 1E graphs, 
relating to a reduction in snoring loudness and palatal vibrations. 
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Figure 4.54: Two of the three horses experienced a reduction in the amplitudes for the areas under 
the frequency domain curves, which represented spectral density, from 0-200 Hz for the 3E graphs, 
relating to a reduction in snoring loudness and palatal vibrations.  Horse #1 had a slight increase in 
the post treatment amplitudes. 
 
Figure 4.55: Comparing the percent differences in the amplitudes of the pre treatment and post 
treatment spectral densities for the 1E and 3E files from 0-200 Hz, shows an average 47.2% decrease 
for the 1E file and 25.4% decrease for the 3E files. 
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Additionally, the audio data was analyzed in the low frequency range from 0 to 
100 Hz for the 1E and 3E files to correlate to vibrations associated with the soft palate.  
Snoring sounds detected by trained individuals are typically heard in the 0-50 Hz range, 
thus analyzing the audio files from 0-100 Hz would correspond to snoring loudness, as 
well. In all graphs, the pre treatment audio files are represented in red and the post 
treatment audio files are represented in blue.  In general, all three horses experienced a 
decrease in the amplitudes of frequency domain graphs from 0 to 100 Hz in the 1E files.  
For Horse #1, the reduction in amplitudes were noticeable in the 1E graph, but less 
noticeable in the 3E graph, as shown in Figure 4.56. Horse #2 and Horse #3 both 
reflected large reductions in amplitude from 0 to 100 Hz for the 1E and 3E files as 
demonstrated in Figures 4.57 and 4.58, relating to a reduction in snoring loudness and 
soft palate vibrations.  The largest reduction in amplitudes for Horse #1 and Horse #3 
happened below 50 Hz, which corresponds to a reduction in soft palate vibration that 
occurs around 25 Hz.   These results coincide with the post treatment dynamic 
endoscope examinations and owner updates that report these horses as no longer 
experiencing any DDSP symptoms, including soft palate displacements and snoring.    
The areas under the pre treatment and post treatment frequency curves were 
calculated for each horse, as a representation of the spectral density of the audio data, 
and the percent difference between the two curves was determined for the 0-100 Hz 
frequency range.  As previously shown, Figures 4.38-4.43 highlight the areas under the 
curves that were calculated, and these results are displayed in Table 4.8.  Figure 4.59 
and 4.60 show the areas under the curve for pre treatment and post treatment graphs for 
each horse for the 1E files and 3E files, respectively.  Finally, Figure 4.61 plots the 
percent differences between the pre treatment and post treatment audio files for each 
horse for the 1E and 3E files.  Overall, there was an average 55.0% decrease in 
amplitude for the 1E post treatment audio files, and an average 35.6% decrease in 
amplitude for the 3E post treatment audio files.  Again, Horse #1 experienced a slight 
increase in the post treatment area under the curve from 0-100 Hz for the 3E file, most 
likely due to an increase in breathing rate because of a reduction in exercise exertion 
after curing his breathing disorder.   Based on the reduction of the amplitudes in the 0-
100 Hz frequency range, it can be concluded that all three horses experienced a 
decrease in snoring loudness due to the correlation with human snoring frequencies.  
Additionally, based on the reduction in amplitudes below 50 Hz, it can be determined 
that the horses also had a reduction in soft palate vibrations.  These conclusions agree 
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with the individual owner reports and the dynamic endoscope examination results that 
showed a reduction in snoring loudness and palate vibration for two of the horses while 
exercising.  Although, Horse #2 still experienced intermittent DDSP symptoms post 
treatment, his frequency domain graph from 0-100 Hz still shows a reduction in snoring 
loudness and palatal vibrations.  In this case, the 56.9% reduction in the 1E file and 
53.80% reduction in the 3E file for Horse #3 may not have been sufficient to completely 
rid all of the DDSP snoring and palate displacement symptoms. 
 
Figure 4.56: The areas under the frequency domain curve for the 1E (left) file shows a reduction in 
amplitudes from the pre treatment to the post treatment graphs, relating to a reduction in snoring 
loudness for Horse #1.  The 3E (right) file shows a reduction in frequencies below 50 Hz, relating to a 
reduction in soft palate vibrations. 
 
Figure 4.57: The areas under the frequency domain curve for the 1E (left) and 3E (right) files show a 
reduction in amplitudes from the pre treatment to the post treatment graphs, relating to a reduction 
in snoring loudness for Horse #2. 
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Figure 4.58: The areas under the frequency domain curve for the 1E (left) and 3E (right) files show a 
reduction in amplitudes from the pre treatment to the post treatment graphs, relating to a reduction 
in snoring loudness for Horse #3. 
	
Table 4.8: This table shows the spectral density of the audio data represented by the areas under the 
curve in the frequency domain for the 1E and 3E audio files from 0-100 Hz and the percent 
differences calculated between the pre treatment and post treatment graphs. 
Audio File 
𝑨𝟏𝑬𝚫𝝎
𝝎!𝟐𝟎𝟎
𝝎!𝟎
 
A1E=Audio 
Amplitude for 
1E 
1E 
%Difference 
between Pre 
and Post 
Treatment 
Audio 
𝑨𝟑𝑬𝚫𝝎
𝝎!𝟐𝟎𝟎
𝝎!𝟎
 
A3E=Audio 
Amplitude for 
3E 
3E 
%Difference 
between Pre 
and Post 
Treatment 
Audio 
Horse #1: Pre 
Treatment 
1.65E+03 
 
41.46% 
decrease 
 
1.93E+03 
7.37% increase 
 Horse #1: Post 
Treatment 
9.70E+02 
 
2.07E+03 
 
Horse #2: Pre 
Treatment 
1.22E+03 
 56.93% 
decrease 
 
2.30E+03 
 53.80% 
decrease 
 Horse #2: Post 
Treatment 
5.26E+02 
 
1.06E+03 
 
Horse #3: Pre 
Treatment 
1.29E+03 
 66.68% 
decrease 
 
1.86E+03 
 60.48% 
decrease 
 Horse #3: Post 
Treatment 
4.29E+02 
 
7.36E+02 
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Figure 4.59: All three horses experienced a reduction in the amplitudes for the areas under the 
frequency domain curves, which represented spectral density, from 0-100 Hz for the 1E graphs, 
relating to a reduction in snoring loudness and palatal vibrations. 
 
Figure 4.60: Two of the three horses experienced a reduction in the amplitudes for the areas under 
the frequency domain curves, which represented spectral density, from 0-100 Hz for the 3E graphs, 
relating to a reduction in snoring loudness and palatal vibrations.  Horse #1 had a slight increase in 
the post treatment amplitudes. 
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Figure 4.61: Comparing the percent differences in the amplitudes of the pre treatment and post 
treatment spectral densities for the 1E and 3E files from 0-100 Hz, shows an average 55% decrease 
for the 1E file and 35.6% decrease for the 3E files. 
Finally, the 1E files were analyzed from 20 to 80 Hz in the 0-100 Hz frequency 
domain graphs to correspond with the previous study completed by Franklin et al.  In this 
study, a common ‘DDSP’ peak was located at 41 ± 21Hz for the in vitro horses and at 53 
± 24 Hz for in vivo, as shown in Figure 4.62 [55].  The frequency domain graphs were 
analyzed for all three horses to see if the ‘DDSP’ peak existed in the pre treatment audio 
graph, and to see if it disappeared in the post treatment audio graph.   As shown in 
Figure 4.63, Horse #1 had two prominent peaks in the 40-50 Hz range and in the 60-70 
Hz range in the pre treatment frequency domain curve, which could correspond with the 
‘DDSP’ peak because both of these peaks fall near the average peak location from 
Franklin’s study.  In the post treatment curve, both of these peaks have disappeared for 
Horse #1.  This supports the dynamic endoscope examination results because Horse #1 
was cured of DDSP, therefore, any ‘DDSP’ peaks should be nonexistent in the post 
treatment frequency domain graph. Horse #2 had a medium peak around 35 Hz and a 
large peak around 70 Hz in the pre treatment frequency domain graph as shown in 
Figure 4.64.  Both of these peaks disappear in the post treatment curve; however, a 
new, smaller amplitude peak appears around 60 Hz.  Horse #2 was diagnosed with still 
having DDSP in the post treatment dynamic endoscope examination; therefore, the 
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appearance of a new peak in the post treatment curve corresponds with these results. 
Finally, for Horse #3, there was a prominent peak between 70-90 Hz in the pre treatment 
curve as shown in Figure 4.65.  In the post treatment curve, all of the peaks are 
noticeably decreased from the pre treatment curve, including the potential ‘DDSP’ peak 
between 70-90 Hz, corresponding with the owner’s reports that Horse #3 is no longer 
experiencing any DDSP symptoms.  
 
Figure 4.62: From the Franklin et al study, the top graph demonstrates the ‘DDSP’ peaks found for in 
vitro cadaveric horses, and the bottom graph shows the ‘DDSP’ peak found for the in vivo exercising 
study horses with DDSP [55].  
 
Figure 4.63: Horse #1 had two prominent peaks in the 20-80 Hz range in the pre treatment audio file 
that could be related to the ‘DDSP’ Peak. Both of these peaks disappeared in the post treatment 
curve, relating to a non DDSP dynamic endoscope diagnosis. 
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Figure 4.64: Horse #2 had two prominent peaks in the 20-80 Hz range in the pre treatment audio file 
that could be related to the ‘DDSP’ Peak.  In the post treatment audio file, both of the original peaks 
disappeared, but a new ‘DDSP’ peak appeared, leading one to believe that the horse still experienced 
DDSP, as confirmed by the dynamic endoscope results.  
 
Figure 4.65: Horse #3 had a prominent peak in the pre treatment graph corresponding to a potential 
‘DDSP’ peak.  In the post treatment curve, all of the prominent peaks have disappeared, supporting 
the owner’s report that Horse#3 no longer experiences any symptoms of DDSP.   
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4.1.7 Histological Analysis 
The three soft palates from the safety phase horses were harvested upon 
completion of the in vivo study.  Upon thawing, the three palates were observed and 
divided into six sections per palate as previously described.  The soft palate from Horse 
#4, as shown in Figure 4.66, had two noticeable thickened and elevated ‘pillow-like’ 
regions around the injection site.  When cutting into these areas, the tissue was a dark 
blue color, indicating that it had been crosslinked by the genipin reagent.  This was most 
likely due to either the ‘pillowing’ or inflation effect of the soft palate that occurred during 
the injections or to an errant injection in which the needle was not fully inserted into 
tissue, causing the reagent to be injected closer to the respiratory mucosal layer.  The 
palate from Horse #5 had a small area of necrosis, but otherwise looked normal as 
demonstrated in Figure 4.67.  The necrotic area from palate of Horse #5 was crosslinked 
blue from the genipin treatment on the inside.  Similarly, Horse #6’s palate showed a 
large region of necrotic tissue on the surface of the soft palate encircled by a fibrotic 
encapsulation around the injection area, as seen in Figure 4.68.  Inside of this necrotic 
tissue, the region had a small area of dark blue crosslinking, but otherwise it appeared to 
be non-crosslinked, unhealthy, damaged tissue.   
  Once all observations were complete, the palates were cut in half into left (L) and 
right (R) sections, and then three segments were cut from each half: top (T), middle (M), 
bottom (B) with the top closest to the epiglottis and the bottom closest to the hard palate.  
From each half, at least one of the segments was taken from a perceived untreated 
section as indicated by an apparent absence of blue coloration. This produced 18 
segments total: 4LT, 4LM, 4LB (untreated), 4RT, 4RM, 4RB (untreated), 5LT, 5LM, 5LB 
(untreated), 5RT, 5RM, 5RB (untreated), 6LT (untreated), 6LM, 6LB, 6RT (untreated), 
6RM, and 6RB.  These samples were then fixed in 10% formalin for six days, then 
placed in 70% ethanol and shipped to IDEXX BioResearch Pathology Services for 
histological analysis.  
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Figure 4.66: The soft palate from Horse #4 showed two large regions of distended ‘pillowed’ tissue 
as demonstrated in the full soft palate picture on the left.  Upon cutting into these regions, it was 
discovered that the inside tissue was a dark blue color as shown by the yellow arrow, indicating that 
it had been crosslinked by the genipin treatment as shown in the picture on the right.  
 
Figure 4.67: The soft palate from Horse #5 had a small necrotic region in the top area as highlighted 
by the yellow circle in the picture on the left.  Inside this region, the tissue was crosslinked blue as 
pointed out by the white arrow surrounded by a small pocket of apparent light gray necrotic tissue 
as shown by the yellow arrow in the picture on the right.  
Epiglottis	
Hard	
palate	
Hard	
palate	
Epiglottis	
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Figure 4.68: The soft palate from Horse #6 had a large region of gray necrotic tissue surrounded by a 
fibrotic encapsulation as seen in yellow circle in the picture on the left.  Inside of this region, the 
tissue had some evidence of blue crosslinking, but it also had evidence of damaged tissue as seen 
in the picture on the right. 
 Dr. Cynthia Besch-Williford, a licensed veterinary pathologist, completed the 
histological analysis.   Each sample was processed for paraffin infiltration, blocked, 
sectioned, stained with H&E and examined microscopically.   A few of the samples were 
too large to fit in one cassette, so they were bisected and placed into two cassettes. 
Observed microscopic changes were described to the extent and grade of inflammation 
using terms including minimal, mild, moderate, and marked.  
Overall, there was no specific trend in the severity or extent of inflammatory 
infiltrates related to the treated sections.  However, the inflammatory response was 
linked to the extent of tissue necrosis.  Two untreated samples, 4RB and 6LT, had tissue 
damage, fibroplasia and inflammatory responses similar to the treated tissues, 
suggesting to Dr. Besch-Williford that the crosslinking reagent had migrated to these 
regions despite the lack of any blue coloration. It is not likely that Dr. Besch-Williford 
came to the correct conclusion in this regard, being unfamiliar with the direct link 
between genipin penetration and the presence of blue coloration.  In all samples, there 
was a moderate to extensive region of tissue disruption and necrosis in the middle or the 
core of the soft palate with abundant neutrophils associated with regions of tearing and 
lesions as shown in Figures 4.69 and 4.70.  These results were most likely due to the 
consistently observed expansion, or pillowing of the tissue during the injections to 
accommodate the two 1 mL volumes of reagent (or 1.5 mL in the case of Horse #5) plus 
any aberrant amount of air used to push the reagent into the tissue, which caused the 
Epiglottis	
Hard	
palate	
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tissue to be disrupted.  Figure 4.71 demonstrated expanded vessels in the submucosa, 
caused by edema formed from mechanical disruption or tissue freezing.  Bacteria 
colonized the necrotic region on the exterior of the soft palate from Horse #6, with 
encysted Sarcocystis bradyzoites also observed in the viable muscle as seen in Figure 
4.72. The inflammation and fibroplastic responses of this tissue were most likely 
increased as a result of the bacteria present.  Summaries of inflammation and fibroplasia 
scores for each section are listed in Table 4.9, and detailed histological analysis 
descriptions from IDEXX are listed in Appendix C4.  
Based on the disruptive reagent delivery technique, it is unclear to what extent 
the tissue disruption, inflammatory response and scar tissue formation was due to the 
mechanics of the injections or due to the genipin reagent.  By the presence of tissue 
disruption, inflammatory and fibroplastic responses in the control regions of the soft 
palate that had not been contacted by the genipin crosslinker, it is clear that the injection 
technique itself contributed to these histological observations.  Additionally, the 
inadvertent creation of fibrotic tissue as a result of the disruptive delivery technique could 
have assisted in stiffening the soft palate, thus preventing dorsal displacement of the soft 
palate and causing a reduction in snoring. Due to the effects of the adverse reagent 
delivery technique, the relative contribution of the genipin agent itself has yet to be fully 
determined. Also, the histologic results are at a single, seven-day time point post 
injection and may not adequately reflect the long-term responses of the treatment and 
fibrotic tissue formation.    
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Table 4.9 Relative scores of inflammation and fibroplasia for each sample with 0=no significant 
change noted, 1=minimal, 2=mild, 3=moderate, and 4=marked.  
Sample ID Group Inflammation 
Severity 
Inflammation 
Extent 
Central Tissue 
Necrosis 
Fibroplasia 
4LT Treated 4 3 4 2 
4LM Treated 3 3 2 2-3 
4LB Control 0 0 0 0 
4RT Treated 4 4 4 2-3 
4RM Treated 4 4 4 3 
4RB Control 4 4 4 3 
5LT Treated 4 4 4 3 
5LM Treated 4 4 4 3 
5LB Control 0 0 0 0 
5RT Treated 3 4 3 2-3 
5RM Treated 3 4 2 2-3 
5RB Control 0 0 0 0 
6LT Control 2 2 1 1 
6LM Treated 4 3 4 2-3 
6LB Treated 4 4 4 3 
6RT Control 0 0 0 0 
6RM Treated 4 4 4 3 
6RB Treated 4 4 4 3 
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Figure 4.69: An image taken at 20X magnification from sample 4LM shows abundant neutrophils in 
the core of the biopsy with a mild to moderate zone of necrotic tissue.  In this sample, degenerated 
palatine muscle with fibroplasia is also evident. 
 
Figure 4.70: The 20x magnification image of sample 4RT showed an extensively necrotic core with 
distended blood vessels.  The surrounding tissue had an abundant amount of neutrophil infiltrates 
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Figure 4.71: The connective tissue fibrils of the 4LT sample at 20x magnification were widely 
separated from edema, perhaps secondary to mechanical disruption, or tissue freezing as indicated 
by the arrows in the picture.  Otherwise, the sample had necrotic collagenous stroma that was 
moderately infiltrated with neutrophils. 
 
Figure 4.72: The 20x magnification image of the 6LM sample showed an extensively necrotic core 
surrounded by a region of fibroplasia.  This sample had a few neutrophils present as well.  
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4.2 Soft Palate Mechanical Testing Study 
The soft palate mechanical testing study examined the effects of the genipin 
treatment in cadaveric equine samples on the mechanical properties of the soft palate.  
The results of the hysteresis, stress relaxation, and tensile loading to failure tests were 
summarized in this section.  Additionally, statistical analysis for each sample were 
completed and described.   
4.2.1 Sample Preparation 
Twelve cadaveric equine soft palates were obtained from Conboy Enterprises, 
Inc. in Lexington, KY.  Each palate was thawed for 24 hours and extracted from the 
surrounding tissue.  Then, two to four sections were cut from each palate following the 
Figure 3.10 from Chapter 3 with two top sections cut closest to the edge contacting the 
epiglottis and with two bottom sections cut closest to the hard palate.  Palates #5, #6, 
and #9 only had two sections cut from it, and Palate #1 only had three sections cut from 
it due to size and quality issues with the individual palate specimens.  The remaining 
palates had four sections cut from them. The palate sections were then divided into 3 
test groups. The control group had 14 total samples, with 8 top sections and 6 bottom 
sections.  The buffer group had 12 total samples, with 6 top sections and 6 bottom 
sections.  The genipin group had 17 total samples, with 9 top sections and 8 bottom 
sections.   
Each sample was then treated with the appropriate reagent or left untreated 
based on their specific test group based on Figure 3.11 from Chapter 3.  The reagents 
were delivered into the middle of the sample at an approximately 30-degree angle from 
the horizontal.  The best way to ensure even coverage of the reagent, based on trial and 
error injection tests, was to insert the needle slightly toward one end but adjacent to the 
halfway point of the length of the sample, and then dispense the reagent as the needle 
was being pulled out.  The needle was inserted to about half of the depth of the tissue, 
then the reagent was injected with even pressure at a rate of approximately 0.1 mL per 
second as the needle was being slowly extracted.  This method allowed the reagent to 
cover a larger cross-sectional area and helped to prevent any expansion of the tissue to 
accommodate the liquid.  If the entire reagent volume was injected entirely in one 
location, then the tissue would expand like a ‘pillow’ to accommodate the extra fluid.  As 
noted, in the histology results from the in vivo study, the ‘pillowing’ effect was associated 
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with tearing and lesions within the tissue leading to neutrophil invasion and necrotic 
tissue in and around the injected area, so the ‘pillowing’ effect was avoided in the 
mechanical testing study. The injection time and location on the soft palate were noted 
for each sample. After incubation, the samples were necked down to approximately 1 cm 
wide, which was about half of the starting width of each sample.  The length, width and 
depth of the entire sample and necking region were measured using a ruler and 
recorded.   For the genipin samples, the area of blue visible on the outside surface of the 
sample was also measured using a ruler and recorded.   In most of the top samples, the 
genipin reagent covered the entire cross-sectional area of the necking region based on 
observations of the outside edges of the specimen.  In thicker samples, the volume of 
genipin injected was not sufficient to cover the entire cross-sectional area of the tissue; 
therefore, the blue crosslinked region would be located more towards the top layer of the 
samples only.  All pertinent information and testing notes for the soft palate mechanical 
testing study is included in Table 4.10 in Appendix D1.   
4.2.2 Mechanical Testing 
Each sample first underwent the hysteresis test.  For all samples, a load of 10 N 
was applied, and then the sample was displaced ± 3 mm from the starting point for 20 
cycles.  One sample, SP8BLB, underwent the hysteresis test twice because the 10 N 
preload was not applied in the first one.   Using the time (s), stroke (mm), and load (N) 
values recorded from the tensile testing machine, the 1st cycle hysteresis, 20th cycle 
hysteresis, change in hysteresis and hysteresis ratio were calculated.   Additionally, the 
1st and 20th cycle hysteresis curves, as well as the entire hysteresis graph, were plotted 
for each specimen.   Example 1st cycle, 20th cycle, and entire hysteresis curves for a 
control, buffer and genipin sample are shown in Figures 4.73 – 4.78.  In general, based 
on the graphs, the genipin treated experienced a trend of more hysteresis in the 1st 
cycle, but the difference was not statistically significant.  Additionally, the genipin treated 
samples experienced a larger change in hysteresis over the course of the 20 cycles, but 
the difference was not statistically significant.   The hysteresis test parameter results for 
all individual samples are shown in Table 4.11 in Appendix D2.    
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Figure 4.73: The 1st and 20th cycles for the hysteresis curve for the control sample show a reduction 
in the area between the curves for the two cycles.  
 
Figure 4.74: The entire hysteresis curve for the control samples demonstrates where the 1st and 20th 
cycle are in relation to the rest of the curve.  It also demonstrates the reduction in maximum stress 
as the cycle number increases.  
 
Figure 4.75: The 1st and 20th cycles for the hysteresis curve for the buffer sample show a large 
difference in the area between the curves for the two cycles.  
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Figure 4.76: The entire hysteresis curve for the buffer samples demonstrates where the 1st and 20th 
cycle are in relation to the rest of the curve.  It also demonstrates the reduction in maximum stress 
as the cycle number increases.  
 
Figure 4.77: The 1st and 20th cycles for the genipin sample show a smaller difference in the area 
between the curve compared to the buffer and control samples.    
 
Figure 4.78: The entire hysteresis curve for the genipin samples demonstrates where the 1st and 20th 
cycle are in relation to the rest of the curve.  It also demonstrates a longer toe region when applying 
load during cyclical loading for the genipin samples.  
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Next, each sample underwent the stress relaxation test, where the sample was 
preloaded with 10 N and held at a constant deformation for 5 minutes.  One sample, 
SP3TRB, underwent the stress relaxation test twice because the first set of data was not 
recorded.  Using the time (s), stroke (mm), and load (N) values recorded from the tensile 
testing machine, the minimum stress, maximum stress, stress relaxation, relaxation 
modulus, and normalized relaxation modulus were calculated, and the respective graphs 
were plotted.  Examples of stress relaxation graphs for the control, buffer and genipin 
samples are shown in Figure 4.79.  Based on the figure, the buffer specimen appears to 
have a larger stress relaxation, however, the differences between the three groups was 
not statistically significant as further discussed below in Section 4.2.3.  
 
Figure 4.79: Typical stress relaxation curves for the buffer, genipin, and control groups.  
Also, the relaxation modulus and normalized relaxation modulus were calculated 
for each sample.  The normalized relaxation modulus was calculated by dividing the 
individual sample strain by the average strain for that test group.  The averages for the 
control group, buffer group and genipin group were 0.2771 MPa, 0.3027 MPa, 0.2355 
MPa, respectively.  The normalized relaxation modulus in general showed an increase 
for the genipin and buffer treated samples as shown in Figure 4.80, but the differences 
were not statistically significant.  The stress relaxation test results for individual samples 
are shown in Table 4.11 in Appendix D2. 
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Figure	4.80:	The	normalized	relaxation	modulus,	which	was	normalized	to	the	individual	averages	for	each	test	
group,	displayed	an	increase	for	the	genipin	and	buffer	treated	samples,	although	the	differences	were	not	
statistically	significant. 
Finally, each sample underwent a tensile load to failure test at a rate of 1 
mm/second.  During the SP4TLG sample’s tensile test, the tissue slipped out of the grips 
during the early loading phase before any failure was observed, thus requiring the test to 
be repeated.  In general, the samples failed diagonally along the outer layer fibers in the 
middle of the sample for 34 of the 44 samples, or 77% of the time.  The remaining 
samples failed outside of the middle region, closer to the grips.  Using the time (s), 
stroke (mm), and load (N) values recorded from the TestResources system, tensile 
stress and strain parameters were determined.  Then, the stress-strain curve was 
plotted, and from that, the toe region slope, Young’s Modulus, yield stress, yield strain, 
toughness, energy, and resilience were calculated.  Examples of stress strain curves for 
the control, buffer and genipin samples are shown in Figures 4.81-4.83.  In general, the 
different treatment groups all had similar stress-strain profiles, with a defined toe region, 
linear region and yield point. The tensile test results for individual samples are shown in 
Table 4.11 in Appendix D2.   
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Figure 4.81: The stress strain curve allowed many important parameters to be calculated for each 
test group.  This sample stress strain curve for the control group shows an obvious yield point at 
the intersection of the curve and the offset strain line.  
 
Figure 4.82: The stress strain curve allowed many important parameters to be calculated for each 
test group.  This sample stress strain curve for the buffer group highlights the toe region and linear 
region, as well as the offset strain line, that were used to calculate the respective slopes and yield 
point. 
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Figure 4.83: The stress strain curve allowed many important parameters to be calculated for each 
test group.  This sample stress strain curve for the genipin group demonstrates how the maximum 
point on the graph is usually not equal to the yield point, as shown by the offset strain line 
intersection with the stress strain curve.  
4.2.3 Mechanical Testing Analysis 
Once all of the parameters were determined for each sample, the outliers were 
removed using the three-sigma rule, meaning that any sample with results more than 
three standard deviations away from the mean in a specific parameter was considered to 
be an outlier for that category.  Any sample that had five category outliers was 
considered to be an overall outlier, and removed from the data set.  There were five 
outliers in total: SP1TLG, SP7TLG, SP12BLG, SP3TRB, and SP10TRC.  The three 
genipin samples, SP1TLG, SP7TLG, and SP12BLG, all failed above the blue, 
crosslinked region, meaning the tensile testing data did not test the genipin treated area.  
The buffer sample, SP3TRB, was an outlier because the stress relaxation test was 
repeated twice, leading to different mechanical testing results because of the collagen 
fibers were more relaxed.  The control sample, SP10TRC, was a very flimsy and 
unhealthy sample.  This left 12 samples in the control group, with 6 tops and 6 bottoms; 
11 samples in the buffer group with 5 tops and 6 bottoms; and 14 samples in the genipin 
group with 8 tops and 6 bottoms.   A summarized chart of the samples in each group 
and their values for all parameters is included in Table 4.12 in Appendix D3.  
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All of the viscoelastic and elastic-plastic parameter averages and standard 
deviations were calculated for each test group, as well as for the separated top samples 
and bottom samples.  The top samples data was analyzed separately from the bottom 
samples because the thickness of the soft palate varies significantly when moving from 
the free end of the soft palate toward the hard palate.  Therefore, the thinner top 
samples cut closest to the free end of the palate had a larger density of crosslinking 
treatment compared to the thicker bottom samples cut closer to the hard palate because 
the collagen content decreases when moving from the epiglottis to the hard palate, 
causing there to be a large variation in the results among test groups.  Separating the 
top and bottom samples allowed for smaller standard deviations for each parameter.  
The averages and standard deviations for each group with the outliers removed are 
summarized in Table 4.13 in Appendix D4.   
Using the averages for each parameter, the percent differences were 
determined.  First, the percent differences between the control group and buffer group 
were calculated to see if injection of the buffer alone had any effect on the mechanical 
properties of the soft palate, as summarized in Table 4.14.  Any statistically significant 
percent difference greater than 25% were noted in red. The percent differences between 
the buffer group and genipin group were calculated to determine the effect of the genipin 
treatment on the mechanical properties of the soft palate.  Any statistically significant 
percent difference greater than 25% were highlighted in red, as summarized in Table 
4.15.  Some differences were expected between the buffer-only treated samples and the 
control samples due to the dramatically increased hydration in these samples.  Using 
these differences, the effect of the genipin injection could be deduced based on the 
effects of the increased hydration caused by the injection of the solvent on the 
mechanical properties. 
For the statistical analysis, either a t-test or Mann-Whitney U non-parametric test 
were completed based on whether the variance of the sample groups could be 
considered the same, as determined by the F-test.  To complete the F-test, first the 
critical F-value (Fcrit) was determined for each comparison using an F-table.  Then, the F 
value was calculated.   If the F value was less than the Fcrit value, then the variances 
were considered to be the same and the t-test was used.  If not, then the Mann Whitney 
U test was used.  The Fcrit values for each comparison are shown in Table 4.16, and the 
individual F values for each parameter are listed in Table 4.17 in Appendix D5.  All F 
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values that are larger than the Fcrit value for that comparison are highlighted in red.  
Based on the results of the F-test, the t-test could be applied to the buffer versus control 
comparison for the overall samples and the top only samples, and to the buffer versus 
genipin comparison for the tops only samples because the variances were assumed to 
be the same with an alpha of 0.05.  For the remaining comparisons, the Mann-Whitney 
U non-parametric test was completed because the variances could not be assumed to 
be the same based on the failure of the F-test with an alpha of 0.05.  Statistically 
significant parameters are marked with an asterisk (*) in Tables 4.14 and 4.15.  
Individual p-values for each parameter are shown in Table 4.18 in Appendix D6. 
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Table 4.14: COMPARISON OF BUFFER-ONLY GROUP TO CONTROL GROUP – The percent 
differences for the buffer samples compared to the control samples for each parameter were broken 
down into the top samples only, bottom samples only and overall samples. The results were 
reported based on how the buffer group average relates to the control group average. Statistically 
significant results with a p value less than 0.05 with α=0.05 are marked with an asterisk and 
highlighted in red (*). 
Parameter Top Samples 
Only 
Bottom Samples 
Only 
Overall Samples 
Cross Sectional Area 14.64 % 
decrease 
22.90 % decrease 18.57 % decrease 
Ultimate Tensile Stress 6.40 % decrease  65.88 % increase* 16.24 % increase 
Ultimate Tensile Strain 6.49 % decrease 33.08 % increase 11.14 % increase 
Yield Strain 3.24 % increase 12.14 % increase 7.10 % increase 
Yield Stress 4.48 % increase 34.54 % increase 14.02 % increase 
Young’s Modulus 4.42 % decrease 11.35 % increase 0.26 % decrease 
Resilience 20.11 % 
decrease 
276.07 % increase 49.67 % increase 
Toe Region Modulus 17.28 % increase 30.61 % decrease 6.55 % decrease 
Toughness 56.17 % 
decrease 
140.94 % 
increase* 
35.29 % decrease 
Energy to Failure 58.63 % 
decrease 
92.34 % increase 34.49 % decrease 
1st Cycle Hysteresis 4.44% increase 17.66% increase 8.52% increase 
Change in Hysteresis 9.48 % increase  16.63 % increase 11.38 % increase 
Hysteresis Ratio 13.94 % 
decrease 
4.47 % decrease 10.09 % decrease 
Stress Relaxation 19.39 % increase 48.98 % increase 29.98 % increase 
Relaxation Modulus 24.36 % increase 30.22 % increase 26.69 % increase 
Normalized Relaxation 
Modulus 
78.16% increase 42.26% increase 58.32% increase 
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Table 4.15: COMPARISON OF GENIPIN AND BUFFER-ONLY INJECTED GROUPS – The percent 
differences for the genipin samples compared to the buffer samples for each parameter were broken 
down into the top samples only and overall samples. The results were reported based on how the 
genipin group average relates to the buffer group average.  Statistically significant results with a p 
value less than 0.05 with α=0.05 are marked with an asterisk and highlighted in red(*). 
Parameter Top Samples 
Only 
Overall Samples 
Cross Sectional Area 11.95 % 
decrease 
20.49 % decrease 
Ultimate Tensile Stress 51.67 % 
increase* 
31.20 % increase 
Ultimate Tensile Strain 32.89 % 
decrease 
30.88 % 
decrease* 
Yield Strain 34.57 % 
decrease 
30.65 % decrease 
Yield Stress 53.04 % 
increase* 
42.69 % increase* 
Young’s Modulus 63 % increase* 56.02 % increase* 
Resilience 6.43 % decrease 27.51 % decrease 
Toe Region Modulus 118.34 % 
increase 
118.33 % increase 
Toughness 11.99 % increase 9.71 % increase 
Energy to Failure 6.60 % increase 6.99 % decrease 
1st Cycle Hysteresis  10.31% increase 23.41% increase 
Change in Hysteresis 1.08 % decrease 14.88 % increase 
Hysteresis Ratio 30.20 % increase 23.24 % increase 
Stress Relaxation 4.09 % increase 9.19 % increase 
Relaxation Modulus 74.10 % increase 71.54 % increase 
Normalized Relaxation 
Modulus 
96.28% increase 69.61% increase 
 
When comparing the buffer samples to the control samples, it was expected that 
an increase in hydration would have an effect on the mechanical properties of the buffer-
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only treated samples, however, there should not be many parameters with a statistically 
significant difference of more than 25%.  Based on the results summarized in Table 
4.14, the tops only buffer treated group and the overall buffer treated group had no 
parameters that had statistically significant differences from the control group. Since the 
tops only and the overall category did not have any statistically significant differences 
between the buffer treated samples and the control samples, it proves that the buffer 
treatment alone does not have any significant effect on the mechanical properties of the 
soft tissue for these test groups, despite the increase in hydration.  This means that 
when the buffered genipin reagent is injected into the soft palate, the crosslinking affect 
caused by the genipin is presumed to be the primary contributor towards any changes in 
the mechanical properties.   
On the other hand, the bottom only group had two parameters with statistically 
significant differences between the buffer treated group and the control group.  Due to 
the statistically significant differences for two of the parameters, the bottom only group 
was determined to demonstrate a change in the mechanical properties when treated 
with the buffer only group.  An effect by the buffer only treatment could be evident in the 
bottom only samples due to the large variation in the collagen content compared to the 
tops only samples.  Additionally, the thicker samples may have retained more of the 
injected water, causing an increase in hydration that had an effect on the tissue’s 
properties.   Finally, since the bottom samples were thicker, the volume of genipin 
reagent injected may not have been able to adequately cover the entire cross-sectional 
area of the tissue compared to the thinner samples.  Therefore, the bottom only samples 
were not used to compare the effect of the genipin treatment on the soft palate.  
Finally, the genipin samples were compared to the buffer samples to determine 
the effect of the genipin treatment on the mechanical properties of the soft palate.  
Again, only the tops-only and the overall groups were statistically analyzed due to the 
bottoms-only group showing significant effects caused by a variety of reasons, as 
previously explained.  The tops-only groups had statistically significant differences from 
the buffer treated samples in three parameters: ultimate tensile stress, yield stress and 
Young’s modulus.  The overall group had statistically significant differences for three 
categories as well: ultimate tensile strain, yield stress, and Young’s Modulus.  
None of the parameters from the hysteresis test demonstrated a statistically 
significant difference between the genipin treated samples and the buffer treated 
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samples.   Similarly, the stress relaxation test did not produce any parameters with 
statistically significant differences.  Consequently, there was no measurable effect of the 
genipin crosslinker on the viscoelastic properties of the soft palate.  
  The tensile test produced three parameters with statistically significant 
differences between the genipin treated group and the buffer treated group.  Ultimate 
tensile stress (p=0.021) and strain (p=0.006) had statistically significant results for the 
tops only group and the overall group, respectively.  The increase in ultimate tensile 
stress shows an increase in strength for the genipin treated samples, which is supported 
by a previous study that crosslinked spinal discs with genipin and demonstrated a 
statistically significant 20.7% increase in ultimate tensile strength (p=0.036) [19].  
Another study that treated equine tendons produced statistically significant results in the 
ultimate tensile stress (p<0.0001) and strain (p=0.01) for genipin treated tissues [71].  
The decrease in ultimate tensile strain showed an increase in stiffness.  Both of these 
results enhance the soft palate, making it stronger and stiffer, and thus better able to 
resist displacement.  Similarly, Young’s modulus had a statistically significant (p=0.026 
for tops-only and p=0.014 for overall) increase, demonstrating that the treated tissue is 
stiffer due to the genipin crosslinking, which was supported by an increase Young’s 
modulus for the genipin treated samples in the tendon study (p<0.0001) [71].   
 As previously mentioned, yield stress and strain are important parameters in soft 
tissue applications because they mark the point at which the material begins to 
plastically deform, resulting in permanent deformation or injury to the tissue.  The yield 
stress showed a statistically significant (p=0.017 for tops-only and p=0.049 for overall) 
increase in the strength of the genipin treated tissue for both the tops only and overall 
groups.  This result was supported by previous studies that utilized genipin to crosslink 
spinal discs, which showed a statistically significant increases in yield stress (p=0.012) 
[19-20].  Yield strain was not statistically significant, but appeared to trend more than 
25% lower for both the tops-only and overall groups.  
Also, the statistically significant increase in yield stress without a statistically 
significant change in resilience suggests that there was no increase in the brittleness of 
the tissue compared to the buffer-only samples.  The percent differences for resilience 
supported this because they were all less than 15%, showing that the energy required to 
plastically deform the genipin treated tissues was not statistically different than the 
control samples. Similar studies conducted in the tendon and intervertebral disc showed 
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statistically significant increases in the resilience (p=0.01 and p=0.019, respectively), 
meaning that genipin typically increases the resilience in tissues with a higher 
percentage of collagen content [19-20,71].  Since the soft palate has less collagen 
present, it makes sense that the resilience would not necessarily be as affected by the 
genipin treatment.  Similarly, the energy required to permanently deform the tissue 
increased, but it was not statistically significant meaning that the toughness of the soft 
palate tissue was not affected by the genipin treatment. This was supported by similar 
tests in the disc that showed an increase in toughness, without statistical significance 
(p=0.170), meaning that genipin does not negatively affect the toughness of the tissue 
[19-20].  Based on these results, the genipin treatment created statistically significant 
differences in the ultimate tensile stress, ultimate tensile strain, yield stress and Young’s 
modulus categories, exhibiting an increase in strength and stiffness of the soft palate.   
5. Conclusions 
 Snoring and OSA are sleep disorders caused, in part, by mechanical degradation 
of the soft palate due to accumulated damage from snoring.  Some current treatments 
focus on preventing snoring and OSA by increasing stiffness through fibrotic tissue 
formation, even though fibrosis formation leads to inferior mechanical properties.  A 
genipin reagent was used as a treatment for the soft palate to prevent snoring and 
deformations and to also improve the mechanical properties by crosslinking the native 
collagen fibers.  The genipin treatment was tested using a pilot equine in vivo study and 
a soft palate mechanical testing study.  
The success of the pilot equine in vivo study relied upon the results of the 
respiratory audio recording, the dynamic endoscope examinations and the owner’s 
reports.  At least one of the horses was diagnosed as no longer having DDSP, and no 
longer shows any symptoms associated with the disorder.  Another horse did not have a 
post treatment dynamic endoscope examination completed; however, based on the 
audio analysis and the owner’s update, the horse is no longer experiencing any DDSP 
symptoms, including snoring, palatal displacements, or exercise intolerance.  The final 
horse was diagnosed with DDSP still, but has showed improvements in exercise 
tolerance and snoring loudness. Histological results showed no specific inflammatory 
infiltrate trends.  However, there was evidence of adverse responses due to errant 
injections, such as the necrotic tissue on the mucosal surface and the tearing and 
lesions due to the ‘pillowing’ of the soft palate during transnasal endoscopic injections.  
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The histology samples also had an appearance of fibroplasia, which could mean that the 
effective treatment of the DDSP horses may be due to a combination of the inadvertent 
fibroplastic response to the over-extension of the soft palate during injection and of the 
mechanical effects of the genipin treatment.   
Future in vivo studies should focus on reduced injection volumes and alternative 
delivery methods to avoid errant injections and the over-extension of the soft palate 
during injections.  Using the 1-meter long endoscope proved to be difficult to inject the 
soft palate due to issues with controlling the endoscope and clearly seeing the injection 
site.  New possibilities for delivery methods include using coated sutures to release the 
genipin and to avoid errant injections, or using reduced injection volumes and multiple 
injection sites to avoid the ‘pillowing’ effect.  Also, a video endoscope could be used to 
make viewing the injection area easier.  Likewise, a larger in vivo study should be 
completed to test the effectiveness of the genipin treatment at different volumes and 
concentrations.  Eventually, the genipin treatment should be tested in human trials to 
test the efficacy of the genipin injections for snoring and OSA applications.  
 The soft palate mechanical testing study produced statistically significant results 
in four categories for the genipin treated samples compared to the buffer treated 
samples, with an increase in ultimate tensile stress, yield stress, and Young’s modulus 
and a decrease in yield strain.   These results demonstrate an increase in tissue strength 
and stiffness, leading to an increase in tissue stability.    The location of the samples in 
relation to the hard palate proved to have an effect on the results of the mechanical 
tests.  The samples taken closer to the epiglottis produced statistically significant 
improvements in the mechanical properties due to their higher collagen content 
compared to the samples closer to the hard palate, thus indicating that the preferred 
treatment location is closer to the free edge of the soft palate near the epiglottis.  
 Future research should focus on standardizing the reagent delivery method.  
There is a large learning curve when it comes to injecting the reagent uniformly 
throughout the entire cross-section of the sample.  Therefore, research should be done 
to determine the ideal injection angle, pressure and location. Similarly, the appropriate 
volume of the reagent to administer should be determined based on the cross-sectional 
area of the specific sample since the thickness of the soft palate increases from the free 
edge near the epiglottis to the hard palate.  Finally, the mechanical testing study should 
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be repeated with human soft palates to determine the effects of the genipin treatment on 
human soft palate mechanical properties.  
Overall, the in vivo study and mechanical testing study supported the hypothesis 
by showing reduction of aberrant vibrations and displacements while also improving the 
mechanical properties of the soft palate.  The reduction in snoring loudness and palatal 
displacement in the in vivo study agreed with the increase in tissue stiffness from the 
mechanical testing study. The increase in tissue strength suggests that the stability of 
the tissue was increased by the genipin treatment.   The histology results suggested that 
the microstructural and compositional integrity could be conserved with proper reagent 
delivery.  This was further supported by the maintenance of the viscoelastic properties of 
soft palate as demonstrated by the hysteresis and stress relaxation tests.  In essence, 
the genipin treatment demonstrated an increase in tissue strength, stiffness and stability 
based on the results from the in vivo study and the mechanical testing study, suggesting 
that genipin-based treatments should be further evaluated, and could become an 
effective and safe treatment for snoring and OSA applications.    
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APPENDIX A1: Dr. Sprayberry’s questions and answers for in vivo study 
Answers by Dr. Kim Sprayberry in bold 
General Questions: 
1. What needs to be done to obtain the DDSP horses? 
• What is necessary is to contact either trainers or veterinarians in 
the Illinois/Indiana/Missouri region who have horses with DDSP 
and would be willing to transport them to the study center. 
• I do not know many trainers or vets in those areas, and the few 
contacts I do have, have not been able to summon up any 
affected horses. 
2. What needs to be done to obtain the thoroughbreds? 
• Same answer: the Thoroughbreds are the DDSP horses, and we 
need to contact people in the area of the contract researcher so 
we can enroll some horses.  The problem is that this is a region 
of the country where racehorses are less numerous than in 
Kentucky, and I do not have many contacts there. 
 
Pre-Treatment Exam: 
1. Can this be done at the horse’s barn prior to sending the horse to Missouri or 
does this need to be completed at Missouri?  
• A horse with DDSP would likely have already had an endoscopic 
exam to confirm the diagnosis.  So yes, this pretreatment exam 
COULD be done at the horse’s home barn.  However, for the 
purposes of recording ‘before’ and ‘after’ pictures and 
comparing, it would be more uniform and repeatable if the B & A 
photos were done with the same equipment. 
2. What does the exam all need to include? 
a. Endoscopic exam? Yes. 
b. General exam? Yes. 
c. Record breathing? Yes, although the abnormal breathing heard 
with DDSP typically is only audible during exercise, not at rest. 
3. Can their regular veterinarian complete this exam or do all exams need to be 
completed by you? 
• Any veterinarian with an endoscope can do this.  The only caveat 
is if we are going to be using B&A images to judge or score 
results.  Then we’d run into a confounding factor with image 
variability stemming from different scopes, light sources, and 
other factors. 
 
Transportation: 
1. Is there a certain company you recommend to transport the horses to 
Missouri? 
• Not really; any company or individual with experience in hauling 
horses should be fine. 
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Timeframe: 
1. Approximate dates of study that would work for you? 
• I can spend 2 days at a time, and would most easily be available 
for this beginning mid July.  I am teaching summer school in the 
first session, meaning I’ll be tied up from mid June until mid 
July.  After that, I am very flexible and relatively uncommitted.  I 
will also be in Lexington for 3-5 days sometime in late July or 
early August.  
2. How many days would you want the horses there before the study? 
• Just 1. 
3. Any health requirements? 
a. Shots required? No 
b. Coggins? Only as required for transport across state lines. 
c. Health Certificate? Ditto 
 
Breathing Recording: 
1. Should the horse’s breathing be recorded just during exercise or during both 
exercise and rest? 
• Both 
2. How long to record the horse’s breathing during exercise? i.e. is 5 minutes 
sufficient or do you suggest shorter or longer? 
• 5 minutes should be sufficient.  We may find that a trainer will 
relate that his/her horse only begins making the noise after being 
on the track for 10 minutes, and in this regard, horses can vary 
among individuals.  But most horses are on the track for no more 
than 10 minutes in the mornings, and that is when the abnormal 
sound associated with DDSP are heard.  
3. How strenuous should the horse be exercising? i.e. walk, jog, lope, gallop, 
etc.  
• Galloping 
4. Does the breathing recording need to be completed within a certain 
timeframe? Does a week before study work or would a day before the study 
be sufficient? 
• Either interval would be fine 
5. Do you think a microphone attached to the halter/bridle be sufficient data to 
record DDSP frequency? 
• The best way of objectively confirming that any given horse has 
DDSP is to have a dynamic endoscope in place while the horse is 
galloping and record real-time images of the laryngeal 
abnormality.  This equipment is increasingly in use.  
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APPENDIX A2: Digital voice recorder specifications 
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APPENDIX A3: in vivo study consent form
  
 
                                                                                                                             
 
 
 
 1 1501 Bull Lea Road, Suite 103, Lexington, KY 40511-1285 
Phone: 512.818.8468     Email: thedman@orthopeutics.com  
 
 
AGREEMENT FOR EXPERIMENTAL EQUINE TREATMENT 
 AND OWNER’S INFORMED CONSENT 
This AGREEMENT FOR EXPERIMENTAL EQUINE TREATMENT AND OWNER’S INFORMED CONSENT 
(referred to as “Agreement and Consent”) is between: 
______________________________________, having an address of______________________________________ 
(referred to as “Owner”); 
Orthopeutics, LP, a Kentucky limited liability company, having an address of 1501 Bull Lea Rd. #103, Lexington, KY 
40511 (referred to singly as “Orthopeutics” and collectively with Sinclair Research Center, LLC as “Orthopeutics-
Sinclair”); and 
Sinclair Research Center, LLC, a Missouri biomedical research facility at the University of Missouri, having an address of 
562 Missouri DD, Auxvasse, MO 65231 (referred to singly as “Sinclair” and collectively with Orthopeutics, LP as 
“Orthopeutics-Sinclair”). 
Owner, Orthopeutics, and Sinclair are referred to collectively as the “Parties”.  The Effective Date of this Agreement and 
Consent is the date it is signed by the Parties. 
BACKGROUND 
NEXT stands for Nonsurgical Exogenous crosslink Therapy.  NEXT, sometimes referred to herein as NEXT Technology 
is a chemically made device formed following injection of a crosslinking agent into the soft palate of an animal, such as a 
horse, which interacts with the native proteins (e.g., collagen) causing the tissue to reduce its flaccidity and vibration and 
to increase its strength, resilience, toughness and fatigue resistance.  Strengthening the soft palate may help horses 
diagnosed with dorsal displacement of the soft palate (DDSP), which involves a form of awake snoring and apnea. 
The therapeutic effect of NEXT Technology typically begins within 30 minutes of application, and provides mechanical 
stabilization of the tissue within 24 hours of application. 
Orthopeutics’ spin out company, Equinext, LLC holds a worldwide exclusive license for NEXT technology for all animal 
applications. With potential commercialization benefits for Equinext, Orthopeutics-Sinclair are conducting the second 
stage of a First in Equine (FIE) study of the effects of NEXT on horses (referred to as the “Study”). 
Owner voluntarily elects to have the horse identified in Schedule 1 (referred to as “Horse”) participate in the Study for the 
treatment of DDSP and the soft palate.  Orthopeutics has determined that the Horse fits the NEXT treatment protocol, and 
Orthopeutics-Sinclair are willing to enroll the Horse in the Study subject to the agreements and Informed Consent 
expressed herein.   
Accordingly, the Parties agree and state as follows: 
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 2 1501 Bull Lea Road, Suite 103, Lexington, KY 40511-1285 
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AGREEMENTS 
1. Orthopeutics-Sinclair in their sole discretion, may remove the Horse from the Study at any time.  Owner may remove 
the Horse from the Study with a 14-day notice to Orthopeutics-Sinclair. 
2.  Owner shall be responsible for all normal and typical veterinary-related costs incurred before, during, and after the 
Horse’s participation in the Study. 
3.  It is the Owner’s sole responsibility, before agreeing to allow the Horse’s participation in the Study, to obtain 
professional input from the Horse’s veterinarian about whether NEXT Technology is reasonably likely to promote healing 
effects on the soft palate of the Horse, and whether the likely benefit justifies participation when weighed against possible 
adverse outcomes or side effects. 
4.  Owner shall follow the recommendations provided by the Horse’s veterinarian regarding care, evaluation, and 
rehabilitation following the administration of NEXT Technology, including but not limited to periodic clinical and 
endoscopic evaluations, and other types of pre-operative and post-operative evaluations as appropriate.  Owner, not 
Orthopeutics-Sinclair, shall be responsible for the costs of all forms of care, evaluation, and rehabilitation contemplated 
by this paragraph. 
5.  Orthopeutics-Sinclair may use any and all clinical or laboratory data related to the Horse and the NEXT Technology 
for any purpose, provided that the Horse’s and the Owner’s identity are kept confidential.  Owner shall maintain the 
confidentiality of all clinical and non-clinical outcomes in association with the NEXT Technology, unless otherwise made 
public by Orthopeutics within its sole discretion according to this paragraph. 
6. ORTHOPEUTICS-SINCLAIR DISCLAIM ANY AND ALL EXPRESS AND IMPLIED WARRANTIES IN 
CONNECTION WITH NEXT TECHNOLOGY AND THE AGENTS USED IN NEXT THERAPY, INCLUDING BUT 
NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY AND OF FITNESS FOR A 
PARTICULAR PURPOSE. 
7.  Liability of Orthopeutics-Sinclair, if any, is limited to the cost of the agents utilized in the NEXT Technology on the 
Horse, and Owner’s recovery and remedies are limited to such cost.  All further liability for all actual, direct, indirect, 
special, compensatory, and punitive damages, including but not limited to lost profits and consequential damages, which 
may occur for any reason are expressly disclaimed by mutual agreement of the Parties. 
8.  For the duration of this study, owner agrees to not utilize any other alternative treatment therapies on the Horse.  
Owner agrees to follow after care instructions and rehabilitation program as provided by Orthopeutics-Sinclair. 
9. Owner understands that the Horse must be shipped to the Sinclair Research Center in Missouri and acknowledges the 
inherent risks that are involved in shipping and transporting horses.  These risks may include but are not limited to, illness, 
disease, trauma, injury, or death of the Horse. Owner understands that Orthopeutics-Sinclair and the associated 
transporting company do not provide insurance.  Owner hereby holds Orthopeutics, Sinclair, and the transporting 
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company harmless for any liability that could incur for property damage or bodily injury to any horse and/or patrons while 
loading, transporting, unloading or handling the Horse.   
10. In the event that the horse requires veterinary care while in transport, Orthopeudics-Sinclair will immediately notify 
Owner.  If the Owner cannot be reached, Orthopeudics-Sinclair will contact the first available licensed veterinarian. 
Owner shall be responsible for all fees listed by said veterinarian, with no liability to Orthopeudics, Sinclair, or the 
transporting company. 
11, This Agreement and Informed Consent shall be governed by the laws of the Commonwealth of Kentucky, without 
regard to Kentucky’s or any other state’s rules concerning conflicts of law.  The Parties agree that Kentucky Courts shall 
have jurisdiction over them personally as well as over the subject matter of any dispute that arises in connection with this 
Agreement and Informed Consent.  Any lawsuit filed in connection with this Agreement must be commenced in Fayette 
County, Kentucky. 
 
INFORMED CONSENT 
1. The experimental nature of NEXT Technology has been fully explained to Owner and/or Owner’s agent.  Further, 
Owner is aware that potential risks, side effects, and adverse complications of NEXT Technology (referred to as 
“Complications”) may include, without limitation, lack of repair, deterioration of condition, soft palate damage, 
infection, inflammation, and bleeding.  However, the possibility of other unexpected responses including the 
possible need to euthanize the animal is not excluded.  Owner is aware that Complications may be either 
anticipated or unanticipated, and may be either immediately known or not immediately knowable.  While it is 
expected that Complications, if any, will be minimal, no guarantees or warranties of any kind are being provided 
regarding the outcome of the Study and/or the effects of NEXT Technology on the Horse. 
2. Owner understands that NEXT Technology on the Horse may include mild sedation, injection of a local 
anesthetic, and one or more injections of Genipin, and consents to same. 
3. The Parties acknowledge that Owner’s decision to allow the Horse to participate in the Study is entirely 
voluntary. 
4. By signing below, I, as the Owner or the Owner’s agent, acknowledge that I have read this Agreement and 
Informed Consent in its entirety, I have been provided with a description of the NEXT Technology, I have had the 
opportunity to ask further questions of Orthopeutics-Sinclair, and that the risks of potential Complications have 
been explained to my satisfaction. I give informed consent to the administration of NEXT Technology to the 
Horse in connection with the Study. 
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Signatures 
IN WITNESS WHEREOF, the parties have accepted and agreed to the above by and through their authorized agents as of 
the Effective Date: 
On Behalf of Owner,                                                 On Behalf of  
_______________________ :          Orthopeutics, LP: 
              _______________________________                       _____________________________ 
Name:  _______________________________           Name:   ______________________________ 
Title:  ________________________________           Title:     ______________________________ 
Date:  ________________________________           Date:     ______________________________       
 
On Behalf of: 
Sinclair Research Center, LLC: 
___________________________ 
Name:  _____________________________ 
Title:  ______________________________ 
Date:  ______________________________ 
 
 
 
 
 
 
	 135	
 
                                                                                                                             
 
 
 
 5 1501 Bull Lea Road, Suite 103, Lexington, KY 40511-1285 
Phone: 512.818.8468     Email: thedman@orthopeutics.com  
 
 
 
 
1. SCHEDULE 1 
Information about horse: 
Name:____________________________________   Discipline:______________________________ 
Breed:________________  Sex:   Mare    Gelding   Stallion      Age:______________ 
Veterinarian:__________________________  Vet phone:____________________  Email:______________________ 
Date of DDSP ("Snoring") Onset:______________  Frequency of Displacement:____________________  
Loudness of “Snoring”: _____________ 
Previous Health Conditions/Surgeries: _______________________________________________________________ 
Work Level of Horse:____  Pasture (no work)   ____  light work    ____  moderate work  ____  full work (1 hr/5 days wk) 
Purchase price of horse: ____________ 
Declared Value of Horse:______________________  Insured:    Yes      No 
Has insurance company been contacted?     Yes     No 
If insured, please provide following information: 
Insurance Co:_______________________   Phone:____________________  Contact:______________________ 
Owner Information: 
Name/Address:___________________________________________ 
                         ___________________________________________ 
                         ___________________________________________ 
Cell phone:____________________________________  Email:_________________________________ 
Information provided by:_____________________________________ Date:_______________ 
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 1 1501 Bull Lea Road, Suite 103, Lexington, KY 40511-1285 
Phone: 512.818.8468     Email: thedman@orthopeutics.com  
!
AGREEMENT FOR DONATION OF EQUINE FOR EXPERIMENTAL EQUINE TREATMENT 
 
This AGREEMENT FOR DONATION OF AN EQUINE FOR EXPERIMENTAL EQUINE 
TREATMENT (referred to as “Agreement”) is between:  
 
_____________________________________, having an address of ______________________________ 
(referred to as “Owner”); and 
 
Orthopeutics, LP, a Kentucky limitied liability company, having an address of 1501 Bull Lea Rd. #103, 
Lexington, KY 40511 (referred to as “Orthopeutics”).   
 
Owner and Orthopeutics are referred to collectively as the “Parties.”  The Effective date of this Agreement is 
the date it is signed by the Parties.  
 
AGREEMENTS 
1. Owner voluntarily donates the horse identified in Schedule 1 (referred to as “Horse”) to Orthopeutics to 
be used in the study for the treatment of dorsal displacement of the soft palate (DDSP) in equines 
(referred to as “Study”) at Sinclair Research Center at the University of Missouri (referred to as 
“Sinclair”).  
 
2. The Owner relinquishes all rights and responsibilities pertaining to the Horse to Orthopeutics.  
 
3. The Owner acknowledges that the Horse will be used for scientific research as a part of the Study, 
including but not limited to, anesthesia, soft palate injections, sound recordings, or endoscope 
examinations.  
 
4. Orthopeutics will be responsible for ensuring humane care of the Horse throughout the study.   
 
5. The Owner acknowledges that the Horse will be humanely euthanized at the conclusion of the study by 
licensed veterinarians at Sinclair.  
 
6. Owner acknowledges that there will be no money compensation for the donation of the Horse to 
Orthopeutics for the Study.  
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!
SIGNATURES 
 
IN WITNESS WHEREOF, the parties have accepted and agreed to the above by and through their authorized 
agents as of the Effective Date:  
 
On Behalf of Owner, 
 
____________________________________: 
  
 _______________________________________ 
 
Name: ________________________________________ 
 
Title: _________________________________________ 
 
Date: _________________________________________ 
 
 
On Behalf of 
 
Orthopeutics, LP:  
 
 _________________________________________ 
 
Name: _________________________________________ 
 
Title: __________________________________________ 
 
Date: __________________________________________ 
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Phone: 512.818.8468     Email: thedman@orthopeutics.com  
!
1. SCHEDULE 1 
Information about horse: 
 
Name:____________________________________   Discipline:______________________________ 
 
Breed:________________  Color: _____________ Sex:   Mare    Gelding   Stallion      Age:______________ 
 
Veterinarian:_______________________  Vet phone:_________________ Email:______________________ 
 
Previous Health Conditions/Surgeries: 
_______________________________________________________________ 
 
Work Level of Horse:____  Pasture (no work)   ____  light work    ____  moderate work  ____  full work (1 
hr/5 days wk) 
 
Purchase price of horse: ____________ 
 
Declared Value of Horse:______________________  Insured:    Yes      No 
 
Has insurance company been contacted?     Yes     No 
 
If insured, please provide following information: 
 
Insurance Co:______________________   Phone:____________________ Contact:______________________ 
  
Owner Information: 
 
Name/Address:___________________________________________ 
 
                         ___________________________________________ 
 
                         ___________________________________________ 
 
Cell phone:____________________________________  Email:_________________________________ 
 
Information provided by:_____________________________________ Date:______________________ 
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APPENDIX A5: Veterinary transcript for DDSP horses 
 
Hello Dr. [INSERT VET NAME HERE], 
 
I am a graduate student in the Department of Biomedical Engineering at the University of 
Kentucky.  I am currently working on an in vivo study on dorsal displacement of the soft 
palate, or DDSP, in horses.  The study consists of injecting the soft palate with a natural 
substance to stiffen it and decrease vibrations, thus reducing the frequency of soft palate 
displacement.  The study is being funded by a National Institute of Health SBIR Phase 1 
grant.  
 
I am actively searching for three horses with DDSP to be used in our study in the next 
couple of weeks.  The DDSP horses in the study would be transported to the Sinclair 
Research Center in Missouri.  The study would consist of an initial exam, including 
recording their breathing noises while running and an endoscopic evaluation.  Then, the 
horse will be sedated and their soft palates injected using a transendoscopic injection 
needle.  Finally, a post exam, similar to the initial exam, would be completed.  The 
horses would then be returned to their owners at the end of the study.  Licensed 
veterinarians at Sinclair Research Center would monitor the horses throughout the 
study.   
 
Do you know of any horses that would be good candidates for the study?  If you do not, 
do you know of anyone that could possibly help me? 
 
Please feel free to email me or call me with any questions or concerns.  I look forward to 
hearing from you. 
 
Thank you, 
Stephanie Hunt  
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APPENDIX A6: Reagent calculations for in vivo study 
 
Genipin Calculations: 100 mM 
100 𝑚𝑚𝑜𝑙
1𝐿
𝑥
1 𝑚𝑜𝑙
1000 𝑚𝑚𝑜𝑙
𝑥
226.22 𝑔
1 𝑚𝑜𝑙
𝑥
1𝐿
1000 𝑚𝐿
𝑥
2 𝑚𝐿
1 𝑏𝑜𝑡𝑡𝑙𝑒
= 0.045244
𝑔
𝑏𝑜𝑡𝑡𝑙𝑒
= 45.24
𝑚𝑔
𝑏𝑜𝑡𝑡𝑙𝑒
 
 
Buffer Calculations: 10% DMSO, 45 mM EPPS-P 
22.5 mL EPPS-P 
22.5 mL Distilled Water 
5 mL DMSO 
100 𝑚𝑀 𝐸𝑃𝑃𝑆 − 𝑃𝑥 !!.! !" !""#!!
! !"##$%
𝑥 ! !"##$%
!" !"
= 45 𝑚𝑀 𝐸𝑃𝑃𝑆 − 𝑃  
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APPENDIX A7: Respiratory audio analysis Matlab codes 
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APPENDIX A8: ImageJ Protocol 
 
1. Open ImageJ 
2. Import image 
3. Select image from the menu bar à color à split channels 
4. Using the green channel, select image à adjust à threshold 
5. Use the default values, then press okay. 
6. Select analyze à analyze particles 
The output will provide the count of the red squares, the area, and the percent area of 
red squares.  
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APPENDIX B1: Reagent calculations for mechanical testing study 
 
Genipin Reagent: 50 mM 
50 𝑚𝑚𝑜𝑙
1𝐿
𝑥
1 𝑚𝑜𝑙
1000 𝑚𝑚𝑜𝑙
𝑥
226.22 𝑔
1 𝑚𝑜𝑙
𝑥
1𝐿
1000 𝑚𝐿
𝑥
2 𝑚𝐿
1 𝑣𝑖𝑎𝑙
= 0.0226
𝑔
𝑣𝑖𝑎𝑙
= 22.6
𝑔
𝑣𝑖𝑎𝑙
 
 
Saline Buffer: 0.9% NaCl 
4.5 𝑔 𝑁𝑎𝐶𝑙
500 𝑚𝐿
𝑥
1000 𝑚𝐿
1 𝑣𝑖𝑎𝑙
= 9
𝑔
𝑣𝑖𝑎𝑙
 
 
Saline-Phosphate Buffer: 50 mM tri-sodium phosphate 
!" !!"#
!!
𝑥 ! !"#
!""" !!"#
𝑥 !"#.!" !
! !"#
𝑥 ! !
!""" !"
𝑥 !""" !"
! !"#$
= 19.01 !
!"#$
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APPENDIX B2: Soft palate extraction protocol  
Soft	Palate	Extraction	
1. Soft	palates	will	arrive	with	trachea	and	surrounding	tissues.		
	
	
2. Locate	the	epiglottis.		Flip	the	epiglottis	tip	below	the	notch	of	the	soft	palate.			
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
epiglottis	
Soft	palate	
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3. Cut	the	tissue	directly	above	the	soft	palate	along	the	median.		
	
	
4. Open	the	tissue	you	just	cut	to	expose	the	epiglottis,	soft	palate	and	larynx.	
	
	
5. Cut	along	the	outer	edges	of	the	soft	palate	to	separate	the	excess	tissue.		The	tissue	
along	the	edge	of	the	soft	palate	will	be	very	thin	and	transparent	–	this	is	a	good	place	
to	cut	along	to	ensure	the	entire	palate	is	included.		
	
	
	
	
	
	
	
	
Larynx	
Soft	Palate	
Epiglottis	
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6. Cut	along	the	bones	below	the	epiglottis	to	remove	the	pant	legs.	
	
7. Trim	any	excess	tissue	from	soft	palate.	
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APPENDIX B3: Mechanical testing protocol 
Mechanical	Testing	Protocol	
Hysteresis	Test	
1. Load	Sample	
2. Preload	10	N	
3. Set	up	program	
a. Show	Cycling	Panel:	Axial:	Stroke,	Mean:	ht	of	sample,	Amplitude:	3	mm,	Freq:	
0.5,	Phase:0,	Cycles:20,	Sine,	mean	down	
4. Set	up	DAQ	file	at	a	sampling	rate	of	50	Hz	
5. Start	recording	
6. Start	cycle	
7. Stop	recording	
8. Export	data	
	
Stress	Relaxation	Test	
1. Load	Sample	
2. Preload	10	N	
3. Create	program	
a. Step	1:	ramp	up	to	10	N,	rate	1	mm/s	
b. Step	2:	hold	300	s	
c. Step	3:	Idle	
4. Set	up	DAQ	file.	Change	DAQ	Rate	to	25	Hz	
5. Start	Recording	
6. Start	cycle	
7. Stop	recording	
8. Export	data	
	
Tensile	Test	
1. Load	sample	
2. Return	displacement	to	0	and	wait	30	seconds	
3. Set	up	function	generator	
a. Axial	mode:	stroke,	target	point:	39,	ramp	1mm/s	
4. Set	up	DAQ	at	a	sampling	rate	of	50	Hz	
5. Start	recording	
6. Start	ramp	
7. Stop	recording	
8. Export	data	
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APPENDIX B4: Hysteresis Parameter Calculations 
Hysteresis	Calculations:	
First,	the	starting	point	was	used	to	offset	the	stroke	data	to	find	the	absolute	displacements.		
For	example,	if	the	starting	point	was	42	mm,	the	stroke	data	was	offset	by	42	mm.	Then,	strain	
was	calculated	by	dividing	the	displacement	by	the	gauge	length.		Next,	stress	in	MPa	was	
calculated	by	dividing	the	load	by	the	cross-sectional	area	of	the	sample.		Finally,	stress	in	Pa	
was	calculated	by	raising	the	stress	in	MPa	values	to	the	sixth	power.		
Once	the	strain	and	stress	in	Pa	were	calculated,	the	hysteresis	graphs	were	plotted.		First,	the	
cyclical	loading	was	plotted	with	load	on	the	y-axis	and	time	on	the	x-axis	to	determine	the	
location	of	the	1st	and	20th	cycles.		The	1st	cycle	was	determined	to	be	from	the	first	local	
minimum	to	the	second	local	minimum	as	shown	in	red	in	Figure	1.		The	20th	cycle	was	
determined	to	be	from	the	19th	local	minimum	to	the	20th	local	minimum.			
	
Figure	1:	Hysteresis	Cycles	shown	as	load	versus	time	to	determine	location	of	1st	and	20th	cycles.	
Then, the corresponding local minimum points were extracted and graphed to create the 
individual cycle hysteresis curves with stress on the y-axis and strain on the x-axis.  For 
the 1st cycle, the stress and strain were plotted from corresponding values at the 1st local 
minimum point to the 2nd local minimum point as shown in Figure 2.  For the 20th cycle, 
the stress and strain were plotted from corresponding values at the 19th local minimum 
point to the 20th local minimum point as shown in Figure 3.   
	
	
Figure	2:	1st	cycle	hysteresis	curve	
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Figure	3:	20th	Cycle	hysteresis	curve	
Then,	the	entire	hysteresis	cycle	was	plotted	with	strain	on	the	x-axis	and	stress	on	the	y-axis	as	
shown	in	Figure	4.		The	1st	and	20th	cycle	curves	were	highlighted	in	red	and	black	respectively.	
	
Figure	4:	Hysteresis	Curve	for	all	Cycles	
Finally, the hysteresis for each point was calculated using the equation below.    
	
𝐼𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝐻𝑦𝑠𝑡𝑒𝑟𝑒𝑠𝑖𝑠 =
𝑆𝑡𝑟𝑒𝑠𝑠 𝑃𝑜𝑖𝑛𝑡 1 + 𝑆𝑡𝑟𝑒𝑠𝑠 𝑃𝑜𝑖𝑛𝑡 2
2
∗ (𝑆𝑡𝑟𝑎𝑖𝑛 2 − 𝑆𝑡𝑟𝑎𝑖𝑛 1)	
	
Once	all	of	the	individual	hysteresis	points	were	calculated,	the	total	hysteresis	for	the	cycle	up	
and	the	total	hysteresis	for	the	cycle	down	were	calculated	for	the	1st	curve.			The	total	
hysteresis	for	the	cycle	up	was	calculated	by	adding	together	all	of	the	individual	hysteresis	
values	from	the	1st	local	minimum	to	the	1st	cycle	maximum.		The	total	hysteresis	for	the	cycle	
down	was	calculated	by	adding	together	all	of	the	individual	hysteresis	values	form	the	1st	cycle	
maximum	to	the	2nd	local	minimum.		Then	the	difference	between	the	cycle	up	total	hysteresis	
and	the	cycle	down	hysteresis	was	calculated	to	determine	the	area	between	the	curves.		This	
was	repeated	for	the	20th	cycle.		
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APPENDIX B5: Stress relaxation parameter calculations 
The	stress	relaxation	graphs	were	analyzed	for	the	relaxation	force	and	for	the	relaxation	
modulus.		First,	the	stress	relaxation	graph	was	plotted	with	time	on	the	x-axis	and	stress	in	MPa	
on	the	y-axis	as	shown	in	Figure	1.		From	this	graph,	the	maximum	and	minimum	stresses	were	
determined.		Then	the	relaxation	force	was	calculated	by	calculating	the	difference	between	the	
maximum	and	minimum.		
	
Figure	5:	Stress	Relaxation	Graph	
Finally,	the	stress	relaxation	modulus	was	calculated	at	each	point	using	Equation	1.		Then,	the	
maximum	and	minimum	relaxation	modulus	values	were	determined,	and	the	relaxation	
modulus	difference	was	calculated	by	subtracting	the	minimum	value	from	the	maximum	value.		
𝑅𝑒𝑙𝑎𝑥𝑎𝑡𝑖𝑜𝑛 𝑀𝑜𝑑𝑢𝑙𝑢𝑠 =  !(!)
!
	(Equation	1)	
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APPENDIX B6: Tensile test parameter calculations 
Tensile	Test	
Goal:	Find	the	Peak	Stress,	Strain,	Toughness,	Energy	to	Peak,	Toe	Region	Slope,	Young’s	
Modulus	and	Yield	Point.			
1. Using	the	stroke	data	offset	the	values	by	the	starting	point.		For	example,	if	all	data	
starts	at	-42mm,	offset	the	values	by	42	mm.		
2. Find	the	strain	by	dividing	the	offset	stroke	by	the	length.		
3. Find	the	stress	by	dividing	the	load	by	the	cross	sectional	area.		
4. Find	the	peak	stress	by	finding	the	absolute	maximum	stress.		
5. The	strain	at	peak	is	determined	by	finding	the	strain	at	the	absolute	peak	stress	value.		
6. Plot	the	stress	vs.	strain	graph.		
7. Plot	the	toughness	values	from	the	start	of	the	graph	to	the	final	non	zero	point.		Add	a	
trendline	with	the	equation	and	R2	value.		The	trendline	should	be	raised	to	the	3rd	
power.		
8. Determine	the	toughness	by	dividing	each	part	of	the	toughness	equation	by	the	strain	
raised	to	the	respective	power	and	adding	them	together.		
9. Calculate	the	energy	for	the	entire	curve	by	multiplying	the	toughness	by	the	cross	
sectional	area.		
10. 	Locate	the	toe	region	by	highlighting	from	the	first	non-zero	value	in	the	stress	region	
to	0.05	MPa.		
11. 	Plot	the	toe	region	and	add	a	trendline	with	the	equation	and	R2	value.		The	equation	
should	be	raised	to	the	2nd	power.			
12. Find	the	slope	of	the	toe	region	by	taking	the	derivative	of	the	equation.		
13. Find	the	start	of	the	linear	region	by	adding	50	points	onto	the	end	of	the	toe	region.		
Take	the	end	of	the	linear	region	to	be	about	150-200	points	from	the	beginning,	unless	
there	is	an	obvious	break	from	linearity	in	the	graph.		
14. Plot	the	linear	region	and	trendline	with	the	equation	and	R2	value.			The	Young’s	
Modulus	is	the	slope	of	the	linear	region.	
15. To	determine	the	yield	point,	first	find	the	offset	strain	line	by	taking	the	linear	region	
equation	and	offsetting	it	by	.02.			
16. Plot	the	offset	strain	line	and	determine	the	point	of	intersection	with	the	curve.		The	y	
value	of	the	intersection	point	is	the	yield	point.		
17. Find	resilience	by	calculating	the	area	under	the	curve	to	the	yield	point.		
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APPENDIX C1: Bright Humor’s dynamic endoscope diagnoses 
 
Pre Treatment: 
Natanya M. Nieman, DVM 
3241 Pisgah Pike 
Versailles, KY 40383 
(859)537-5000 
 
 
BRIGHT HUMOR 
Scope report 
 
March 23, 2014- 
Left arytenoid completely paralyzed and thickened, partially scarred up out of the 
airway (previous tieback surgery that was released. Dorsal displacement of the soft 
palate-displaced 90% of the exam. Epiglottis is moderately flaccid and of normal 
size. 
 
Previous surgeries: 
Tie Back 
Tie Back Release 
Tie Forward 
Laser edge of soft palate 
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Post Treatment: 
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APPENDIX C2: Talladega Hall’s dynamic endoscope diagnoses
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APPENDIX C3: Post treatment clinical observations 
Table	4.3:	Post	treatment	clinical	observations	from	in	vivo	study	for	each	horse	
Study	
ID	
Study	
Day	 Time	 Clinical	Observations	
1	 1	
13	hr	post	 clearing	throat	repeatedly	but	not	excessive	
15	hr	post	 slight	teeth	grinding	and	licking	
2	
0	 1	hr	post	 still	slightly	sedated	
1	
25	hr	post	 slight	clear	nasal	discharge	bilaterally,	breathing	normally	
28	hr	post	 licking	occasionally	
29	hr	post	 twitching	lips	and	licking	occasionally	
3	
59	hr	post		 laying	down	
68	hr	post	 mild	mucoid	nasal	discharge	from	both	nares	
3	
0	
1	hr	post	 still	slightly	sedated	
2	hr	post	 licking/chewing	
1	
21	hr	post	 mild	hypersalivation,	reduced	appetite	
22	hr	post	 eating	normally	
23	hr	post	 mild	hypersalivation,	licking	side	of	stall,	breathing	normally	
24	hr	post	 occasional	licking	
25	hr	post	 mild	hypersalivation,	licking	back	of	stall,	breathing	normally	
28	hr	post	 slight	clear	nasal	discharge	from	right	nostril,	breathing	normally,	eating	well	
2	 43	hr	post	 some	feed	remaining	
4	
0	
11	hr	post	 smacking	continuously	
12	hr	post	 continues	to	smack	
1	
14	hr	post	 clearing	throat	repeatedly	but	not	excessive	
15	hr	post	 constantly	chewing	and	licking,	no	respiratory	difficulty		
16	hr	post	 small	amount	licking	
19	hr	post	 clearing	throat	repeatedly			
2	 43	hr	post	 laying	down	
5	
0	
1	hr	post	 still	slightly	sedated	
11	hr	post	 good	amount	of	smacking	and	tongue	movement	in	and	out,	cleared	throat	several	times	
2	
55	hr	post	 chewing	
57	hr	post	 chewing	
6	 1	
13	hr	post	 laying	down	quietly	
16	hr	post	 laying	down	quietly	
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APPENDIX C4: Detailed histological analysis for individual samples 
 
  
 
HISTOPATHOLOGY REPORT 
 
4LT 1-2 Two sections through the treated palate 4LT are examined.  The biopsy has intact mucosa on both the 
respiratory and oral sides. The core of the biopsy is necrotic and connective tissue fibrils are widely 
separated. The separation may be from edema or from expansion associated with tissue freezing.   Few 
muscular fascicles adjacent to the necrotic core retain their striations and are diffusely basophilic. 
Surrounding the necrotic core is a marked zone of abundant neutrophils, many of which have 
degenerated into basophilic smears (degenerated chromatin).  In the palatine muscles adjacent to the 
necrotic core, neutrophil infiltrates widely separate muscle fibers within fascicles. Muscle fibers are 
swollen and most retain striations.  Some myofibers have granular cytoplasm with large clear vacuoles. 
The vacuoles may be from freezing artifact as similar cytoplasmic vacuoles are observed in the control 
palate sections.  Outside of the neutrophils, a wide zone of the collagenous stroma is necrotic.  
 
Between the necrotic core and the viable submucosa of the oral mucosal epithelium is a moderate band 
of spindloid cells with plump nuclei interpreted to be fibroblasts and mild amounts of irregular bands of 
collagen. Mild numbers of eosinophils infiltrate the viable submucosa and a few small lobules of mucous 
glands are observed. The stratified epithelium of the oral mucosa is unremarkable.  
 
On the respiratory side, the necrotic collagenous stroma is moderately infiltrated with neutrophils. In the 
submucosa are variably-sized clear spaces lined with a simple endothelium and filled with a minimal 
amount of flocculent eosinophilic material. These clear spaces may represent vessels (lymphatic and 
/or vascular) that may have expanded because of freezing. Also in the submucosa are mild to moderate 
numbers of eosinophils. The respiratory mucosa is mildly infiltrated with granulocytes and cilia are not 
observed. The lack of cilia may be associated with the transition of respiratory to oral mucosa. 
  
4LM 1-2 Two sections through the treated palate 4LM are examined.  The biopsy has intact mucosa on both the 
respiratory and oral sides. The core of the biopsy contains abundant neutrophils.  Surrounding the core 
of neutrophils is a mild to moderate zone of necrotic collagenous stroma.  
 
Neutrophil infiltrates occasionally extend through the necrotic stroma and surround degenerated lobules 
of mucous glands on the oral side. Between the necrotic stroma and the viable submucosa of the oral 
mucosa is a moderate band of spindloid cells with plump nuclei interpreted to be fibroblasts and 
abundant dense irregular collagen. In some regions, collagenous fibers are separated by pale 
eosinophilic material (suggestive of edema or freezing artifact). The submucosa is infiltrated with mild to 
moderate numbers of neutrophils and lymphocytes that extend to the basal cells of the mucosa. Few 
inflammatory cells infiltrate mildly edematous rete pegs of the mucosa.  
 
Many muscle fascicles adjacent to the necrotic stroma on the respiratory side have myofibers with 
single cytoplasmic vacuoles (freezing artifact). A minor number of muscle fascicles contain small 
myofibers separated by mild numbers of spindloid cells and mild amounts of irregular collagenous 
fibers, which are changes associated with fibroplasia. Many of the small myofibers have central plump 
nuclei, a change associated with muscle hyperplasia or repair. Between the regenerating muscle and 
the submucosa are moderate bands of plump spindloid cells or fibroblasts, with occasional mitotic 
figures, with moderate amounts of irregular collagen fibrils.  Between the regions of fibroplasia and the 
mucosa are numerous lobules of mucous glands that have an edematous interstitial stroma. In the 
submucosa are variably-sized clear spaces lined with a simple endothelium and filled with a minimal 
amount of flocculent eosinophilic material. These clear spaces may represent vessels (lymphatic and 
/or vascular) that may have expanded because of freezing. Also in the submucosa are mild to moderate 
numbers of eosinophils. The respiratory mucosa contains small vacuoles that separate epithelial cells.  
 
4LB 1-2 Two sections of the control palate 4LB are examined. No significant lesions are observed. The 
pseudostratified columnar ciliated epithelium on the respiratory side of the palate is intermittently folded 
to form glandular-like pockets. The submucosa is moderately populated with tubuloalveolar mucous 
glands in a well-vascularized stroma of fine collagenous fibrils.  Around the base of the mucous glands 
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and diffusely within the stroma are mild infiltrates of lymphocytes and plasma cells. Deep to the 
submucosa are moderately-sized arteries and bands of dense collagen, tendons and fascicles of the 
palatine skeletal muscles.  Skeletal myofibers occasionally contain cytoplasmic clear vacuoles which 
are most likely a consequence of ice crystal formation associated with freezing. Toward the oral side of 
the palate, abundant large lobules of mucous glands are adjacent and occasionally separate the 
muscular fascicles. Glandular lobules are separated from each other by thick bands of dense 
connective tissue.  Closer to the mucosal surface and within the dense collagenous stroma of the 
submucosa are multiple lymph nodules, each with multiple germinal centers.   Interspersed between 
lymphoid nodules are smaller bands of skeletal muscle and cross-section of ducts – likely from the 
mucous glands. The oral mucosa is slightly folded and composed of acanthotic non-keratinized 
stratified squamous epithelium with prominent rete pegs. 
 
4RT 1-2 Two sections through the treated palate 4RT are examined.  The biopsy has mostly intact mucosa on 
both the respiratory and oral sides. The core of the biopsy is extensively necrotic.  Vessels in the 
necrotic core are distended and contain fibrillar eosinophilic material which may represent fibrin. 
Surrounding the necrotic core are abundant infiltrates of neutrophils. Outside of the zone of neutrophils, 
a wide zone of the collagenous stroma is necrotic.   
 
Between the necrotic stroma and the viable submucosa of the oral mucosal epithelium is a mild band of 
spindloid cells with plump nuclei interpreted to be fibroblasts and mild amounts of dense collagen. The 
submucosa is infiltrated with mild numbers of eosinophils and lymphocytes. The mucosa is 
unremarkable. 
 
On the respiratory side, neutrophil infiltrates widely separate muscle fibers within many fascicles. 
Muscle fascicles contain swollen and fragmented myofibers separated by moderate numbers of 
spindloid cells (fibroblasts) and mild amounts of collagenous fibers, which are changes associated with 
fibroplasia. Between the injured muscle and the submucosa are degenerated mucous glands, moderate 
infiltrates of plump fibroblasts, mild deposits of irregular collagen and mild to moderate infiltrates of 
eosinophils and lymphocytes.  Neutrophil infiltrates within the necrotic stroma extend to the submucosa 
in many regions.  The submucosa is mildly edematous. In a few regions of the submucosa are variably-
sized clear spaces lined with a simple endothelium and filled with a minimal amount of flocculent 
eosinophilic material. These clear spaces may represent vessels (lymphatic and /or vascular) that may 
have expanded because of freezing. In the respiratory mucosa are minimal inflammatory cells. Cilia are 
not observed.  
 
4RM 1-2 Two sections through the treated palate 4RM are examined.  The biopsy has mostly intact mucosa on 
both the respiratory and oral sides. The core of the biopsy is extensively necrotic.  Vessels in the 
necrotic core are distended and contain fibrillar eosinophilic material which may represent fibrin. 
Surrounding the necrotic core are abundant infiltrates of neutrophils. Outside of the zone of neutrophils, 
a wide zone of collagenous stroma is necrotic.  
 
Between the necrotic stroma and the viable submucosa of the oral mucosal epithelium is a moderate 
band of spindloid cells with plump nuclei interpreted to be fibroblasts and moderate amounts of dense 
irregular collagen. Lobules of mucous glands are degenerated with loss and attenuation of glandular 
epithelium. The submucosa is edematous and infiltrated with moderate numbers of eosinophils and 
lymphocytes. Occasional inflammatory cells are within the mucosa and occasional mitoses are 
observed in basal epithelial cells.   
 
Neutrophil infiltrates widely separate muscle fibers within many fascicles on the respiratory side. Muscle 
fascicles contain swollen and fragmented myofibers separated by moderate numbers of spindloid cells 
(fibroblasts) and mild deposits of irregular collagen, which are changes associated with fibroplasia. 
Many muscle fascicles adjacent to the necrotic stroma contain small myofibers with central plump 
nuclei, a change associated with muscle hyperplasia or repair. Between the regenerating muscle and 
the submucosa are moderate bands of plump fibroblasts with moderate irregular collagen deposits.  
4
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Between the regions of fibroplasia and the mucosa are numerous lobules of mucous glands.  Neutrophil 
infiltrates of the necrotic stroma extend to the submucosa in many regions. In most of the biopsy, the 
submucosa is mildly edematous and moderately infiltrated with lymphocytes, neutrophils and few 
eosinophils. The respiratory mucosa is mildly infiltrated with granulocytes and cilia are not observed. 
The lack of cilia may be associated with the transition of respiratory to oral mucosa. 
 
4RB 1-2  Two sections through the control palate 4RB are examined.  The biopsy has mostly intact mucosa on 
both the respiratory and oral sides. The core of the biopsy is extensively necrotic which may be from 
carryover from the treated sites.  Vessels in the necrotic core are distended and contain fibrillar 
eosinophilic material which may represent fibrin. Surrounding the necrotic core are abundant infiltrates 
of neutrophils.. Outside of the abscess, a wide zone of the collagenous stroma is necrotic.   
 
Between the necrotic stroma and the viable submucosa of the oral mucosal epithelium is a moderate 
band of spindloid cells with plump nuclei interpreted to be fibroblasts and moderate deposits of dense 
irregular collagen. Lobules of mucous glands are degenerated with loss and attenuation of glandular 
epithelium. The submucosa is edematous and infiltrated with moderate numbers of eosinophils and 
lymphocytes. Occasional inflammatory cells are within the mucosa and occasional mitoses are 
observed in basal epithelial cells.   
 
On the respiratory side, necrosis of the stroma with moderate neutrophil infiltrates extends to the 
submucosa in many regions.  Neutrophil infiltrates widely separate muscle fibers within many fascicles. 
Muscle fascicles contain swollen and fragmented myofibers separated by moderate numbers of 
spindloid cells (fibroblasts) and mild amounts of collagenous fibers, which are changes associated with 
fibroplasia. Many muscle fascicles adjacent to the necrotic stroma contain small myofibers with central 
plump nuclei, a change associated with muscle hyperplasia or repair. Between the regenerating muscle 
and the submucosa are moderate bands of plump fibroblasts with moderate irregular collagen deposits.  
Between the regions of fibroplasia and the mucosa are numerous lobules of mucous glands within an 
edematous interstitial stroma. The submucosa is mildly edematous and moderately infiltrated with 
lymphocytes, neutrophils and few eosinophils. The respiratory mucosa is mildly infiltrated with 
granulocytes. 
 
5LT One section through the treated palate 5LT is examined.  The biopsy has a limited amount of mucosa 
on the respiratory and oral sides. The core of the biopsy is extensively necrotic.  Within the necrotic 
tissue are scattered bacterial colonies. Moderate to marked infiltrates of neutrophils surround the 
necrotic core. Outside of the neutrophilic zone, a wide zone of the collagenous stroma is necrotic.  
 
Between the necrotic stroma and the viable submucosa of the oral mucosal epithelium are moderate 
bands of spindloid cells with plump nuclei interpreted to be fibroblasts and moderate amounts of dense 
collagen.  These bands of fibroplasia frequently surround foci of necrotic stroma and extend up to the 
level of the mucous glands. Mild infiltrates of neutrophils are among the fibroblasts at the interface of 
the necrotic stroma and many small blood vessels are observed within the fibroplastic tissue. The 
submucosa and oral mucosa are within normal limits.    
 
On the respiratory side, necrosis of stroma and muscular fascicles with moderate to marked neutrophil 
infiltrates extend to the submucosa and occasionally to the base of the mucosa. Some mucous glands 
are degenerated and infiltrated with mild numbers of lymphocytes and plasma cells. Muscle fascicles 
contain swollen and fragmented myofibers separated by moderate numbers of spindloid cells and mild 
amounts of collagenous fibers, which are changes associated with fibroplasia. On the periphery of the 
necrotic tissue, muscle fasicles are separated by moderate amounts of dense and fine collagen fibrils 
with fewer and smaller spindloid cells (interpreted to be fibrocytes) and minimal inflammatory cell 
infiltrates. This expanded stroma may represent artifactual separation associated with freezing. The 
mucous glands in this region are mildly infiltrated with lymphocytes and plasma cells. In the submucosa 
are multiple variably-sized clear spaces lined with a simple endothelium and rarely filled with a minimal 
amount of flocculent eosinophilic material. These clear spaces may represent vessels (lymphatic and 
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/or vascular) that may have expanded because of freezing.  The submucosa has mild to moderate 
numbers of lymphocytes that often extend to the base of the mucosa. The respiratory mucosa 
occasionally contains small vacuoles that separate epithelial cells. No cilia are observed. 
 
5LM  One section through the treated palate 5LM is examined.  The biopsy has a limited amount of mucosa 
on the respiratory and oral sides. The core of the biopsy is extensively necrotic at one margin.  
Surrounding the necrotic core are mild to moderate infiltrates of neutrophils. Outside of the neutrophilic 
zone are multiple regions of necrotic collagenous stroma.    
 
Between the necrotic stroma and the viable submucosa of the oral mucosal epithelium are moderate 
bands of spindloid cells with plump nuclei interpreted to be fibroblasts and moderate amounts of dense 
irregular collagen.  Mild infiltrates of neutrophils are among the fibroblasts at the interface of the necrotic 
stroma and many small blood vessels are observed within the fibroplastic tissue. Mucous glands in the 
region with the most inflammation and fibroplasia have mild interstitial edema.  The submucosa in the 
region of inflammation has mild numbers of infiltrating eosinophils, plasma cells and lymphocytes. The 
oral mucosa is unremarkable.    
 
On the respiratory side, collagenous stroma and muscular fascicles are necrotic with moderate to 
marked neutrophil infiltrates. Neutrophilic infiltrates extend from the necrotic tissue to the submucosa 
and base of the mucosa. Some mucous glands in this region are moderately to markedly degenerated 
and infiltrated with mild numbers of neutrophils, lymphocytes and plasma cells.  Muscle fascicles 
contain swollen and occasionally fragmented myofibers separated by moderate numbers of spindloid 
cells, interpreted to be fibroblasts, mild to moderate amounts of irregular collagen and mild infiltrates of 
neutrophils and occasionally eosinophils. On the periphery of the necrotic tissue, muscle fasicles are 
separated by moderate amounts of dense and fine irregular collagen fibrils with fewer and smaller 
spindloid cells (interpreted to be fibrocytes) and minimal inflammatory cell infiltrates. This expanded 
stroma may represent artifactual separation of normal stroma associated with freezing. Mild interstitial 
infiltrates of lymphocytes and plasma cells are observed in the mucous glands in this region. In the 
submucosa are multiple variably-sized clear spaces, most of which are lined with a simple endothelium. 
These clear spaces may represent vessels (lymphatic and /or vascular) that may have expanded 
because of freezing.   The submucosa has mild to marked numbers of lymphocytes that often extend to 
the base of the mucosa. The respiratory mucosa occasionally contains small vacuoles that separate 
epithelial cells. No cilia are observed. 
 
5LB One section of the control palate 5LB is examined. No significant lesions are observed. The surface 
epithelium on the respiratory side of the palate is intermittently folded to form glandular-like pockets and 
overlays multiple large submucosal lymphoid nodules, each composed of lymphoid aggregates with 
prominent germinal centers.  The epithelium overlying the nodules is a simple low columnar epithelium 
while that of the infolded regions is pseudostratified and columnar. Between and beneath the lymphoid 
nodules are mucous glands in a well-vascularized stroma of fine irregular collagenous fibrils.  Around 
the base of the mucous glands and diffusely within the stroma are mild infiltrates of lymphocytes and 
plasma cells. Deep to the mucous glands is a broad band of dense regular collagen populated with 
medium-sized arteries and multiple small clusters of lymphocytes.  Beneath this layer is a fascial plane 
composed of mild amounts of collagen surrounding arteries, nerves and clusters of adipose tissue. The 
core of the biopsy contains a moderate band of large dense collagenous fascicles interpreted to be the 
tendon aponeurosis.  Between the tendon aponeurosis and the oral side of the palate are abundant 
lobules of mucous gland.  Few bands of collagen associated with ductal structures extend from the 
submucosa into the glands. Closer to the mucosal surface and within the dense collagenous stroma of 
the submucosa are multiple lymph aggregates and ducts.  The oral mucosa is slightly folded, 
nonkeratinized stratified squamous epithelium with prominent rete pegs. 
 
5RT 1-2 Two sections through the treated palate 5RT are examined.  One portion of the biopsy (5RT1) is 
interpreted to be within normal limits and is not described. Changes are observed on section 5RT2. The 
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core of the biopsy is necrotic with moderate neutrophilic infiltrates at one margin.  Outside of the 
neutrophilic zone are multiple regions of necrotic collagenous stroma.   
 
Between the necrotic stroma and the viable submucosa of the oral mucosal epithelium are moderate 
bands of spindloid cells with plump nuclei interpreted to be fibroblasts and moderate amounts of dense 
irregular collagen.  Mild to moderate infiltrates of neutrophils are among the fibroblasts at the interface 
of the necrotic stroma and many small blood vessels are observed within the fibroplastic tissue. Mucous 
glands in the region with the most inflammation and fibroplasia have mild interstitial fibrosis, edema (or 
freezing artifact) and mild infiltrates of lymphocytes and plasma cells.  The submucosa in the region of 
inflammation has minimal numbers of infiltrating eosinophils, plasma cells and lymphocytes. The oral 
mucosa is unremarkable.    
 
On the respiratory side, collagenous stroma and muscular fascicles are necrotic with moderate to 
marked neutrophil infiltrates. Neutrophilic infiltrates extend from the necrotic tissue to the submucosa 
and base of the mucosa. Some mucous glands in this region are mildly to moderately degenerated and 
infiltrated with mild numbers of neutrophils, lymphocytes and plasma cells.  Muscle fascicles contain few 
myofibers separated by moderate numbers of spindloid cells, interpreted to be fibroblasts, mild to 
moderate amounts of irregular collagen and mild infiltrates of neutrophils and occasionally eosinophils. 
Many muscle fascicles adjacent to the necrotic stroma contain small myofibers with central plump and 
peripheral nuclei, a change associated with muscle hyperplasia or repair. Between the regenerating 
muscle and the submucosa are moderate bands of fibroblasts with moderate irregular dense collagen 
deposits. Mild interstitial infiltrates of lymphocytes and plasma cells are observed in the mucous glands 
in this region. In the submucosa are multifocal variably-sized clear spaces, most of which are lined with 
a simple endothelium. These clear spaces may represent vessels (lymphatic and /or vascular) that may 
have expanded because of freezing.   The submucosa has mild diffuse to marked focal numbers of 
lymphocytes that often extend to the base of the mucosa. The respiratory mucosa occasionally contains 
small vacuoles that separate epithelial cells. No cilia are observed. 
 
 
5RM 1-2 Two sections through the treated palate 5RM are examined.  One portion of the biopsy (5RM2) is 
interpreted to be within normal limits and is not described. Changes are observed on section 5RM1. The 
core of the biopsy is mildly necrotic with moderate to marked  neutrophilic infiltrates at one margin.  
Outside of the neutrophilic zone are multiple regions of necrotic stroma.   
 
Between the necrotic stroma and the viable submucosa of the oral mucosal epithelium are moderate 
bands of spindloid cells with plump nuclei interpreted to be fibroblasts and moderate amounts of dense 
irregular collagen.  Mild to moderate infiltrates of neutrophils are among the fibroblasts at the interface 
of the necrotic stroma and many small blood vessels are observed within the fibroplastic tissue. Mucous 
glands in the region with the most inflammation and fibroplasia have mild interstitial fibrosis, edema (or 
freezing artifact) and mild infiltrates of lymphocytes and plasma cells.  The submucosa in the region of 
inflammation has minimal numbers of infiltrating eosinophils, plasma cells and lymphocytes. The oral 
mucosa is unremarkable.   
 
On the respiratory side, collagenous stroma and muscular fascicles are necrotic with moderate to 
marked neutrophil infiltrates. Neutrophilic infiltrates extend from the necrotic tissue to the submucosa 
and base of the mucosa. Some mucous glands in this region are mildly to moderately degenerated and 
infiltrated with mild numbers of neutrophils, lymphocytes and plasma cells.  Many muscle fascicles 
adjacent to the necrotic stroma contain small myofibers with central plump and peripheral nuclei, a 
change associated with muscle hyperplasia or repair. Viable muscle fascicles frequently contain few 
myofibers separated by moderate numbers of spindloid cells, interpreted to be fibroblasts, mild to 
moderate amounts of irregular collagen and mild infiltrates of neutrophils and occasionally eosinophils. 
Between the regenerating muscle and the submucosa are moderate bands of plump fibroblasts with 
moderate irregular collagen deposits. Mild interstitial infiltrates of lymphocytes and plasma cells are 
observed in the mucous glands in this region. In the submucosa are multifocal variably-sized clear 
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spaces, most of which are lined with a simple endothelium. These clear spaces may represent vessels 
(lymphatic and /or vascular) that may have expanded because of freezing.  The submucosa also has 
mild diffuse to marked aggregates of lymphocytes that often extend to the base of the mucosa. No cilia 
are observed on respiratory mucosal epithelia. 
 
5RB One section of the control palate 5RB is examined. No significant lesions are observed. The oral 
mucosa is slightly folded nonkeratinized stratified squamous epithelium with prominent rete pegs. The 
submucosa contains dense collagenous stroma with multiple lymph aggregates and ducts of mucous 
glands. Few bands of collagen associated with ductal structures extend from the submucosa into the 
glands.  Between the submucosa are abundant lobules of mucous glands.  No respiratory mucosa is 
present in the section. 
 
6LT One section of the control palate 6LT is examined. The pseudostratified columnar ciliated epithelium on 
the respiratory side of the palate is absent in half of the section. The submucosa is moderately 
populated with tubuloalveolar mucous glands in a well-vascularized stroma of fine collagenous fibrils. In 
the region missing the mucosa, the submucosa contains several foci of necrotic stroma surrounded by 
and infiltrated with mild numbers of neutrophils.  It is likely this is carryover damage from the treated 
portions of the same soft palate. Around the base of the mucous glands and diffusely within the stroma 
are mild infiltrates of lymphocytes and plasma cells. Deep to the submucosa are moderately-sized 
arteries and bands of dense collagen, tendons and abundant fascicles of skeletal muscle.  Toward the 
oral side of the palate are many large lobules of mucous glands. Glandular lobules are separated from 
each other by small bands of dense connective tissue.  Closer to the mucosal surface and within the 
dense collagenous stroma of the submucosa are multiple cross-sections of ducts – likely from the 
mucous glands. The oral mucosa is occasionally folded and composed of acanthotic non-keratinized 
stratified squamous epithelium with prominent rete pegs. 
 
6LM One section through the treated palate 6LM is examined.  The biopsy has mostly intact mucosa on the 
oral side. No mucosa is observed on the respiratory side. The core of the biopsy is extensively necrotic.  
Vessels in the necrotic core are distended and contain fibrillar eosinophilic material which may 
represent fibrin. Within the necrotic area are moderate numbers of coccobacillary bacterial colonies. 
Surrounding the necrotic core are abundant infiltrates of neutrophils. Outside of the neutrophil infiltrates, 
a wide zone of the collagenous stroma is necrotic.  
 
Between the necrotic stroma and the viable submucosa of the oral mucosal epithelium is a mild band of 
spindloid cells with plump nuclei interpreted to be fibroblasts and mild amounts of dense irregular 
collagen. The submucosa is infiltrated with mild numbers of eosinophils and lymphocytes. Multifocal 
lymphoid nodules with lymphoid aggregates and germinal centers are observed.  The mucosa is 
unremarkable. 
 
Neutrophil infiltrates and collagen fibrils widely separate muscle fibers within many fascicles adjacent to 
the necrotic core on the respiratory side. Muscle fibers are small, most retain striations and have central 
nuclei consistent with regeneration.  Some muscle fascicles contain myofibers separated by moderate 
numbers of fibroblasts and mild deposits of irregular collagen fibers, which are changes associated with 
fibroplasia. There is minimal submucosa and no respiratory mucosa present in the section. 
 
In the palatine muscles distant from the treatment site is an intracytoplasmic cyst filled with banana-
shaped protozoal organisms consistent with Sarcocystis.  No inflammation was associated with the 
presence of the encysted protozoa. 
 
6LB 1-2 Two sections through the treated palate 6LB are examined.  The biopsy has a small portion of intact 
mucosa on the respiratory side and a limited amount of oral mucosa. The core of the biopsy is 
extensively necrotic. Within the necrotic tissue are multiple mineralized foci and coccobacillary bacterial 
colonies. Surrounding the necrotic core are abundant infiltrates of neutrophils. Outside of the zone of 
neutrophils is a wide zone of necrotic collagenous stroma. On the respiratory side is a broad region of 
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diffuse basophilia (representing degeneration) of muscle, fascia and mucosa. A small portion of viable 
respiratory mucosa is on one section.   
 
Between the necrotic stroma and the viable submucosa of the oral mucosal epithelium is a moderate 
band of spindloid cells with plump nuclei interpreted to be fibroblasts and moderate amounts of dense 
irregular collagen. Some lobules of mucous glands are degenerated with loss and attenuation of 
glandular epithelium. The submucosa is infiltrated with mild numbers of eosinophils and lymphocytes. 
Occasional inflammatory cells are within the mucosa.   
 
On the respiratory side, collagenous stroma and muscular fascicles are necrotic with moderate to 
marked neutrophil infiltrates. Neutrophilic infiltrates extend from the necrotic tissue to the submucosa 
and base of the mucosa.  In this area, muscle fascicles are separated by moderate numbers of 
fibroblasts and mild deposits of irregular collagen which are changes associated with fibroplasia. Many 
myofibers in fascicles adjacent to the necrotic stroma are absent and some are small with central plump 
nuclei, a change associated with muscle hyperplasia or repair. Between the regenerating muscle and 
the submucosa are moderate bands of plump fibroblasts with moderate irregular collagen deposits.  
Between the regions of fibroplasia and the mucosa are numerous lobules of mucous glands, some with 
degenerated glandular epithelium, and all with moderate interstitial infiltrates of lymphocytes, 
neutrophils and few eosinophils. The submucosa is mildly edematous and moderately infiltrated with 
lymphocytes, plasma cells, neutrophils and few eosinophils. The respiratory mucosa is mildly infiltrated 
with granulocytes. 
 
6RT One section of the control palate 6RT is examined. No significant lesions are observed. The 
pseudostratified columnar ciliated epithelium on the respiratory side of the palate is intermittently folded 
to form glandular-like pockets. The submucosa is moderately populated with tubuloalveolar mucous 
glands in a well-vascularized stroma of fine collagenous fibrils.  Around the base of the mucous glands 
and diffusely within the submucosa are minimal infiltrates of lymphocytes, plasma cells and occasional 
eosinophils. Deep to the submucosa are moderately-sized arteries and bands of dense collagen, 
tendons and abundant fascicles of skeletal muscle.  Skeletal myofibers occasionally contain 
cytoplasmic clear vacuoles which are most likely a consequence of ice crystal formation associated with 
freezing. Toward the oral side of the palate, abundant large lobules of mucous glands are adjacent to 
and occasionally separate the muscular fascicles. Glandular lobules are separated from each other by 
thick bands of dense connective tissue.  Closer to the mucosal surface and within the dense 
collagenous stroma of the submucosa is an aggregate of lymphocytes, smaller bands of skeletal muscle 
and cross-section of ducts – likely from the mucous glands. The oral mucosa is slightly folded and 
composed of acanthotic non-keratinized stratified squamous epithelium with prominent rete pegs. 
 
6RM 1-2 Two sections through the treated palate 6RM are examined.  One portion of the biopsy (6RM2) is 
interpreted to be within normal limits and is not described. Changes are observed on section 6RM1.  
The core of the biopsy is extensively necrotic. Within the necrotic tissue are multiple mineralized foci 
and coccobacillary bacterial colonies. Surrounding the necrotic core are abundant infiltrates of 
neutrophils. Outside the zone of neutrophils on the respiratory side is a broad region of diffuse 
basophilia (representing degeneration) of muscle, fascia and portions of mucosa.   
 
Between the necrotic stroma and the viable submucosa of the oral mucosal epithelium is a large region 
of stroma composed of spindloid cells with plump nuclei interpreted to be fibroblasts and moderate 
amounts of dense irregular collagen. In this area are a few muscle fascicles with mild to moderate 
interstitial infiltrates of plump fibroblasts, mild amounts of irregular collagen fibrils and mild infiltrates of 
plasma cells and lymphocytes. Between the fibroplastic regions and mucosa is abundant regular 
collagenous stroma with a single lobule of mucous glands.  Stroma and submucosa are infiltrated with 
minimal numbers of eosinophils and lymphocytes.   
 
On the respiratory side, collagenous stroma and muscular fascicles are necrotic with moderate to 
marked neutrophil infiltrates. Neutrophilic infiltrates extend from the necrotic tissue to the submucosa 
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and base of the mucosa. In this area, muscle fascicles are separated by moderate numbers of spindloid 
cells or fibroblasts and mild deposits of irregular collagenous fibers. Many myofibers in fascicles 
adjacent to the necrotic stroma are absent and some are small with central plump nuclei, a change 
associated with muscle hyperplasia or repair. Between the regenerating muscle and the submucosa are 
moderate bands of plump fibroblasts with moderate irregular collagen deposits. Between the regions of 
fibroplasia and the mucosa are numerous lobules of mucous glands, some with degenerated glandular 
epithelium, and all with mild interstitial infiltrates of lymphocytes, neutrophils and few eosinophils. The 
submucosa is mildly edematous and moderately infiltrated with lymphocytes, plasma cells, neutrophils 
and few eosinophils. The respiratory mucosa shows the transition from pseudostratified columnar to 
stratified squamous epithelium in this region. The mucosa is mildly infiltrated with granulocytes. 
 
In the palatine muscles distant from the treatment site is an intracytoplasmic cyst filled with banana-
shaped protozoal organisms consistent with Sarcocystis.  No inflammation was associated with the 
presence of the encysted protozoa. 
 
6RB One section through the treated palate 6RB is examined.  The core of the biopsy is extensively necrotic. 
Within the necrotic tissue are multiple mineralized foci. Surrounding the necrotic core are abundant 
infiltrates of neutrophils. Outside the zone of neutrophils on the respiratory side is a broad region of 
diffuse basophilia (representing degeneration) of muscle, fascia and portions of mucosa.   
 
Between the necrotic stroma and the viable submucosa of the oral mucosal epithelium is a large region 
of stroma composed of spindloid cells with plump nuclei interpreted to be fibroblasts and moderate 
amounts of dense irregular collagen. In this area are a few muscle fascicles with mild to moderate 
interstitial infiltrates of plump spindloid cells, mild amounts of collagenous fibers and mild infiltrates of 
plasma cells and lymphocytes. Between the fibroplastic regions and mucosa is abundant regular 
collagenous stroma.  Stroma and submucosa are infiltrated with mild numbers of plasma cells, 
lymphocytes and minimal numbers of eosinophils.   
 
On the respiratory side, necrosis of the stroma with moderate neutrophil infiltrates partially extends to 
the submucosa only in the region with viable mucosa.  In this area, muscle fascicles are separated by 
moderate numbers of fibroblasts and mild to moderate deposits of irregular collagenous fibers. Many 
myofibers in fascicles adjacent to the necrotic stroma are absent and some are small with central plump 
nuclei, a change associated with muscle hyperplasia or repair. Between the regions of fibroplasia and 
the mucosa are numerous lobules of mucous glands, one with degenerated glandular epithelium and 
the others with mild interstitial infiltrates of lymphocytes, neutrophils and few eosinophils. The 
submucosa is moderately infiltrated with lymphocytes, plasma cells, neutrophils and few eosinophils. 
The respiratory mucosa shows the transition from pseudostratified columnar to stratified squamous 
epithelium in this region. The mucosa is mildly infiltrated with granulocytes. 
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APPENDIX D3: Summarized data with outliers removed 
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APPENDIX D4: Averages and standard deviations of data 
 
Table	4.13:	Averages	and	standard	deviations	for	each	parameter.		The	percent	differences	comparing	each	group	
are	also	listed. 
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APPENDIX D5: F-test results for each parameter 
  
Table	4.16:	Critical	F	values	for	each	comparison	for	the	mechanical	testing	study 
Table	4.17:	F-test	results	for	each	individual	parameter.		Values	that	do	not	pass	the	test	are	highlighted	in	pink	
with	red	text. 
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APPENDIX D6: p-value results for each parameter 
Table	4.18:	p-value	results	for	each	parameter.		The	categories	that	failed	the	F-test	were	analyzed	with	the	Mann-
Whitney	U	non-parametric	test,	and	those	that	passed	were	analyzed	with	the	t-test.		Statistically	significant	values	
with	a	p	value	<	0.05	at	α	=	0.05	are	highlighted	in	red	and	pink.	
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